Biopharmaceutical companies are regaining interest in metabolic dysfunction-associated steatohepatitis (MASH) innovator drug development. MASH innovator drugs witnessed over $2.5 billion increase in the total value...
Eli Lilly and Co is on the brink of reshaping the pharmaceutical landscape with its groundbreaking treatments, Mounjaro (tirzepatide) for obesity and the highly anticipated...
Over the past two decades, there has been a marked increase in obesity rates among US adults, with projections indicating a continuing upward trend. Two...
Arrowhead Pharmaceuticals has recently unveiled final data from its Phase II SHASTA-2 clinical trial for plozasiran, previously recognized as ARO-APOC3. The data indicates a substantial...
The FDA has approved Basilea Pharmaceutica's advanced generation cephalosporin antibiotic, Zevtera (ceftobiprole medocaril), for the treatment of three major indications: Staphylococcus aureus bacteremia (SAB), including right-sided...
Nanoscope Therapeutics’ gene therapy MCO-010 (sonpiretigene isteparvovec) is in the spotlight with encouraging Phase IIb results from its RESTORE trial (NCT04945772) in the retinitis pigmentosa...
Generic drugs are often hailed as an effective cost-containment measure for healthcare systems that often have outdated or ineffective financing mechanisms. Despite their increasing usage,...
Pfizer’s oral drug, Velsipity (etrasimod), recently received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of active moderate to...
Osteoporosis, characterized by bone mass reduction, poses challenges in early detection due to often painless fractures. As a result, addressing inconsistent drug compliance rates in...
In the dynamic landscape of the pharmaceutical industry, collaboration often serves as the key to innovation and expanding market presence. In recent years, the Asia-Pacific...
China has emerged as a major force in the research and development of innovative therapies. Against this backdrop, Chinese companies have entered significant partnerships in...
Lifestyle disorders pose an escalating health challenge in India due to the adoption of modernized lifestyles. Obesity stands as a prominent concern, correlating with the...
The recent submission of clinical trial data for Sanofi/Regeneron’s Dupixent and Verona’s Ensifentrine to the Food and Drug Administration (FDA) indicates the entry of new...
World Tuberculosis (TB) Day is marked annually on 24 March, the anniversary of the discovery of the causative mycobacterium by Dr. Robert Koch. The day...
Since Roche's Zelboraf gained (vemurafenib) FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations...
Following the news on 14 March 2024 that FDA has granted accelerated approval for Madrigal Pharmaceuticals’ thyroid hormone receptor (THR)-β agonist Rezdiffra (resmetirom) for the...
GLP1 agonist drugs transformed the weight loss and diabetes landscape in 2023, propelled by robust clinical trial results and a surge in endorsements from celebrities...
Following the partnership between Amazon and Eli Lilly that will make available the latter’s drugs including the highly requested weight-loss drug Zepbound for home delivery...
The recently concluded AD/PD 2024 International Conference on Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) focused on innovative approaches poised to revolutionize the treatment of...
Within the current treatments of Parkinson’s disease (PD) there is an unmet need for addressing the loss of dopaminergic neurons and non-motor symptoms. At the...
Pharmaceutical companies are increasingly recognizing the importance of empowering patients to take charge of their health. However, there is still room for improvement in supporting...
Perrigo recently announced that Opill (norgestrel) will be sold over-the-counter, making it the first daily birth control pill to be available without a prescription in...
The diagnosed incident cases of non-small cell lung cancer (NSCLC) in the eight major markets (8MM*) are projected to increase at an annual growth rate...
The biopharmaceutical industry is witnessing a shift in investor sentiment. Despite facing challenges such as declining venture financing and macroeconomic pressures, there exists optimism about...
Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma (mUC). With...
Novo Nordisk recently announced positive results from the kidney outcomes trial FLOW, in which Ozempic (semaglutide) 1.0mg reduced the risk of kidney disease progression and...
Parkinson’s disease (PD) prevention through a combination of early diagnosis and the development of disease-modifying therapies (DMTs) that can halt the progression of PD was...
Following the Phase III LUCIDITY trial (NCT03446001) results announced by TauRx at the AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases, for hydromethylthionine mesylate...
In healthcare, the foundation of effective care lies in the trust between patients and healthcare professionals (HCPs). Central to this trust is the quality of...
The Medicines and Healthcare products Regulatory Agency (MHRA) approved Vertex’s exagamglogene autotemcel (Casgevy) in late 2023. Subsequently, it became the inaugural CRISPR-based drug for the...
Cell and gene therapies (CGTs) have been gaining traction within the medical community as treatment options that are expected to replace lifelong management of chronic...
Beacon Therapeutics’ gene therapy AGTC-501 (laruparetigene zovaparvovec) is in the spotlight with encouraging interim results from SKYLINE trial in the retinitis pigmentosa (retinitis) market. Offering...
Attention-deficit/hyperactivity disorder (ADHD) is a clinically heterogenous neurodevelopmental disorder with high rates of comorbidity with other childhood-onset psychiatric disorders as well as learning disorders. As...
Innovative approaches are poised to revolutionize the treatment of amyotrophic lateral sclerosis (ALS), a challenging and rare disease. The current therapies have limitations in efficacy,...
The recent approval of Takeda’s Eohilia (budesonide oral suspension) for patients 11 years of age and older, by the US FDA presents an opportunity for...
Biogen’s stance at the upcoming AD/PD 2024 International Conference on Alzheimer’s disease (AD) and Parkinson’s disease (PD) that will be held on March 5-9 will...
The FDA has approved Allecra Therapeutics' novel antibiotic combination, EXBLIFEP (cefepime/enmetazobactam), to treat complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP), in patients ≥...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently recommended the refusal of the marketing authorization for Nezglyal (leriglitazone). Nezglyal...
Following the news that the FDA denied approval for Minerva Neurosciences for its roluperidone for the treatment of negative symptoms in patients with schizophrenia; Christie Wong,...
AN2 Therapeutics recently announced a decision to voluntarily pause enrollment of the Phase III portion of the Phase II/III trial, EBO-301, in light of potentially...
Following the release of positive results for Phase III trial of ViiV Healthcare and GSK’s long-acting injectable antiretroviral treatment (ART) Cabenuva (cabotegravir + rilpivirine); Barbora Salcman,...
Takeda has decided to discontinue the development programs of its four oncology assets—Phase III asset modakafusp alfa (TAK-573) and three Phase I chimeric antigen receptor...
Following the news that the FDA has accepted the BLA submission for datopotamab deruxtecan in non-squamous NSCLC patients; Israel Stern, MSc, Oncology & Hematology Analyst at...
Iovance Biotherapeutics’ Amtagvi has been introduced as the first FDA-approved T-cell immunotherapy for a solid tumor, employing a polyclonal tumor infiltrating lymphocyte (TIL) cell therapy....
The pharmaceutical landscape has undergone a significant shift towards collaboration and partnership between global big pharma and Indian pharmaceutical firms in recent years to drive...
Biora Therapeutics recently announced the initiation of Phase I clinical trials of BT-600, a novel drug-device combination for ulcerative colitis (UC) patients. BT-600 aims to...
Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disorder characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), leading to an increased risk of cardiovascular...
The International Gaucher Alliance (IGA) marks its 30th anniversary with a five-year strategic plan to advocate for Gaucher patients globally. The plan underscores a commitment...
The prevalence of colorectal cancer (CRC) is surging across the eight major markets (8MM*) due to an aging population and increased mutation testing. With a...
Mycovia Pharmaceuticals Inc has recently announced that Jiangsu Hengrui Medicine Co Ltd has commercially launched Vivjoa* (oteseconazole) in China, making available an innovative oral azole...
In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD). The objective of the...
Otsuka Pharmaceutical is poised for a strategic transition as it approaches the loss of market exclusivity of Abilify Maintena (Aripiprazole) in Europe and the US...
Systemic lupus erythematosus (SLE) is a chronic autoimmune that can affect multiple major organ systems in the body. One of its most severe manifestations is...
Following the news that Novo Holdings, the parent company to Novo Nordisk, has agreed to acquire contract development and manufacturing organization (CDMO) Catalent for $16.5...
In late 2023, Vertex Pharmaceuticals and CRISPR Therapeutics made history by gaining the first FDA approval for a CRISPR-based drug, exagamglogene autotemcel (Casgevy) for the...
A groundbreaking study may revolutionize the diagnosis of lupus nephritis (LN) by unveiling unique microRNAs (miRNAs) in the blood serum of systemic lupus erythematosus (SLE)...
Merck has recently agreed to acquire cancer drug developer Harpoon Therapeutics for about $680 million. The deal includes promising compounds undergoing Phase II trials for...
GSK’s vaccine Arexvy is currently undergoing regulatory review with the potential of being approved in Europe for use in adults aged between 50 and 59...
BrainStorm Cell Therapeutics is still navigating a three-year regulatory journey for the NurOwn therapy that was initiated in February 2021, marked by the FDA's initial...
Inflation in healthcare refers to the persistent increase in the cost of medical goods and services over time. This phenomenon is driven by a combination...
Innovent Biologics has recently made a significant breakthrough in obesity treatment with mazdutide, showcasing promising Phase III (GLORY-1) results. Poised to enter the Chinese market,...
AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody (mAb), has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory...
Japan has recently approved argenx’s Vyvdura (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous (SC) injection for the treatment of adult patients with generalized myasthenia gravis (gMG), who...
Antibody-drug conjugates (ADCs) represent a significant breakthrough in targeted cancer therapy. By blending the specificity of monoclonal antibodies with the potency of cytotoxic drugs, ADCs...
The global messenger ribonucleic acid (mRNA) vaccine market currently consists entirely of vaccines for COVID-19. The rapid sequencing of the SARS-CoV-2 viral genome and the...
The number of global fatalities due to fungal diseases has seen a significant increase over the past decade. This rising trend underscores the urgent need...
Gaucher disease, a rare genetic disorder with significant health implications, has been at the forefront of recent medical discussions due to concerns over delayed diagnoses...
Despite the current Bruton tyrosine kinase (BTK) inhibitor market being valued at approximately $6 billion, sales specifically for chronic lymphocytic leukemia (CLL) are predicted to...
Novo Nordisk and Eli Lilly have been dominating the obesity scene in the past year with the approval of their glucagon-like peptide-1 receptor (GLP-1R) agonists...
Stimulants, amphetamines, and methylphenidates are the first-line treatment for moderate to severe attention-deficit/hyperactivity disorder (ADHD) across the seven major markets (7MM*). Non-stimulants are mainly utilized...
XORTX Therapeutics, a Canada-based late-stage clinical pharmaceutical company, has recently submitted a new patent for the treatment of chronic kidney disease (CKD). XORTX’s patent submission...
Laminar Pharmaceuticals’ first-in-class autophagy inducer Minerval (LAM561, 2-hydroxyoleic acid (2-OHOA)) has reportedly demonstrated encouraging activity in the difficult-to-treat malignant braintumor patient population, placing it as...
Zosurabalpin, a novel antibiotic currently in Phase I development by Roche, has recently showed promise in ending a 50-year drought in effective treatment against carbapenem-resistant...
The current unmet needs in the female contraceptives market are similar to those that were present 10 years ago. Currently, marketed contraceptives carry the risk...
On January 8, Amgen presented at JP Morgan’s 42nd Annual Healthcare Conference 2024 (JPM24), highlighting their pillars of business. One of these pillars was the...
The sales growth of gout therapies across the seven major markets (7MM: the US, 5EU, and Japan) is set to increase at a compound annual...
Following the news that AbbVie has launched Produodopa (foscarbidopa/foslevodopa), to treat severe motor fluctuations in patients with advanced Parkinson’s disease (PD) in the European Union...
Following the news that Johnson & Johnson (J&J) has entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Ambrx Biopharma for $2.0 billion; Israel Stern,...
Over 2022 and 2023, biotech funding saw significant change, with a marked downturn in investment. Hoverer, the post-pandemic slump is expected to end with the...
Following the news that Massachusetts-based biotechnology company bluebird bio Inc (bluebird bio) has signed a second outcomes-based reimbursement deal with a large commercial payer for...
The major depressive disorder (MDD) market is forecast to grow from $4.7 billion in 2019 to $9.6 billion by 2029 across the eight major markets...
The age-related macular degeneration market (AMD) in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is set to...
In November 2023, the Indian Union Health Ministry authorised the sale of four generic medications for the treatment of rare diseases. This approval is a...
Although not a common disease, bronchiectasis has been in the spotlight of research as no therapies have been approved for its treatment. Bronchiectasis is a...
Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in...
Vertex Pharmaceuticals and CRISPR Therapeutics made history last month by gaining approval for the first CRISPR-based drug, exagamglogene autotemcel (Casgevy). However, given that 88% of...
The market for Gaucher disease, a rare inherited metabolic disorder characterized by hepatosplenomegaly, bone disease, and anemia, is set to experience a compound annual growth...
The insomnia market across the seven major markets (7MM*) is poised to grow at a compound annual growth rate (CAGR) of 2.6% from $3.2 billion...
Ractigen Therapeutics, headquartered in China, submitted a clinical trial application for RAG-01 in Australia. This application paves the way for Phase I trial of RAG-01...
Lingering inflation, geopolitical tensions, and conflicts, as well as continuous pressures to cut drug prices, will be the top challenges for the pharmaceutical industry in...
Eli Lilly recently published the results of a Phase III trial investigating the maintenance of Zepbound’s weight loss effects in overweight and obesity patients. Zepbound...
In recent years, the increase in inflammatory bowel disease (IBD) biologic treatments has been a major driving force in the growth of this market. In...
The female contraceptives market across the seven major markets (7MM*) is forecast to slightly increase at a compound annual growth rate (CAGR) of 0.5% from...
Novo Nordisk's Ozempic (semaglutide) took the weight loss sector by storm in 2023, propelled by strong efficacy and safety data, coupled with social media buzz...
Melinta Therapeutics and Cidara Therapeutics released extensive data from two global clinical trials on their candidemia and invasive candidiasis drug Rezzayo (rezafungin acetate). The findings...
South Korea has issued guidelines to monitor the side effects of the two approved CAR-T therapies - Kymriah (tisagenlecleucel) from Novartis and Carvykti (ciltacabtagene autoleucel)...
In a new move within the pharmaceutical industry, Sanofi, a global pharmaceutical giant, has entered a monumental $140 million deal with Aqemia, a French pharmaceutical...
Following the FDA’s acceptance of Madrigal Pharmaceuticals’ new drug application (NDA) and priority review for its THR-β agonist (resmetirom) in non-alcoholic steatohepatitis (NASH) in September...
CASI Pharmaceuticals and Juventas Cell Therapy recently received approval from China's National Medical Products Administration (NMPA) for Yuanruida (Inaticabtagene Autoleucel/CNCT19), a domestic CD19-targeting CAR-T therapy...
Stimulants, amphetamines, and methylphenidates continue to dominate the attention deficit hyperactivity disorder (ADHD) market across the seven major markets (7MM*), serving as the primary pharmacological...
Following the news that AbbVie has agreed to buy biotech ImmunoGen , the maker of the FDA-approved ovarian cancer treatment Elahere, for $10.1 billion; Israel Stern,...
December 1 commemorates World AIDS Day – a day of awareness and support for those living with HIV/AIDS, as well as a global remembrance for...
In the dynamic landscape of pharmaceutical contract manufacturing, the year 2022 witnessed unprecedented growth in revenues, marking the highest surge since 2011. The total commercial...
The diagnosed prevalent cases of non-alcoholic steatohepatitis (NASH/MASH) in the seven major markets (7MM*) are projected to increase from 22.04 million in 2022 to 26.55...
Chimeric Antigen Receptor- T (CAR-T) cell therapy, a revolutionary approach to treating certain types of cancer, has gained significant attention globally for its potential to...
Roche may be able to join the list of companies that have approved therapies for the treatment of lupus nephritis (LN), as recent results published...
World AMR Awareness Week (WAAW)* is observed on 18-24 November every year with the aim of improving awareness and understanding of antimicrobial resistance (AMR) and...
AstraZeneca recently announced its strategy for the cardiometabolic market, in particular treating obesity and its comorbidities, by combining the glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy...
The Korean Ministry of Food and Drug Safety (MFDS) has recently given clearance to Hanmi Pharmaceutical to conduct Phase III trial for its Korean-optimized obesity...
Eli Lilly recently received FDA approval for Zepbound (tirzepatide), its glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist for patients with obesity. In response to Zepbound’s...
Following the conclusion of International Gaucher Disease Awareness Month, key opinion leaders (KOLs) interviewed by GlobalData believe pipeline gene therapies will significantly impact the Gaucher...
At this year’s American Heart Association Scientific Session, positive results were presented from Lexicon Pharmaceuticals’ SCORED analysis of Inpefa (sotagliflozin), providing insight into the drug’s...
PDS Biotech recently announced the initiation of a Phase III pivotal trial for its immunotherapy asset PDS0101 in recurrent/metastatic HPV-16+ head and neck squamous cell...
AbbVie recently announced its publication in The Lancet showing that administration of Ubrelvy (ubrogepant) during the prodrome stage of a migraine can reduce the likelihood...
CStone Pharmaceuticals’ sugemalimab (Cejemly) has been approved by the China National Medical Products Administration (NMPA) for the treatment of relapsed or refractory extranodal natural killer/T-cell...
At the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Arrowhead Pharmaceuticals unveiled the Phase II clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3)....
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are common in solid tumors, including lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The introduction of...
In October 2023, the FDA granted Fast Track designation for Altimmune’s incretin mimetic, pemvidutide, in non-alcoholic steatohepatitis (NASH). Pemvidutide is a glucagon-like peptide 1 (GLP-1)...
Concerns have been raised over the suitability of current FDA-approved treatments for myelofibrosis due to the negative associations with anemia. In response, the FDA has...
Following the news that the UK Medicines and Healthcare Products Regulatory Agency has granted conditional marketing authorization to Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy, marking...
The shortage of talents that have specific digital skills continues to be a pressing issue for businesses since the lockdowns caused by COVID-19. Despite the...
The diagnosed incident cases of multiple myeloma (MM) in the eight major markets (*8MM) are projected to increase from 80,305 in 2022 to 95,349 in...
Valneva recently announced the approval of IXCHIQ by the US Food and Drug Administration (FDA), marking the approval of the world’s first chikungunya vaccine. IXCHIQ...
The COVID-19 pandemic catalyzed the adoption of decentralized clinical trials (DCTs) even though they have been in use for decades. DCTs offer the advantage of enabling...
Globally, 71% of healthcare industry professionals expressed that the COVID-19 pandemic had the greatest impact on digital transformation in the healthcare sector during the last...
Small cell lung cancer (SCLC), comprising 15% of lung tumors, is a highly aggressive form of malignancy. However, tarlatamab, a bispecific T-cell engager (BiTE) developed...
Novartis’ blockbuster drug Tasigna (nilotinib) is set to lose its exclusive status in the US in January 2024. A pivotal treatment for chronic myeloid leukemia...
Zydus Lifesciences is one of the leading players to focus on new chemical entity (NCE) research and development in India. The company was able to...
Following the news that Eli Lilly’s Zepbound (tirzepatide) has received the US Food and Drug Administration (FDA) approval; Sara Reci, MSc, Senior Pharma Analyst at GlobalData,...
The market for myasthenia gravis (MG), an autoimmune and neuromuscular disease characterized by muscle weakness and fatigue, is set to experience a compound annual growth...
The type 2 diabetes (T2D) landscape has historically been dominated by insulin receptor (IR) targeting drugs. However, driven by the success of recent glucagon-like peptide...
AnaptysBio's groundbreaking Phase III trial results for imsidolimab, a novel inhibitor, bring renewed hope to patients battling Generalized Pustular Psoriasis (GPP). With a promising safety...
Pfizer has recently announced the FDA approval of Penbraya, the first and only pentavalent vaccine for coverage against the most common serogroups causing meningococcal disease...
The future of Crohn’s disease (CD) therapy will be highly dynamic and competitive, with the advancement of developing novel mechanisms of action, both in biologics...
On 30 October, the European Medicines Agency (EMA) announced that it has validated the application of Bristol Myers Squibb’s Opdivo for the front-line treatment of...
The hormone receptor-postivie (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) market has seen promising results with the advent of cyclin dependent...
Roche’s primary patents for Actemra/RoActemra (tocilizumab) have already expired in major markets, including Europe and the US. In September 2023, the FDA approved Tofidence (tocilizumab-bavi,...
Immunoadoptive Cell Therapy Private Limited (ImmunoACT)'s NexCAR19 (actalycabtagene autoleucel) chimeric antigen receptor T-cell (CAR-T) therapy was approved in October by the Central Drug Standards Control...
The FDA recently rejected Eli Lilly’s biologic license application (BLA) for their anti-interleukin (IL) -13, lebrikizumab, which is in development for the treatment of atopic...
In 2022, global regulatory authorities awarded a record 10 review designations for respiratory syncytial virus (RSV)-indicated drugs. This surge acted as a precursor for the...
Novo Nordisk recently announced that its FLOW trial, which studies Ozempic (semaglutide) in diabetic patients with chronic kidney disease (CKD), will come to a halt...
Dizal (Jiangsu) Pharmaceutical Co Ltd's golidocitinib was granted priority review designation by the China National Medical Products Administration (NMPA) in September 2023. As a result,...
With influenza season well underway, vaccination campaigns are in full force in the northern hemisphere. In the UK, the National Health Service (NHS) has delivered...
In the midst of International Gaucher Disease Awareness Month, which is observed in October every year, GlobalData sheds light on a critical issue within the...
A promising dendritic cell (DC) therapy currently in clinical trials is displaying the potential to revolutionize the multiple myeloma treatment paradigm. If successful, its growth...
Artificial intelligence (AI) algorithms can analyze vast amounts of patient data, identify patterns and trends, and make predictions based on this information. This technology can...
Traditionally, the pharmaceutical landscape has been dominated by small molecules. In contrast to this dominance, biologics have become the leading molecule type within the solid...
In September 2023, Ionis Pharmaceuticals unveiled positive Phase III clinical data for olezarsen, a ligand-conjugated antisense (LICA) designed to inhibit apolipoprotein C-III (apoC-III). Phase III...
The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) focused licensing agreements from 2017-2022 and reached a peak of...
BeiGene became the first Chinese-origin pharma company to market a Programmed Cell Death Protein 1 (PD1) therapy for oncology indications in various global markets, beginning...
Cellipoint Bioservices entered an agreement with Diakonos Oncology in October 2023 for the development and manufacturing of DOC1021, an autologous dendritic cell (DC) vaccine. The...
With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market is expected to grow at...
Supernus Pharmaceuticals recently announced that it has resubmitted a New Drug Application (NDA) for its subcutaneous apomorphine infusion device (SPN-830) for the continuous treatment of...
The seasonal influenza-vaccinated population in the seven major markets (7MM*) is projected to increase from 270 million in 2022 to 284 million in 2032, with...
In the ever-evolving landscape of oncology, small-molecule drugs are carving a significant niche in lung cancer treatment. In 2015, AstraZeneca’s Tagrisso achieved landmark approval from...
The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in 2025 in the US and...
As the healthcare landscape undergoes transformation due to factors like aging populations, rising chronic diseases, and shifts in lifestyle choices, technology, particularly artificial intelligence (AI),...
Benzodiazepine-like Z-drugs have dominated the insomnia pharmacological treatment market for the past 30 years. However, due to their unfavorable side effect profile, there is a...
A novel diagnostic tool, the steatosis-associated fibrosis estimator (SAFE) algorithm, may revolutionize the early detection of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)....
Novo Nordisk's obesity medication Wegovy (semaglutide) will soon be accessible through the National Health Service (NHS) in England, albeit with limited supply. To maintain controlled...
The current treatment landscape for Fabry disease in China is completely dependent on enzyme replacement therapies (ERTs) developed by western companies like Sanofi (Fabrazyme) and...
September 26 marks World Contraception Day across the world. An essential gap in the realm of female contraception revolves around educating patients about the diverse...
The acquisition of Intercept Pharmaceuticals by the Italian pharmaceutical company Alfasigma became inevitable due to the failed development of Intercept's flagship asset, obeticholic acid, as...
The idiopathic pulmonary fibrosis (IPF) market is underserved with just two licensed pharmaceutical treatments which are available globally, Roche’s Esbriet/Pirespa (pirfenidone) and Boehringer Ingelheim’s (BI)...
Following the news that Japan’s health ministry has approved Eisai’s intravenous formulation of lecanemab, branded as Leqembi, for use in Alzheimer’s disease; Barbora Salcman, Neurology Analyst...
At the 2023 European Society of Cardiology (ESC) Congress, study results found that early initiation of Forxiga (dapagliflozin) failed to improve diuretic efficiency in hospitalized...
The diagnosed prevalent cases of heart failure (HF) in the seven major markets (7MM*) are set to register an annual growth rate (AGR) of 1.68%...
Following the news that Relmada Therapeutics’ antidepressant REL-1017 demonstrated rapid and sustained therapeutic effects in an open label, registrational Phase III trial (NCT04855760); Philippa Salter, Senior...
Genexine recently released positive interim findings from the Phase III clinical trial of GX-E4 (Efepoetin alfa) for anemia induced by chronic kidney disease (CKD) or...
Eli Lilly received approval for its dual glucagon-like peptide-1 receptor agonist (GLP-1)/gastric inhibitor polypeptide receptor agonist (GIP) therapy Mounjaro (tirzepatide) in August 2023 for use...
This week (18-22 September) marks Fungal Disease Awareness Week (FDAW) in the US, an annual event in which the Centers for Disease Control and Prevention...
Myasthenia gravis (MG) is an autoimmune and neuromuscular disease characterized by muscle weakness and fatigue. Currently, most of the first-line treatment options are off-label symptomatic...
CureVac, in collaboration with GSK, recently announced the advancement of its multivalent, modified mRNA seasonal influenza vaccine candidate into Phase II clinical trials. The interim...
While there are no marketed drugs for nonalcoholic steatohepatitis (NASH) in the EU or US, most NASH therapies in development primarily focus on treating patients...
World Sepsis Day is commemorated on the 13th of September every year to raise awareness about this life-threatening condition, resulting in at least 11 million...
The FDA granted an orphan drug designation (ODD) to Redx’s zelasudil (RXC007) in August 2023. Zelasudil is an oral, selective rho-associated coiled-coil containing protein kinase...
The latest results from a Phase II study highlight the potential of an all-oral combination therapy, featuring Bristol Myers Squibb's (BMS) cereblon E3 ubiquitin ligase...
There is a transformative shift taking place in the Crohn's disease (CD) treatment market, challenging AbbVie's Humira's long-standing dominance. Adalimumab biosimilars are reshaping the landscape,...
Amgen’s olpasiran, a small interfering RNA (siRNA), is making strides in reducing Lp(a) levels significantly in patients with cardiovascular disease. This is noteworthy as elevated...
Samsung Bioepis and Organon recently announced positive topline results from a Phase IV clinical trial of SB5, a biosimilar to the reference tumor necrosis factor...
The Biden Administration has released its highly anticipated list of 10 drugs selected for Medicare drug price negotiation under the Inflation Reduction Act. The list...
With the rise of mRNA-based treatments, the field of oncology is about to go through a big change. The global market for mRNA-based oncology therapies...
The diabetic macular edema (DME) market in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is set to...
Novo Nordisk and Eli Lilly achieved the highest year-on-year (YoY) revenue growth when compared to the top 20 pharmaceutical firms by sales during the second...
The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic...
Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo (RSVpreF) recently received FDA approval for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused...
There was a substantial backlash from major pharmaceutical trade associations and companies to the European Commission’s (EC) feedback initiative on the introduction of a pan-European...
Daewoong Pharmaceutical recently obtained approvals for its indigenous therapies—sodium–glucose linked transporter-2 (SGLT-2) inhibitor Envlo (enavogliflozin) and its metformin combination drug Envlomet—in South Korea. As prescription...
A US District Court’s decision to postpone the trial of Teva Pharmaceuticals for Medicare fraud, which was originally planned to take place in September, suggests...
August is observed as National Immunization Awareness Month (NIAM) in the US to highlight the importance of vaccines in preventing serious illness, complications, and death...
The diagnosed prevalent cases of Crohn’s disease (CD) in the eight major markets (*8MM) are projected to increase from 1.63 million in 2022 to 1.69...
The global pharma industry is bracing itself for more headaches in its most profitable market as US House Democratic health leaders introduce new legislation, which...
The potential for German Chancellor Olaf Scholz’s government to secure pro-pharmaceutical industry concessions related to the proposed overhaul of EU pharmaceutical legislation may have received...
Shanghai Junshi Biosciences supplemental new drug application (sNDA) for toripalimab, the company’s anti-PD-1 monoclonal antibody, in combination with axitinib for the first-line treatment of patients...
The prevalence of nonalcoholic steatohepatitis (NASH), a more advanced stage of nonalcoholic fatty liver disease (NAFLD), continues to increase. Following the receipt of a complete...
Following the news that the FDA granted approval for Sage Therapeutics and Biogen’s novel antidepressant Zurzuvae (zuranolone) for the treatment of postpartum depression (PPD) but...
The dyslipidemia market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) is forecast to increase at a...
ADC Therapeutics recently announced plans to discontinue the Phase II LOTIS-9 trial investigating the combination of Zynlonta and rituximab in unfit or frail previously untreated...
A promising shift towards the development of antibody-drug conjugates (ADC) for cancer treatment is taking place in the pharmaceutical industry. A recent look at the...
The loss of exclusivity of AbbVie’s Humira (adalimumab) has become a perfect scenario to test if the Biologics Price Competition and Innovation (BPCI) act in...
Following the news that Sumitomo and Otsuka’s ulotaront failed to meet the primary endpoints in the Phase III DIAMOND 1 and DIAMOND 2 trials, treating...
Janssen Pharmaceuticals recently announced its latest clinical trial results of JNJ-2113, the novel, first-in-class oral interleukin 23 receptor (IL-23R) antagonist peptide in adult patients with...
As the first obesity drug to be approved in Japan in the last three decades, Novo Nordisk’s Wegovy is expected to bring a substantial shift...
As artificial intelligence (AI) increasingly finds its way into healthcare, physicians recognize the true value of its advantages in clinical practice more prominently after successful...
On July 10, Iovance Biotherapeutics announced they received positive feedback from the FDA on the design of their Phase II IOV-LUN-202 study evaluating tumor-infiltrating lymphocyte...
May 2023 saw the world’s first approval of two respiratory syncytial virus (RSV) vaccines, Arexvy by GSK and Abrysvo by Pfizer. However, these vaccines not...
Artificial intelligence (AI) is increasingly becoming embedded in the provision of healthcare. Against this backdrop, 49% of healthcare industry professionals with prior AI experience showed...
India is emerging as a key destination for clinical trials due to its large, diverse population and liberalized regulatory landscape. Despite the increase in the...
The mergers and acquisitions (M&A) activity of well-capitalized pharmaceutical contract manufacturing organizations (CMOs) is set to continue over the coming years despite a challenging borrowing...
The infectious diseases market is forecast to grow at a compound annual growth rate (CAGR) of 5.7% between 2023 and 2029 to reach an impressive...
The Parkinson’s disease (PD) market across the seven major markets (7MM*) is poised to grow at a compound annual growth rate (CAGR) of 6.4% from...
Genentech recently announced positive results from its phase III trial, OCARINA II (NCT05232825), investigating the efficacy of Ocrevus (ocrelizumab) as a subcutaneous injection, administered twice...
As oncology diagnoses increase across the globe, immuno-oncology therapies have emerged as a novel treatment category, outside of chemotherapy and radiotherapy, that can help combat...
China is emerging as a key player in developing novel oncology therapies, particularly in treating non-small cell lung cancer (NSCLC). Kirsten rat sarcoma homolog (KRAS)...
Following the news that Eli Lilly published full results from its TRAILBLAZER-ALZ 2 (NCT04437511) study of anti-amyloid-beta (Aβ) monoclonal antibody (mAb), donanemab, in Alzheimer’s disease...
The atrial fibrillation (AF) market is forecast to decline at a compound annual growth rate (CAGR) of 1.3% from $14.53 billion in 2022 to $12.8...
The National Medical Products Administration (NMPA) has recently approved Innovent Biologics and IASO Bio’s CAR-T therapy equecabtagene autoleucel (Fucaso) for the treatment of relapsed and/or...
Japan’s Ministry of Health, Labour, and Welfare approved FluMist Quadrivalent in March 2023, marking the first approval of an intranasal vaccine in the country’s history....
BioCardia has recently completed the submission of CardiAMP Cell Therapy System to Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval for the indication of...
Approval to dramatically change CAR-T therapies landscape GlobalData forecasts Fucaso sales to reach $69 million in 2029 Manufacturing and logistical challenges may impact commercial...
Following the news that the FDA granted traditional full approval for Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb) Leqembi (lecanemab) as the treatment...
The burden of diagnosed incident cases of venous thromboembolism (VTE) in the 7MM* is expected to increase at an annual growth rate (AGR) of 1.50%...
Eli Lilly’s retatrutide garnered interest recently following the release of results, which set a record for percentage body weight loss in the obesity space. Retatrutide,...
Following the news that the ongoing 25th World Congress of Dermatology (WCD) in Singapore will cover a range of skin-related topics; Ramla Salad, Pharma Analyst...
Following the news that Amneal Pharmaceuticals received a complete response letter (CRL) from the FDA, concerning its new drug application for IPX203 (carbidopa/levodopa) as a...
AstraZeneca’s Soliris (eculizumab) was approved in China in June 2023 for the treatment of adults with refractory generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor...
Annovis Bio recently received a positive safety review for the Phase III trial of buntanetap in patients with early Parkinson’s Disease (PD) (NCT05357989) from the...
Following the news that BioXcel Therapeutics announced positive top-line results from TRANQUILITY II (NCT05271552), a Phase III study of Igalmi (dexmedetomidine sublingual film) for the...
The FDA has recently approved UCB’s subcutaneous formulation of rozanolixizumab-noli, branded as Rystiggo, for use in myasthenia gravis (MG). The approval of Rystiggo comes six...
At Digestive Disease Week (DDW) 2023, a comment was made following a presentation discussing the preliminary induction findings from QUASAR (NCT04033445), the Phase IIb/III trial...
Merck released topline data from a Phase IIa study (NCT04944992) in mid-June 2023, revealing that patients treated with MK-6024 (efinopegdutide) saw a 72.7% mean reduction...
The venous thromboembolism (VTE) market is set to grow at a compound annual growth rate (CAGR) of 2.6% from $3.6 billion in 2022 to $4.6...
The UK has recently announced a two-year pilot scheme aimed at tackling obesity, which has become a significant financial burden on the National Health Service...
The diagnosed prevalent cases of atrial fibrillation (AF) in the eight major markets (8MM*) are set to register an annual growth rate (AGR) of 2.16%...
When it comes to lung diseases, asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis might come to mind. One that may be less familiar...
Pfizer has received FDA approval for Talzenna, a combination therapy with Xtandi, as a treatment for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair...
Astellas Pharma recently filed new drug application (NDA) in Japan for zolbetuximab, a novel chimeric immunoglobulin G1 antibody highly specific for Claudin 18 isoform 2...
NewAmsterdam Pharma presented positive data from its Phase II ROSE2 trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy at...
The FDA’s Gastrointestinal Drugs Advisory Committee (GDAC) has recently voted against Intercept Pharmaceutical’s new drug application (NDA) for obeticholic acid (OCA) 25 mg oral tablets...
UCB recently announced the European Commission approval for Bimzelx (bimekizumab), its humanized monoclonal IgG1 antibody, which exerts simultaneous selective inhibition of interleukin 17A (IL-17A) and...
Following the news that the FDA has approved Argenx’s subcutaneous formulation of efgartimod alfa, branded as Vyvgart Hytrulo, for use in myasthenia gravis (MG); Barbora Salcman,...
In a study published in Science Translational Medicine, researchers from Nagoya University documented how Fusobacterium may play a key role in spurring the development of endometriosis after...
The healthcare industry continues to face the challenges such as persistent inflation in a post-COVID-19 world. Healthcare professionals (HCPs) believe that biosimilars could provide costs...
VALUE-Dx, a first-of-its-kind Innovative Medicines Initiative (IMI) project which aims to improve the use of antibiotics in community care settings, has recently released preliminary information...
Healthcare cost pressures have started easing in most of the countries in 2023, as physicians noticed a decline in the number of patients postponing or...
Injectafer recently secured approval in the US for improvement in exercise capacity in adults with symptomatic heart failure (HF). A significant number of chronic HF...
Alkem Laboratories Ltd and Lupin Ltd have recently launched the world’s first cetuximab biosimilar in India for the treatment of head and neck cancer (HNC)....
The recent rally in Eli Lilly’s market value, which made it to become the most valuable pharmaceutical company in the world, with a market cap...
Interim results from a recent study on influenza vaccine effectiveness (VE) estimations for the 2022/2023 season across six European countries has found VE to be...
The European Commission (EC) recently approved GSK’s novel vaccine, Arexvy, for the prevention of lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV)...
The global pharmaceutical industry is experiencing a profound transformation that will shape its future. By 2028, European pharmaceutical companies are poised to surpass their US...
On May 9, National Fentanyl Awareness Day was observed in recognition of the US opioid crisis. Accordingly, the development of non-opioid painkillers is experiencing a...
The increased response to International NASH Day (8 June) in 2023 demonstrates growing interest from both industry and public bodies in raising the awareness of...
Pharmaceutical giant Merck has filed a lawsuit in the US District Courts against the federal government, claiming it violates constitutional rights and undermines drug pricing...
The Alzheimer's disease (AD) market is projected to experience robust growth at a compound annual growth rate of 20.0% from $2.2 billion in 2020 to...
Pharmaceutical giant Merck has filed a lawsuit in the US District Courts against the federal government alleging that the drug pricing clauses of the Inflation...
The treatment paradigm for myelofibrosis (MF) – a rare type of blood cancer – is expected to experience marked transformation over the next decade in...
The market for ulcerative colitis (UC) is filled with a number of different treatment options, and the pipeline is relatively strong. Pfizer’s etrasimod is a...
The FDA recently announced the approval of Rinvoq (upadacitinib), AbbVie’s Janus kinase inhibitor (JAKi), to treat adults with moderately to severely active Crohn’s Disease (CD)...
Biotech company Alnylam Pharmaceuticals has filed a third patent lawsuit against Pfizer and Moderna, alleging unauthorized use of its proprietary lipid nanoparticle (LNP) vaccine delivery...
Novo Nordisk recently announced that the starter doses of Wegovy (semaglutide) would be limited in the US until September, in an effort to avoid supply...
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J), has recently released new data on Tremfya (guselkumab), a monoclonal antibody that targets IL-23 in adults...
Hefei Tianhui Biotechnology Co. Ltd. (HTIT) has recently submitted a marketing authorization application (MAA) in China for the world’s first oral insulin for type 2 diabetes...
Parkinson’s Disease (PD) is a complex, multi-system neurodegenerative disorder that affects movement control. Current treatments focus on the management of dopamine levels in the brain,...
At the 2023 annual congress of the European Heart Rhythm Association (EHRA 2023), new real-world data was presented by researchers from Hong Kong, demonstrating that...
Immunotherapy-focused biotech Immatics recently announced encouraging interim clinical data from one of the three cohorts of its Phase Ib trial evaluating its leading T-cell receptor-based...
The hematological disorders market is undergoing an impressive surge in sales, cementing its position as the fastest-growing therapy area for the second consecutive year. Notably,...
Servier Pharmaceuticals recently announced the European Commission (EC) approval of Tibsovo (ivosidenib), as a targeted therapy in two difficult-to-treat oncology indications, acute myeloid leukemia (AML)...
The cost of disease-modifying therapies (DMTs) for multiple sclerosis (MS) patients in the US has increased since 2020, placing an increasing financial strain on patients,...
Global market for FRα-targeted therapy in cancer is expected to increase from $3 million in 2022 to $921 million in 2029, with a CAGR...
Sanofi has successfully completed the Phase I trial for its von Willebrand disease (vWD) therapy, efanesoctocog alfa (BIV001), a novel antihemophilic factor recombinant fusion protein...
Artificial intelligence (AI) has been fundamental to the development of Novavax’s COVID-Influenza Combination (CIC) vaccine reflecting a wider industry trend for increased usage of AI...
Immuno-oncology (IO) agents have transformed the oncology landscape in the last decade, particularly immune checkpoint inhibitors (ICIs) in solid tumor settings and chimeric antigen receptor...
Farxiga’s (dapagliflozin) recent approvals will help a broader range of patients with heart failure (HF) in the US. Resultantly, AstraZeneca is expected to see a...
Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a growth of 23% in its sales to $12.5 billion in 2023, consolidating its position...
Ultragenyx has terminated its Phase I/II trial for pipeline candidate UX053, a non-vaccine mRNA therapeutic for glycogen storage disease type III, also known as Cori’s...
National Lipid Day, observed on 10 May every year creates awareness of dyslipidaemia, says GlobalData, a leading data and analytics company. Dr Shireen Mohammad, Cardiovascular &...
US-based Immunogen recently announced positive top-line data from their Phase III MIRASOL trial evaluating Elahere (mirvetuximab) for the treatment of platinum-resistant ovarian cancer. The company...
Bristol Myers Squibb (BMS) recently announced the European Commission approval for Sotyktu (deucravacitinib), its first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for adults with...
While some believed that leaving the EU would bring opportunities for the UK and its life sciences sector, three years on since the UK departed...
The US Food and Drug Administration (FDA) has recently granted accelerated approval for Biogen's Qalsody (tofersen), a drug that targets a specific group of amyotrophic...
Following the news that Japan-based Astellas Pharma entered into a definitive agreement to acquire US-based biopharmaceutical company Iveric Bio for $5.9 billion to create a...
Safety data on AbbVie’s ABBV-951 (foslevodopa/foscarbidopa) and NeuroDerm’s ND0612 (levodopa/carbidopa) for the treatment of Parkinson’s disease (PD) were showcased at the American Academy of Neurology...
Over 95% of the ongoing Phase III trials in the US featuring an immune checkpoint modulator involve either a PD-1 or PD-L1-targeting drug. Given the...
In the race to combat cancer, the field of oncology has experienced strong growth in recent years. With forecasts pointing towards a continued upward trend,...
UK healthcare professionals (HCPs) believe that Brexit had exacerbated the National Health Service (NHS) staffing crisis, according to a survey by GlobalData, a leading data...
More than half of the surveyed healthcare industry professionals indicated that their sentiment on the impact of Brexit on the UK's healthcare sector became more...
Cytokinetics, a San Francisco-based biotechnology company, is set to wind down the Phase III trial of its amyotrophic lateral sclerosis (ALS) pipeline drug, reldesemtiv, as...
German drugmaker Bayer recently announced that it will shift the focus of its drug research away from women’s health to four core therapeutic areas: oncology,...
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder caused by a mutation in lipoprotein lipase. FCS is characterized by the body’s inability to...
Cipla holds a prominent position in the top five therapy areas in India, except for the anti-diabetes and gastrointestinal segment. Against this backdrop, the Indian...
Obesity is a major public health concern with a significant impact on morbidity, mortality, and healthcare costs worldwide. The obesity therapeutics market is expected to...
World Malaria Day is commemorated on 25 April every year to recognize the global efforts to increase public awareness and eradicate malaria. This year’s theme...
The FDA recently rejected Eli Lilly’s biologic license application (BLA) for their anti-interleukin (IL) -23, mirikizumab, which is in development for the treatment of ulcerative...
Navigating the ever-increasing challenges of antimicrobial resistance (AMR), which occurs when bacteria, viruses, fungi, or parasites no longer respond to antimicrobial treatment, has been a...
The ulcerative colitis (UC) market across the eight major markets (8MM*) is forecast to grow at a compound annual growth rate (CAGR) of 2.8% from...
The market for multiple sclerosis (MS) disease-modifying therapies (DMT) is set to experience moderate growth across the seven major markets (7MM*) from $18.9 billion in...
Sanofi (India) has recently received marketing approval by the Central Drugs Standard Control Organization (CDSCO) for soliqua (Insulin glargine and lixisenatide recombinant fixed dose combination)...
The goals of treatment for chronic heart failure (HF) are to relieve symptoms, prevent HF-associated hospitalizations, slow disease progression, and improve survival. The current therapies...
Arbutus Biopharma and Genevant Sciences have recently brought a patent lawsuit against Pfizer and BioNTech in the US federal courts, surrounding the use of the...
The World Health Organization (WHO) recently revised its vaccine guidance following a meeting of the agency’s Strategic Advisory Group of Experts on Immunization (SAGE). SAGE...
With the advent of novel disease-modifying therapies (DMTs), the future of Alzheimer’s disease (AD) diagnosis and management has been a key theme at the AD/PD...
Pharma manufacturers will be challenged by the effects of high inflation and declining FDA drug approvals in 2023. Pharmaceutical companies have a high tendency to...
Biogen/Eisai's newly approved drug, Leqembi (lecanemab) gained FDA approval in January 2023 for the treatment of Alzheimer's disease. Leqembi is currently pending approval in the...
The market for obesity treatments across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is projected to grow...
Antibody-drug conjugates (ADCs) are the novel class of targeted drugs that have been extensively studied in recent years as potential treatment options either as monotherapies...
The late-breaking data on AbbVie’s Skyrizi in plaque psoriasis (PsO) that was presented at the recently concluded American Academy of Dermatology (AAD) Annual Meeting is...
Following the news that Galapagos presented new efficacy and safety data of Jyseleca (filgotinib) 200mg (FIL200) therapy for the treatment of patients with ulcerative colitis...
HSBC’s acquisition of Silicon Valley Bank UK following the collapse of its parent company Silicon Valley Bank may result in new opportunities for biopharmaceutical companies,...
Following the news that the National Institute for Health and Care Excellence (NICE) has recommended the first new treatment for incurable cervical cancer in 14...
Regenerative medicines in early-stage development have seen a change in drug targets compared to therapies in late-stage development. Early-stage therapies are now focused on vascular...
Likang Life Sciences has recently been granted implied approval by the National Medical Products Administration (NMPA) for the clinical trial of its innovative personalized neoantigen-targeted...
Pfizer recently announced the acquisition of Seagen, a US-based biotech with four marketed oncology medicines and a rich pipeline, for $43 billion. If completed, the...
At the European Crohn´s and Colitis Organisation (ECCO), Prometheus Bioscience presented results from its Phase 2a APOLLO-CD clinical trial of PRA023 in Crohn’s Disease (CD)....
Dr. Reddy's Laboratories (DRL) has been strategizing to become a top company in the Indian pharmaceutical market. The company’s focus is on building strong brands...
World Tuberculosis (TB) Day is observed annually on 24 March to raise awareness about TB and efforts to end the global epidemic. TB is reportedly...
Following the news that AbbVie received a complete response letter (CRL) from the FDA, concerning its new drug application for ABBV-951 (foscarbidopa/foslevodopa) to treat motor...
India is preparing to include human papillomavirus (HPV) vaccines as part of the government driven public immunization program popularly known as the “Universal Immunization Program...
Following the FDA’s announcement to review Intercept Pharmaceuticals’ resubmission of its new drug application (NDA) for obeticholic acid (OCA) in patients with pre-cirrhotic liver fibrosis...
At the 72nd annual American College of Cardiology (ACC) meeting, new real-world data was presented from the XARENO study demonstrating that the new oral anticoagulant...
Daiichi Sankyo and AstraZeneca recently announced positive results from the ongoing DESTINY-Pan Tumor02 Phase II study, which included 268 patients with biliary tract, bladder, cervical,...
Esperion Therapeutics’ non-statin therapy “bempedoic acid” has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant patients in the cholesterol lowering...
At this year’s American College of Cardiology (ACC) Scientific Session, Johnson & Johnson has presented positive results from “A DUE” analyses of Opsynvi (macitentan and...
The diagnosed prevalent cases of systemic lupus erythematosus (SLE) in the seven major markets (7MM*) are projected to increase from 0.55 million in 2021 to 0.58...
Given the large market potential and high unmet need for new respiratory syncytial virus (RSV) therapies, drug developers have been focused on new vaccine and...
Eli Lilly recently announced that it will reduce the price of its insulin Humalog by 70% in the US and cap the out-of-pocket cost for...
The diagnosed prevalent cases of ulcerative colitis (UC) in the eight major markets (*8MM) are projected to increase from 1.9 million cases in 2021 to...
Merck recently unveiled the Phase II clinical data for MK-0616, an investigational oral cholesterol-lowering drug, revealing that it significantly reduced low-density lipoprotein (LDL) cholesterol in...
Clene has recently presented updated trial results for its Visionary MS Phase II trial, in which its lead pipeline candidate, CNM-Au8, is being investigated as...
Inflammatory bowel disease (IBD) refers to two autoimmune diseases that cause intestinal inflammation: Crohn’s disease (CD) and ulcerative colitis (UC). The market for the UC...
Galapagos’ Jyseleca (filgotinib maleate), the Janus kinase inhibitor (JAKi) being evaluated as a treatment for adults with moderate to severe Crohn’s Disease (CD), failed to...
The current treatments for Alzheimer’s disease (AD) consist mostly of medications that are aimed at treating the symptoms of the disease. A novel disease-modifying therapy...
The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market comprises a wide range of medications, from anti-malarials to immunosuppressive agents, which are largely genericized...
Terran Biosciences has recently published a PCT patent application for unnamed orally administered novel psilocin prodrugs. The biotech platform company joins a growing number of...
Following the news that Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) and docetaxel has been approved by Japan’s Ministry...
The Central Drugs Standard Control Organisation (CDSCO) approval of AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin heralds a new era of treatment for...
The diabetic neuropathic pain (DNP) market across the seven major markets (7MM*) is poised to grow at a compound annual growth rate (CAGR) of 6.0%...
Pfizer and BioNTech’s COVID-19 vaccine, Comirnaty, witnessed a record demand in 2022 with forecast sales of $37 billion. The vaccine is expected to maintain the...
The diagnosed prevalent cases of obesity and overweight combined in the seven major markets (7MM*) are projected to increase at an annual growth rate (AGR)...
On February 13, it was revealed that Novo Nordisk’s Wegovy (semaglutide) would be available on high-street pharmacies in the UK this spring. Wegovy is of...
The National Medical Products Administration (NMPA) of China has conditionally approved two homegrown oral drugs Simcere Pharmaceutical’s Xiannuoxin and Shanghai Junshi Biosciences' Mindevir for the...
Moderna recently confirmed that its Phase I/II study examining candidate mRNA-3927 is progressing. It also shared that data showed a decrease in the number of...
February is National Heart Month, and heart health is increasingly important globally with rising cases of heart disease. Heart disease refers to several different types...
The FDA recently granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and...
Following the enrollment of the first patient in Bayer’s Phase III OCEANIC-AF clinical trial of asundexian, a potential anticoagulant for stroke prevention in atrial fibrillation...
Rising costs forced patients to postpone or stop treatments in 2022 and it will take years for the conditions to improve to get the backlogs...
4D Molecular Therapeutics (4DMT), the California-based biotechnology company focused on developing gene therapies for rare and cardiovascular, pulmonary, and ophthalmic diseases, has recently been issued...
A genome-wide association study (GWAS) published in the Journal of Clinical Oncology has identified a potential association between a genetic variant, ROBO2, and anthracycline-related cardiomyopathy...
The number of blood cancer patients receiving CD19-directed chimeric antigen receptor T-cell (CD19 CAR-T) therapies is set to boom over the next decade from approximately...
Ionis Pharmaceuticals has recently received the US FDA Fast Track designation for its investigational therapy, olezarsen, in patients with familial chylomicronemia syndrome (FCS). Olezarsen is...
Despite the continued success of prophylactic vaccines such as Pfizer/BioNTech’s messenger RNA (mRNA) vaccine Comirnaty and spikes in COVID-19 case numbers over the winter, prophylactic...
In recent years, there has been a steady increase in the number of agents approved to treat inflammatory bowel diseases (IBD), which has provided physicians...
It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5 billion in 2022. However, increasing competition from Pfizer’s Comirnaty, Novavax’s Nuvaxovid,...
There are currently no approved therapies available for Fragile X Syndrome (FXS), with prescribed treatments consisting exclusively of off-label drugs that target individual symptoms of...
Following the launch of Amgen’s Amjevita (adalimumab-atto), the first biosimilar to AbbVie’s cash-cow immunology biologic therapy, Humira (adalimumab), in the US on 31 January; Vinie Varkey,...
Inflammatory bowel disease (IBD) refers to two autoimmune diseases that cause intestinal inflammation: Crohn’s disease (CD) and ulcerative colitis (UC). The market for the UC...
The FDA has recently granted expanded approval for BeiGene’s oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) for patients with chronic lymphocytic leukemia (CLL) or...
The market for acute lymphocytic leukemia (ALL), the most commonly diagnosed form of leukemia, is expected to see strong growth at a compound annual growth...
Artificial Intelligence (AI) and Big Data will be the two most impactful technologies for the pharmaceutical industry for the fourth year in a row in...
Takeda's Exkivity (mobocertinib) is the first and only targeted therapy to be approved for locally advanced or metastatic epidermal growth factor receptor (EGFR) exon 20...
Intercept Pharmaceuticals’ obeticholic acid could be first drug to be approved for NASH, says GlobalData Following FDA’s acceptance for Intercept Pharmaceuticals’ resubmission of its new drug...
Omicron lineages BA.5.2 and BF.7 account for 97.5% of all local infections in China, according to the Chinese Center for Disease Control and Prevention. With...
Following Versanis Bio’s recent announcement that enrolment had begun for Phase IIb trial BELIEVE on bimagrumab (BYM338); Sara Reci, Pharma Analyst at GlobalData, a leading data...
89bio’s pegazofermin has potential to become one of the major players in the dyslipidemia space if it is successful in Phase III clinical trials, says...
The pharmaceutical industry is considered to be one of the most stable sectors even when pandemics, economic or geopolitical crises hit markets. However, even the pharmaceutical industry is not...
Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval...
Following the news that scientists at Cedars-Sinai have successfully mapped the cellular changes linked to endometriosis; Amy Murray, Healthcare Analyst at GlobalData, a leading data and analytics...
Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple ‘me-too’, generic and biosimilar drugs entering the market. Growth will be primarily driven...
The cardiomyopathies market in the 68M* is set to grow from $3.07 billion in 2021 to $9.63 billion in 2031 at a compound annual growth...
The FDA’s recent approval of TG Therapeutics’ Briumvi (ublituximab) against relapsing forms of multiple sclerosis (MS) is welcome news for the company after suffering a...
Cardiovascular diseases (CVDs) continue to be the leading cause of death globally, with China being no exception. As domestic companies are mostly involved in providing...
Genomics will continue to play a significant role in helping to understand, prevent, and treat diseases throughout 2023. Coupled with continuous advancements in sequencing and...
The biopharmaceutical industry has long been labelled as recession-proof, with stable demand for medicines and new treatment options acting as a protective barrier. Nevertheless, inflation, coupled...
While the treatment options for multiple sclerosis (MS) patients are growing each year with the approval of new agents, all of the currently marketed treatments...
China is expected to record the highest diagnosed prevalence of non-alcoholic fatty liver disease (NAFLD) in 2029, representing 44% of cases within the 16 major...
A relatively novel class of drugs called bispecific T-cell engagers (BiTEs) present a serious threat to the market position of Bristol Myers-Squibb’s Abecma (ide-cel) for...
The congenital fibrinogen deficiency (CFD) market is forecast to increase from $673 million in 2021 to over $800 million in 2031 at a compound annual growth...
Amgen’s AMG-133* has the potential to address a key unmet need for drugs that reduce patient burden among patients with obesity, says GlobalData, a leading...
The pulmonary arterial hypertension (PAH) market in the seven major markets (7MM*) is expected to increase from $4.6 billion in 2019 to $7.5 billion in...
Despite the growing demand for novel therapeutics to treat Alzheimer’s disease, just one innovator drug has been approved in the last decade by the UK’s...
The autism spectrum disorder (ASD) market is expected to grow from $985.5 million in 2021 to $4.0 billion by 2031 across the seven major markets...
Following the news that AbbVie’s Vraylar (cariprazine) gained approval from the FDA for the adjunctive treatment of major depressive disorder (MDD) in adults; Pippa Salter, Senior Neurology Analyst...
Historically, therapeutic cancer vaccines have demonstrated minimal efficacy. However, for the first time, an anti-cancer vaccine has shown significant promise in a clinical trial. The...
The current diabetic neuropathic pain treatment paradigm includes many established analgesics that provide symptomatic relief. However, as these therapies do not target the pathophysiological mechanisms...
Small molecule approvals for rare diseases in China recorded a staggering 300% growth from just 3 to 12 between 2019 and 2022 due to swift...
Three of the 20 drugs currently being developed for primary progressive multiple sclerosis (PPMS) are now in Phase III of development, according to leading data...
Recently, the UK’s Medicines, and Healthcare Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Sanofi & Regeneron’s Dupixent,...
China initiated a 10-year “Made in China 2025” plan in 2015 as part of a strategy to reduce dependence on foreign technology and emerge as...
Following the news that the first patient in the UCL Great Ormond Street Insititute of Child Health’s (GOSH) Phase I TvT CAR7 trial to treat...
According to a survey by GlobalData, 50% of healthcare industry professionals would prioritize artificial intelligence (AI) among other emerging technologies for their investments in the...
In a clear shift away from its long-held stringent zero-COVID policy, China has recently relaxed rules that contained the spread of the virus but impacted...
Following the news that, amid rising cases and deaths nationally, antibiotics could be administered prophylactically in UK schools with cases of streptococcus A (Strep A); Fiona...
Novo Nordisk announced on 4 November 2022, that they had a witnessed a growth in the sales of Ozempic (semaglutide), which is indicated for type...
Following the news that Merck is to acquire Imago Biosciences, a clinical-stage biotech developing the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for the treatment of...
A surge in the cannabinoid drug pipeline has led to cannabinoid receptors becoming the most popular target in preclinical development this year, says GlobalData. However,...
Significant changes in the treatment landscape of diffuse large B cell lymphoma (DLBCL), the most common form of non-Hodgkin’s lymphoma, has led to an explosion...
As cancer treatment is evolving globally, the regular approach of one-size-fits-all is being challenged with precision medicine, a concept that involves genetic screening of the...
There are currently no messenger RNA (mRNA) non-vaccine therapeutics on the market. However, this landscape will reach a total of five marketed products by 2028,...
China has the world’s highest prevalence of type 2 diabetes (T2D) population. The recent approval of Hua’s first-in-class diabetes drug in China in collaboration with...
According to a GlobalData survey, 39% of healthcare industry professionals globally expect to see a decrease in the amount that is being invested in emerging...
Luye Pharma’s pipeline asset LY03010, a once-monthly, long-acting injectable (LAI) form of paliperidone, has achieved the primary endpoint in a pivotal trial and demonstrated comparable...
Following the news that the National Institute of Health and Care Excellence (NICE) has agreed to update its guidelines on endometriosis diagnosis and surgical management...
The release of encouraging interim results from two Phase II trials of LUM-201 has enabled Lumos Pharma to edge closer towards its goal of bringing...
Following the news that Merck reported positive top-line Phase III clinical trial results for its pulmonary arterial hypertension (PAH) pipeline drug, sotatercept; Kaya Olczak, Healthcare Analyst...
Following the news that Arcutis Biotherapeutics announced that its roflumilast met its main endpoints in the Phase III trial INTEGUMENT-1 (NCT04773587) for atopic dermatitis (AD). Ramla...
One of the leading theories for the cause of Alzheimer’s disease (AD) is the collection of abnormal amyloid plaques, a collection of misfolded amyloid A4 beta...
Despite a number of barriers and complications for autologous agents, there are a total 44 CAR-T* therapies in the pipeline for chronic lymphocytic leukemia (CLL),...
Following the news that Roche’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), gantenerumab failed to significantly slow clinical decline in patients with early Alzheimer’s disease (AD)...
Despite plagued with supply issues over the past one year, Novo Nordisk’s glucagon-like peptide-1 (GLP-1) franchise—including Rybelsus, Saxenda, Ozempic, and Wegovy—enjoyed a strong performance. Against...
Anti-itch agents are becoming more prominent in the atopic dermatitis (AD) therapeutic space as pruritis (itchy skin) is an integral symptom, affecting all patients regardless...
Following the news that Insilico Medicine has signed a billion-dollar, multi-target artificial intelligence (AI) drug discovery deal with Sanofi; Urte Jakimaviciute, Senior Director of Market Research...
A successful digital transformation often requires thorough planning, adequate funding, talents, and organizational adaptability. However, the COVID-19 pandemic acted as a catalyst for the healthcare...
The healthcare industry is undergoing constant changes resulting from a range of issues from declining profit margins to stringent regulatory and legislative requirements. Against this...
Atypical hemolytic uremic syndrome (aHUS) is an extremely rare chronic genetic disease with very limited treatment options in Japan. Against this backdrop, the entry of...
A total of 58% healthcare industry professionals globally believe that digital transformation initiatives—involving the implementation of emerging technologies such as artificial intelligence (AI), big data,...
COVID-19 resurgence in China is a great concern globally due to the presence of two new Omicron sub-variants—BF.7 and BA.5.1.7, as they are highly infectious...
Following the news that the Phase III pivotal SIERRA trial investigating Actinium’s targeted therapy Iomab-B (iodine i 131 apamistamab) in patients aged 55 years or...
Monoclonal antibodies (mAbs), which are emerging as promising disease-modifying treatments for Alzheimer’s disease (AD), come with significant challenges associated with their accessibility. The technology to...
Clarity Pharmaceuticals, an Australia-based clinical-stage radiopharmaceutical company, has successfully recruited and treated its first patient in the Phase I/II theranostic trial evaluating 64Cu/67Cu SAR-bisPSMA theranostic...
As a result of the COVID-19 pandemic, demand significantly increased for the manufacture of sterile injectable drugs, due to the extensive outsourcing of vaccine production...
Following the news that Roche has issued a voluntary recall of its Susvimo ocular implant due to manufacturing problems with the device; Vinie Varkey, Healthcare Analyst...
Minerva Neurosciences receiving a refusal to file letter from the Food and Drug Administration (FDA) regarding its new drug application for roluperidone for the treatment...
The European Commission’s (EC) authorization of Eli Lilly’s Mounjaro (tirzepatide) for treating type 2 diabetes (T2D) is of paramount interest to patients as the drug...
Late-stage pipeline therapies that are currently in development for treating dry eye syndrome (DES) reveal that drug developers are exploring a broad set of mechanisms...
Following the news that influenza cases are rising in the US and the UK; Emily Martyn, MPH, Pharma Analyst at GlobalData, a leading data and analytics...
Following the news that Myovant Sciences has rejected a takeover bid from its majority shareholder, Sumitomo Pharma; Amy Murray, Healthcare Analyst at GlobalData, a leading data...
Tenax Therapeutics’ announcement of a delay in its Phase III trial for its oral imatinib drug, TNX-201, in the treatment of pulmonary arterial hypertension (PAH),...
As a result of new therapies being introduced to the schizophrenia market and an increase in the prevalent patient population, its value is expected to...
Trends in the growth of autism spectrum disorder (ASD) cases are inconsistent worldwide, according to research by GlobalData, with countries such as the US seeing...
Due to the growing popularity of new competing therapies for acute migraine treatment, novel reformulations of dihydroergotamine (DHE) such as Satsuma Pharmaceutical’s lead product STS101 and Pulmatrix’s...
Since the onset of the COVID-19 pandemic, multiple new variants with enhanced transmissibility and increased virulence have emerged, causing repeated surges in case numbers and...
Following the news that TauRx Therapeutics’ oral anti-tau product, hydromethylthionine mesylate (HMTM), was found to be effective in improving cognition in patients with early Alzheimer’s...
Following the news that Brazil’s first-round elections ended inconclusively, with left-wing frontrunner Luis Inácio Lula da Silva securing 48.4% of the vote—less than the 50%...
Aucentra Therapeutics recently initiated a Phase II trial of auceliciclib in combination with temozolomide for recurrent or newly diagnosed glioblastoma patients in Australia. Auceliciclib is...
Recently published findings from researchers at the Feinstein Institute in Manhasset, New York, supporting the use of single-cell RNA sequencing in diagnosing endometriosis could help...
Following the unprecedented success of mRNA COVID-19 vaccines, pharma companies are working towards further developing the technology to capitalize on the tremendous growth opportunities. Recently,...
Following the news that Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb) lecanemab was effective in reducing cognitive clinical decline among patients with early...
Great strides will be made in the treatment of atopic dermatitis (AD) in children in the next decade, according to GlobalData, which notes the presence...
Following the news that Sanofi and Regeneron presented analyses from the LIBERTY AD PRESCHOOL (NCT03346434) study of interleukin (IL)-4/13 inhibitor, Dupixent (dupilumab), at the European...
The diabetic macular edema (DME) market in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is set to...
Bayer has recently launched its first-in-class non-steroidal, selective mineralocorticoid receptor antagonist, Kerendia (finerenone), for patients with chronic kidney disease (CKD) associated with type 2 diabetes...
Brain stroke (Acute Ischemic Stroke (AIS)) is the fourth leading cause of death, as well as the fifth leading cause of disability in India. Lack...
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention (pre-exposure prophylaxis (PrEP) and treatment of...
Contrary to some media claims, neither CanSino Biologics’ Convidecia Air nor Bharat Biotech’s BBV154 are the first inhaled COVID-19 vaccines to market, according to GlobalData,...
Increasing inflation and the cost of living crisis, fueled by the COVID-19 pandemic and geopolitical events such as the ongoing Ukraine conflict, continue to challenge...
Last year was a positive year for biopharmaceutical companies, particularly those with COVID-19 vaccines. The majority of the top 20 innovative biopharmaceutical companies reported an...
Following the news that the FDA has approved both the Pfizer/BioNTech and the Moderna omicron-specific booster; Emily Martyn, MPH, Pharma Analyst at GlobalData, a leading data...
Human epidermal growth factor receptor 2-negative/hormone receptor-positive breast cancer (HER2-/HR+ BC) is one of the most prevalent subtypes of BC in China. Historically, foreign companies...
Injectable drugs and their packaging requirements are providing ample opportunities for packaging firms to supply big pharmaceutical companies, given the volume of vaccines, including the...
Diversity within pharmaceutical studies continues to be a problem across a wide variety of clinical trial sectors, with industry sponsors and pivotal studies particularly experiencing...
Bharat Biotech has recently completed the Phase III trials of its COVID-19 intranasal vaccine BBV154 and submitted the data to the Drug Controller General of...
When it comes to lung diseases, asthma, COPD*, and cystic fibrosis might come to mind. One that may be less familiar is bronchiectasis**, however, just...
People living with the lung condition bronchiectasis can expect three new treatments to become available in the next ten years, according to GlobalData. However, the...
With rising inflation and a cost-of-living crunch in the US, the passing of the $740 billion Inflation Reduction Act of 2022, which aims to control...
Based on an interim futility analysis of its global Phase III trial, REALM-DCM, Pfizer has ceased clinical trial development of its therapy emprumapimod. The drug...
Following the news that Axsome Therapeutics’ Auvelity (dextromethorphan + bupropion) has been approved by the FDA for the treatment of major depressive disorder (MDD) in...
Biotech startups in India, which are focused on developing cell/gene (including CAR-T) therapies for the management and treatment of certain life-limiting illnesses that significantly affect...
Alnylam Pharmaceuticals and its partners have identified rare mutations in the INHBE gene that is expressed in the liver and related to a lower waist-to-hip...
Karuna Therapeutics recently announced positive topline results from the Phase III EMERGENT-2 trial of KarXT (xanomeline + trospium chloride) in acutely psychotic hospitalized adult patients with...
The ulcerative colitis (UC) treatment pipeline is flush with promising therapies, with over 13 agents in either Phase IIb or III development. Many of these...
On August 2, the Food and Drug Administration (FDA) announced the approval of Coherus’ Cimerli (ranibizumab-eqrn; FYB201), which demonstrated efficacy and safety results parallel to...
Long-acting injectable (LAI) formulations of antipsychotics to treat patients diagnosed with schizophrenia remain under-utilized in the seven major markets (7MM*) due to the resistance surrounding...
The diagnosed prevalent cases of diabetic macular edema (DME) in the seven major markets (*7MM) are projected to increase from 1.7 million cases in 2021...
Improved treatments options for irritability and novel treatments for core symptoms of autism spectrum disorder (ASD) are the most important unmet needs in the ASD...
The diagnosed prevalent cases of primary myelofibrosis (PMF) in China are expected to increase by 34.8% between 2021 and 2031, according to GlobalData, a leading...
Following the results from Apellis Pharmaceuticals’ Phase III ‘DERBY and OAKS’ study of APL-2 and the post hoc analysis from IVERIC BIO’s Phase III GATHER...
Following the news that the World Health Organization (WHO) has declared the monkeypox outbreak a Public Health Emergency of International Concern (PHEIC); Nancy Jaser, PharmD/MBA, Pharma...
The 12-month diagnosed prevalent cases of schizophrenia are expected to increase from 3.40 million in 2021 to 3.49 million in 2031 across the seven major...
The age-related macular degeneration (AMD) market in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is set to...
AbbVie/Regenxbio recently presented data from a Phase II study of its lead diabetic retinopathy (DR) and neovascular age-related macular degeneration (nAMD) gene therapy candidate, RGX-314,...
SK Bioscience has recently announced that South Korea’s first homegrown COVID-19 vaccine ‘SKYCovione’ adjuvanted with GlaxoSmithKline’s pandemic adjuvant has been authorized by the Korean Ministry...
Although many pharmaceutical companies have launched therapeutic drugs for COVID-19, Pfizer’s Paxlovid takes the top spot as market leader. The drug has expected peak sales...
Research by GlobalData has revealed that the majority of colorectal cancer (CRC) cases were detected at stages I and II in 2021, despite the patient...
Diagnosed prevalent cases of age-related macular degeneration (AMD) in the seven major markets (7MM*) combined is expected to increase from 33.66 million cases in 2021...
Cell therapies are among the most researched treatment types for blood cancer and the product pipeline is oversaturated, with GlobalData revealing that there are over...
Artificial Intelligence (AI) and blockchain stand out as the technologies poised to best support the optimization of electronic health records (EHRs), according to GlobalData, a leading data...
The COVID-19 pandemic has overtaken the existing health concerns such as cancer, diabetes, and cardiovascular diseases to become one of the major contributors to the...
Ashvattha Therapeutics has recently presented the safety data from a Phase 1 study of its lead diabetic macular edema (DME) candidate D-4517.2 at the Association...
The Drug Controller General of India (DCGI) has recently approved Pune-based Gennova Biopharmaceuticals’ two-dose mRNA COVID-19 vaccine ‘GEMCOVAC-19’ for emergency use in adults aged 18...
3 million cardiomyopathy cases expected in the US by 2031, 83% of total cases in the 7MM Lack of epidemiology data and poor lifestyle...
Due to its ability to rapidly assimilate big data from biomedical databases, artificial intelligence (AI) is being increasingly used to enhance computer-aided drug design. This...
The adoption of electronic health records (EHR) is set to bring a number of benefits for patients, healthcare professionals, and healthcare systems, as they have...
It is an exciting time within the schizophrenia market as numerous monotherapies and adjunctive therapies are being developed to address some of the most important...
With rapidly increasing worldwide prevalence, Alzheimer’s disease (AD) has been identified as a major global health threat by the international medical community. However, June was...
Venture financing deal value for US-headquartered biotech companies decreased by 46% in Q1 2022 compared to Q1 2021, according to GlobalData. The leading data and...
The biotech venture financing gap between Europe and the US is growing, with Europe on average receiving five times less per quarter compared to its...
The cardiomyopathies market is set to grow from $1.6 billion in 2021 to $5.2 billion in 2031 across the seven major markets (7MM*) at a compound annual...
Following the news that the Food and Drug Administration (FDA) has denied marketing approval for Spero Therapeutics’ tebipenem Hbr; Nancy Jaser, PharmD/MBA, Pharma Analyst at GlobalData,...
Gut health is linked to diseases ranging from cancer, diabetes, and depression 43% of microbiome-targeting therapies for infectious diseases are being investigated in Clostridioides difficile infections...
The Food and Drug Administration’s (FDA) approval for Sanofi and Regeneron’s interleukin (IL)-4/13 inhibitor, Dupixent (dupilumab), for the treatment of children ages 6 months to...
There is a high level of unmet medical needs in the Osteoarthritis (OA) market such as the lack of disease-modifying OA drugs (DMOADs) and the...
Due to the heterogeneity of bronchiectasis as well as the complex pathophysiology of the disease, the current bronchiectasis market suffers from a lack of disease...
With strong results from its SURPASS program for gastric inhibitory peptide/glucagon-like peptide-1 receptor (GIP/GLP-1) dual agonist Mounjaro (tirzepatide) for the treatment of type 2 diabetes...
In a huge win for GSK, it is highly likely that the company’s newly acquired momelotinib will become the new standard of care for myelofibrosis...
Serum Institute of India’s (SII) Cervavac—a quadrivalent human papillomavirus (qHPV) vaccine— is likely to be the first indigenous qHPV vaccine to be approved in India,...
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma is not yet available in China. However, the China National Medical Products Administration (NMPA) has recently...
The Drugs Controller General of India (DCGI) recently approved Biological E.’s Corbevax vaccine as the first heterogeneous COVID-19 booster vaccine in India for adults above...
The National Medical Products Administration (NMPA) of China has recently approved CStone Pharmaceuticals’ sugemalimumab (Cejemly) to treat patients with stage III non-small cell lung cancer...
Out of 16 markets worldwide*, India saw the third-highest rise in total HER2+ breast cancer cases, according to GlobalData. The leading data and analytics company...
Preclinical research for Oxurion NV’s THR-687 was presented at the Association for Research in Ophthalmology (ARVO) last month, forecasting its promising potential within the DME...
Following the announcement of WatchOS 9 during Apple’s 2022 WWDC event; Ardit Ballhysa, Technology Analyst at GlobalData, a leading data and analytics company, offers his view: “This...
Following the news that researchers from Washington State University have developed a smart pacifier to monitor newborn infants; Alexandra Murdoch, Medical Device Analyst at GlobalData, a...
The news that the largest outbreak of monkeypox in Europe is currently ongoing, with over 100 cases confirmed in over a dozen non-African countries, has...
Biohaven’s migraine nasal spray zavegepant is set to generate annual sales of $206.8 million in the US following the potential approval of its NDA*, which...
Zydus Lifesciences launched a first-in-class oral, non-statin lipid-lowering drug, bempedoic acid, under the brand name Bemdac, for the first time in India in May 2022....
Bavarian Nordic has recently announced an exclusive license and supply agreement with China’s Nuance Pharma to develop and commercialize their candidate MVA-BN respiratory syncytial virus...
The National Medical Products Administration (NMPA) of China has recently approved Pfizer’s third generation ALK inhibitor Borrena (lorlatinib) as the first-line treatment for adults with...
Following the news that the number of monkeypox cases has doubled to 20 in the UK, and over 100 cases have been confirmed in Europe; Emily...
An upcoming influx of new therapies into the Alpha-1 Antitrypsin Deficiency (AATD) space in the next decade is expected to provide a significant boost to...
Positive Phase III trial results from UCB’s two clinical trials in its generalized myasthenia gravis (gMG) program will enable it to become a key future...
The top 20 global biopharmaceutical companies by market capitalization (MCAP) experienced a favorable Q1 2022, despite global economic and financial market uncertainty. The majority of...
The diagnosed prevalent cases of chronic kidney disease (CKD) in the seven major markets (*7MM) are projected to increase from 18 million cases in 2021...
The current osteoarthritis (OA) market has previously suffered from a lack of effective analgesics and disease-modifying osteoarthritis drugs (DMOADs) partially due to the complex pathophysiology...
The complement cascade, an arm of the innate immune system consisting of a collection of small proteins with various functions in targeting pathogens, has been...
Over the last decade, the role of the immune system in the etiology and pathophysiology of neurological diseases has steadily gained clarity, says GlobalData. The...
Based on the uncertainty relating to the comparison of efficacies of Leo Pharma’s anti-IL-13, Adtralza/Adbry (tralokinumab); AbbVie’s oral Janus kinase (JAK) 1 inhibitor, Rinvoq (upadacitinib);...
Alzheimer’s disease (AD) is a progressive fatal neurological disorder and the most common cause of dementia primarily affecting the elderly population, with AD-associated dementia accounting...
Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) market, achieving around $958 million in sales by 2025, according to GlobalData,...
Eli Lilly announced topline results of tirzepatide from its SURMOUNT-1 Phase III clinical trial recently. The participants taking tirzepatide drug lost up to 52 pounds...
The market for T-Cell Lymphomas (TCLs) – a rare type of the blood cancer group of non-Hodgkin’s lymphomas – is expected to see strong growth...
Diabetes has reached epidemic proportions over the last three decades and India continues to have the second-largest number of adults with diabetes worldwide, after China....
Biologics are set to overtake small molecules when it comes to sales revenue, according to GlobalData. Describing them as “primary engines of value creation”, Quentin...
While there have been several significant steps forward when it comes to treating diabetes complication diabetic macular edema (DME) this year, current therapies are still...
Over the past five years, very few licensing agreements for innovator drugs have involved Russian biopharmaceutical companies where the majority involve drugs that are marketed,...
The atopic dermatitis (AD) market is expected to grow from $6.4 billion in 2020 to $16.8 billion in 2030 in the seven major markets (7MM*)...
Sanofi and Regeneron’s positive patient-reported outcome (PRO) data, demonstrated as part of the RELIEVE-AD study last month, can be used to showcase the value that...
At the 71st annual American College of Cardiology (ACC) 2022 meeting, results were presented from MAVA-LTE, the ongoing five-year study of mavacamten in obstructive hypertrophic...
Axsome Therapeutics expects to receive a complete response letter (CRL) from the FDA due to the recently revealed chemistry, manufacturing, and control (CMS) issues identified during...
At the recent American Academy of Neurology (AAN) 2022 Annual Meeting, data from a pivotal trial of Cognoa’s Canvas Dx was presented that demonstrated how...
The international community has imposed a series of some of the most punitive sanctions on Russia, its finances, and many imports due to its invasion...
The peanut allergy segment is expected to be the most valuable within the food allergy market due to sales of Aimmune Therapeutics’ Palforzia, which was...
American biotech company Novavax, together with Japan-based Takeda, has secured Japanese Ministry of Health, Labour and Welfare (MHLW) approval for its recombinant, adjuvanted virus-like particle...
Outlook Therapeutics recently submitted a Biologics License Application to the US Food and Drug Administration (FDA) for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related...
Following the news that the recent severe hepatitis outbreak may be linked to the F41 strain of the adenovirus (hepatitis); Emily Martyn, MPH, Healthcare Analyst at...
The China National Medical Products Administration (NMPA) has recently granted breakthrough therapy (BTD) designation to Innovent Biologics’ (Innovent) IBI310 in combination with sintilimab to treat...
Venture capital (VC) plays a critical role in the identification and commercialization of promising intellectual property, facilitating new therapy development, says GlobalData. The leading data...
Following the results for the EMPULSE trial demonstrating that Boehringer Ingelheim’s (BI) sodium-glucose co-transporter-2 inhibitor (SGLT-2I) empagliflozin (Jardiance) was beneficial at reducing adverse events (AEs)...
The West’s sanctions on Russia, as well as biopharmaceutical companies and venture investment firms halting investment and business with Russian companies, will impact only a...
Alopecia areata (AA) is a chronic inflammatory autoimmune disease which impacts physical as well as psychological health. Currently, there are no approved therapies to treat...
Exploiting big data analytics via emerging technologies such as artificial intelligence (AI) and Internet of Things (IoT) has improved return on investment in the pharma...
The treatment for triple-negative breast cancer (TNBC) in Japan is currently possible only through a combination of immunotherapy (Keytruda or Tecentriq) and chemotherapy. Against this...
At the 71st annual American College of Cardiology (ACC) 2022 meeting, results presented for the SCORED trial will likely lead to a large market share...
At this year’s American College of Cardiology (ACC) Scientific Session, positive results were presented from Bayer’s FIDELITY analyses of Kerendia (finerenone), providing insight into the...
The Food and Drug Administration’s (FDA) increasing approvals and Emergency Use Authorizations (EUAs) of COVID-19 vaccines and drugs, as well as cell and gene therapies,...
BridgeBio’s acoramidis, an orally administered small molecule transthyretin, is currently being assessed in Phase II and Phase III trials and if it passes, it will...
A flourish of activity in the wet age-related macular degeneration (wAMD) market, coupled with anticipated approvals of other products—particularly biosimilars—is expected to widen interest in the AMD market...
Following the news that Sanofi and Regeneron announced that the Food and Drug Administration (FDA) accepted a Priority Review of the supplemental Biologics License Application...
Medical device and pharmaceutical companies are taking a similar approach to global retailers by withdrawing their activities from Russia where possible, however they continue to...
With Eli Lilly and Boehringer Ingelheim (BI)’s Jardiance now approved to address both indications of heart failure (HF), GlobalData expects the drug to become a...
At the AD/PD 2022 International Conference on Alzheimer’s disease (AD) and Parkinson’s disease (PD), Cortexyme presented new data from its COR388* (atuzaginstat) clinical program, highlighting...
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee (AdCom) voting against the new drug application of Amylyx’s AMX0035 for the treatment of amyotrophic...
Corium’s Adlarity (donepezil hydrochloride) has recently received FDA approval as a treatment for patients with mild, moderate, or severe dementia of Alzheimer’s disease (AD). However, as...
The Drugs Controller General of India (DCGI) has recently granted emergency use authorization for Novavax's protein-based COVID-19 vaccine for adolescents aged 12 to 18 years....
The China National Medical Products Administration (NMPA) has recently approved Swedish Orphan Biovitrum’s (Sobi) Gamifant (emapalumab) for the treatment of primary haemophagocytic lymphohistiocytosis (pHLH) in...
An unforeseen rise in special purpose acquisition company (SPAC) mergers and acquisitions (M&As) as a quicker route for biopharmaceutical companies to enter the public capital...
Zynerba Pharmaceuticals’ pipeline drug Zygel is expected to achieve $18.1 million in sales by 2030, according to GlobalData, due to its potential to help fragile...
The most common molecule type for rare disease active pipeline drugs is gene-modified cell therapies, in which cells are genetically modified outside the patient’s body...
To help combat the nationwide insulin affordability crisis, Civica, a nonprofit generic pharmaceutical company, has launched its Insulin Initiative with the JDRF. The initiative aims...
Arvinas’ proteolysis targeting chimeras (PROTACs), bavdegalutamide (ARV-110), which is being investigated as a new therapy for metastatic castration-resistant prostate cancer (mCRPC) in the Phase I/II...
More research is required to determine whether current Omicron treatments are effective against BA.2—the most transmissible of the Omicron subvariants, says GlobalData. The leading data...
Cystic fibrosis (CF) is the most common, life-limiting genetic disorder affecting Australians, with a baby born with the condition every four days. Currently, cystic fibrosis...
Not only has CTI BioPharma’s drug Vonjo (pacritinib) already broken new ground by being the first treatment approved for intermediate and high-risk myelofibrosis patients with...
The development of immune checkpoint inhibitors (ICIs) has been a strong focus of China’s R&D strategy, with these costly agents being used across an increasing...
International Women’s Day commemorates the political, social, economic, and cultural achievements of women throughout history. This important day also creates space to discuss issues that...
With the uncertainty surrounding Russia and Ukraine, it is expected that there will be a large impact on the pharmaceutical industry. More specifically, early phase...
The European Commission (EC) withdrew the marketing authorisation (MA) for Pfizer’s topical phosphodiesterase-4 (PDE4), Staquis (crisaborole) in the EU (known as Eucrisa in the US)....
The cervical cancer market is expected to experience significant growth, from $607 million in 2020 to $4.8 billion in 2030 across the eight major markets...
Novo Nordisk’s success in diabetes and obesity drug sales could be impacted by supply chain issues, for the production of its obesity drug Wegovy (semaglutide), unless...
Cassava Sciences recently announced that the Food and Drug Administration (FDA) had denied a Citizen Petition and associated supplements filed by investors questioning the credibility...
The 12-month diagnosed prevalent cases of atopic dermatitis (AD) across the seven major markets (*7MM) are projected to increase from 42.13 million in 2020 to...
Following the recent discovery that infection with Epstein-Barr virus increases risk of developing multiple sclerosis (MS) by 32-fold, GlobalData highlights that there are currently 15...
Sanofi submitted its Dupixent (dupilumab) data for eosinophilic esophagitis (EoE) to the Food and Drug Administration (FDA) on February 28, just a couple of weeks...
Following the news that Biohaven and Pfizer have recently received a positive opinion for Vydura (rimegepant) from the European Medicines Agency's (EMA’s) Committee for Medicinal...
AbbVie has recently submitted a supplementary new drug application (sNDA) to the FDA for Vraylar (cariprazine) as the adjunctive treatment of major depressive disorder (MDD)....
Increasingly, over the past decade pharmaceutical companies have sought to enhance the efficacy of Immune checkpoint inhibitors (ICIs) by using these in combination with other...
Chinese pharma companies are continuously focusing on the research and development of new innovative oncology therapies. Recently, Innovent Biologics and Gracell Biotechnologies have initiated Phase...
GlobalData anticipates that Evelo Biosciences’ Phase III study of EDP-1815 for the treatment of psoriasis (PsO) will be initiated in Q4 2023. The leading data...
China has recently approved CStone Pharmaceuticals’ Tibsovo (ivosidenib tablets) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) with a susceptible...
Zucara Therapeutics recently announced the publication of ZT-01 preclinical data for the treatment of insulin-induced hypoglycemia in patients with type 1 diabetes (T1D). Zucara is...
Ardelyx’s tenapanor has the potential to capture a slice of the chronic kidney disease (CKD)-hyperphosphatemia (HP) market if the company can successfully appeal the Food...
Sales for Novartis’ Leqvio (inclisiran) for the treatment of high cholesterol may surpass those of Sanofi/Regeneron’s Repatha (evolocumab) and Amgen’s Praluent (alirocumab) by 2027 due...
The bipolar disorder market is expected to grow from $4.1 billion in 2020 to $4.9 billion by 2030 across the eight major markets (8MM*) at...
GlobalData’s Marketplace is now accessible via Snowflake’s cloud data platform, empowering seamless access and direct integration of GlobalData’s intelligence into customer applications and data operations. ...
By 2030, GlobalData highlights that promising pipeline drugs Zygel, zatolmilast, trofinetide, and acamprosate calcium SR are set to offer new treatment options for people with...
Trauma fixation devices are considered to be the essential first-line treatment for bone fractures. According to GlobalData analysis, the trauma fixation market is valued at...
Following the recent news that the woman referred to as ‘the New York patient’, who received haplo-cord treatment four years ago, is now off HIV...
The chronic myeloid leukemia (CML) therapy market is dominated by tyrosine kinase inhibitors (TKIs) targeting aberrant BCR-ABL1. However, with all but one of the currently...
The potential Food and Drug Administration (FDA) acceptance of Anavex Life Sciences’ AVATAR as a pivotal Phase III trial would have an important bearing on...
Due to lack of HPV vaccination program, the diagnosed incident cases of cervical cancer in urban China are expected to increase at an annual growth...
Pharma companies in Japan are still working to bring their first COVID-19 indigenous vaccine, though the pandemic has already completed two years in various parts...
Obesity is a key public health concern and a leading risk factor for other lifestyle-related illnesses in Australia. Currently, four key pharma companies offer marketed...
Despite being years away from exhibiting its full potential, artificial intelligence (AI), together with Big Data, stand out as a versatile combination to address challenges...
Takeda’s decision to cease further support to launch Eohilia (for patients ages 11 years and above) to the eosinophilic esophagitis (EoE) market will result in...
Drug pricing pressures will continue to hinder the growth of the pharmaceutical industry in 2022, forcing companies to reassess their pricing strategies and market focus,...
The recent Food and Drug Administration (FDA) approval of the first T-cell receptor (TCR) therapy, Immunocore’s ($IMCR) Kimmtrak, for the treatment of uveal melanoma offers...
Top pharma Contract Manufacturing Organizations (CMOs) are investing in specialist facilities for manufacturing small molecule active pharmaceutical ingredients (API) requiring containment, according to the GlobalData...
Steady growth is expected for the glaucoma market across the seven major markets* (7MM) from $2.8 billion in 2020 to $3.5 billion in 2030, at...
The top 20 global innovative Bio/Pharma companies* had a favorable year in 2021, reporting a 24.9% growth in aggregate market capitalization (MCAP)—from $2.8 trillion on...
Following the release of Q4 2021 financials from Abbott Laboratories; Chris Onderisin, Medical Devices Analyst at GlobalData, a leading data and analytics company, offers his view:...
Oral contraceptives and non-steroidal anti-inflammatory drugs (NSAIDs) remain first-line therapies in the endometriosis market across the seven major markets (7MM*) due to their affordability, side...
On December 20, 2021, Pfizer announced the unexpected death of a participant in the company’s Phase Ib open-label study (NCT03362502) on PF-06939926 (fordadistrogene movaparvovec), a...
Ionis Pharmaceuticals’ partner Roche recently announced that it will initiate a new Phase II trial to reassess its pipeline antisense therapy, tominersen, in the treatment...
The endometriosis market is set to grow from $1.06 billion in 2020 to $2.91 billion in 2030 across the seven major markets (7MM*), at a...
On January 13, UNION Therapeutics registered a Phase IIb, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of the phosphodiesterase-4 (PDE4)...
A number of exciting new sickle cell disease (SCD) drugs are set to hit the US market, says GlobalData, including gene therapies that could offer...
AVROBIO has cancelled its Fabry disease (FD) gene therapy AVR-RD-01, which was due to launch in H2 2022 following disappointing results from a recent Phase...
AbbVie’s Rinvoq (upadacitinib) and Pfizer’s Cibinqo (abrocitinib) have been approved by the FDA for the treatment of refractory atopic dermatitis (AD), despite ongoing safety concerns...
American biotech company Novavax, together with Korea-based SK Group’s vaccine business subsidiary SK bioscience, has secured the South Korea’s Ministry of Food and Drug Safety...
Driven by an aging population and more people with comorbid conditions, the amount of patients diagnosed with T-cell lymphoma (TCL) is expected to increase at...
Following the news that antibacterial resistance was the third leading cause of death worldwide in 2019, killing more than malaria or AIDS*; Emily Martyn, MPH, Healthcare...
Despite the axillary hyperhidrosis (AH) market in the US growing at an impressive compound annual growth rate (CAGR) of 15.7%, from $65.6 million in 2020...
Upcoming, highly-anticipated gene therapies for progressive muscle-degenerating disease Duchenne muscular dystrophy (DMD) will cost a whopping $2 million per patient per year—double the cost of...
The average price of branded drugs in the US has increased by a whopping 18.3%* per year, according to research by GlobalData. As patients are...
Johnson & Johnson’s (J&J’s) COVID-19 vaccine sales are forecast to consistently decline between 2022 and 2027, according to GlobalData, largely due to competition from Pfizer....
CStone Pharmaceuticals has recently received the National Medical Products Administration (NMPA) of China approval for Cejemly (sugemalimab). Against this backdrop, Cejemly is expected to drive...
Limited treatment options for pediatric patients in the US remain a significant unmet need in the eosinophilic esophagitis (EoE) space, providing an opportunity for developers...
The psoriasis (PsO) market has typically been dominated by injectable biologics. However, this segment has become fairly saturated, given the number of different efficacious biologics...
The US eosinophilic esophagitis (EoE) market, valued at $156.7 million in 2020, is projected to grow at a compound annual growth rate (CAGR) of 25.7%, to...
Following the news that Vertex’s Trikafta/Kaftrio has been approved for children ages six to 11 years with cystic fibrosis (CF); Mandana Emamzadeh, PhD, Healthcare Analyst at...
In light of National Thyroid Awareness Month, GlobalData highlights that the lack of awareness around hypothyroidism (also known as ‘underactive thyroid’) is impacting diagnosis rates...
The bipolar disorder pipeline is moderate in size containing agents in a range of different drug classes, including both tried and tested, and novel classes....
Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin....
The chronic myeloid leukemia (CML) therapy market is dominated by tyrosine kinase inhibitors (TKIs) targeting aberrant BCR-ABL1. However, with all but one of the currently...
Following the Centers for Medicare & Medicaid Services’ (CMS) announcement of draft guidance on its highly anticipated reimbursement decision regarding Aduhelm (aducanumab) and other future...
The female contraception market in Japan is dominated by oral contraceptive pills (OCPs). The use of other contraceptive options such as intrauterine devices (IUDs) and...
According to a survey by GlobalData* the upcoming introduction of oral and topical Janus kinase (JAK) inhibitors for the treatment of atopic dermatitis (AD) has...
Less than 5%* of adults with overactive bladder (OAB) are currently managed with drug therapy due to a combination of low diagnosis rates and the...
Not only is there is a severe lack of effective T-cell lymphoma (TCL) treatments, according to GlobalData — a sentiment reflected by key opinion leaders...
The diagnosed incident cases of brain cancer across the eight major markets (*8MM) are projected to increase from 121,000 cases in 2020 to 147,000 in...
The diagnosed incident cases of chronic myeloid leukemia (CML) across the eight major markets (*8MM) are projected to increase from 15,500 cases in 2020 to...
The burden of total prevalent cases (diagnosed and undiagnosed) of primary open angle glaucoma (POAG) is expected to increase at an annual growth rate (AGR)...
AstraZeneca Singapore signed a contract with technology partners Respiree, OncoShot, Thermaiscan, Ubie and Hewlett Packard Enterprise in November 2021 to offer new digital healthcare solutions...
The FDA has yet to come to a conclusion on the approval of Lilly/Incyte’s JAK1/2 inhibitor Olumiant (baricitinib), AbbVie’s JAK 1 inhibitor Rinvoq (upadacitinib), and...
The psoriasis (PsO) market was valued at $14.2 billion in 2020 and is expected to grow to $27.5 billion by 2030 across the seven major...
Bipolar disorder is a mental disorder characterized by periods of mania and depression. While there are a high number of treatments that can effectively manage...
The National Medical Products Administration (NMPA) of China has recently approved Brii Biosciences’ amubarvimab/romlusevimab combination as the first COVID-19 neutralizing antibody combination therapy in the...
Janssen Pharmaceutical has recently filed for B-cell maturation antigen (BCMA) CAR-T therapy Cilta-cel in Japan. Earlier in March 2021, Bristol-Myers Squibb (BMS) filed for the...
Pharma companies offer support to Japanese patients and rheumatologists with systemic lupus erythematosus (SLE or lupus) through unbranded and branded digital channels providing disease support...
Neurocrine Biosciences has recently announced that its pipeline asset, Ingrezza (valbenazine), achieved the primary endpoint of reducing the symptoms of chorea (involuntary muscle movements) associated...
A total 35% of healthcare professionals worldwide believe that digital transformation — involving the use of technologies such as AI, big data, cloud computing, application...
The current treatments for hypoglycemia (also known as low blood sugar) are meeting practitioners’ needs well, and there are very few areas of improvement, according...
Of the total 3.2 million diagnosed cases of endometriosis forecast in the 7MM* in 2030, 81% are expected to be young women aged between 12...
New class of treatment, especially hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to treat patients with anemia from chronic kidney disease (CKD), is gaining traction...
By 2030, patients living with Duchenne muscular dystrophy (DMD) — a genetic muscle wasting disease caused by mutations on the gene that produces dystrophin —...
Ever since their launch in 2018, anti-CGRP mAbs* have been stealing market share in the migraine treatment space from traditional oral preventative products such as...
For close to 20 years, the available treatments for plaque psoriasis (PsO) — an uncurable condition that forms red, painful inflamed patches on the skin...
Following allegations of a Christmas party at 10 Downing Street during the Tier 3 lockdown in December 2020; Emily Martyn, MPH, Healthcare Analyst at GlobalData, a...
Chinese bio/pharma companies’ initial public offerings (IPOs) have increased since the respective national reforms of 2019, with oncology remaining the top therapy area. However, China...
The number of hypoglycemia cases attributed to type 1 or type 2 diabetes in the seven major markets (*7MM) are projected to increase from 1,484,000...
China reformed its regulatory system in 2015 to include various fast-track programs to drive the development of drugs for unmet medical needs and serious conditions....
Increased screening and early treatment could be exactly what is needed to drive preventative and patient-specific care for type 1 diabetes (T1D), says GlobalData. However,...
Eli Lilly’s move to begin enrolling for a head-to-head trial, pitching its migraine preventative treatment Emgality (galcanezumab) against Biohaven’s Nurtec (rimegepant), is a bold move...
The impact of the COVID-19 pandemic seems to have raised the importance of venture capital funding for Chinese bio/pharma companies involved in the development of...
Following the recent news that Biogen’s Vumerity (diroximel fumarate) was granted marketing authorization by the European Commission for the treatment of adults with relapsing-remitting multiple...
Eli Lilly and Boehringer Ingelheim’s (BI) Jardiance will continue to increase its market share across the heart failure (HF) and type 2 diabetes (T2D) space...
The sepsis and septic shock market is expected to experience significant growth from $3.48 billion in 2020 to $7.5 billion by 2030 across the seven...
Australia recently granted provisional determination for AstraZeneca’s COVID-19 monoclonal antibody (mAb) cocktail postexposure prophylaxis (PEP) therapy Evusheld (tixagevimab + cilgavimab / AZD7442). On expected successful...
Compass Pathways recently announced positive topline results for COMP360 (psilocybin), from the largest clinical trial to date, in conjunction with psychological support from specially trained...
Moving towards digitalization in healthcare was on many governments' agendas prior to the COVID-19 pandemic, but issues with the legislative landscape, reimbursement, and acceptance prevented...
Indian pharma companies have already occupied pole position in the supply of repurposed COVID-19 drugs globally. With the launch of new innovative COVID-19 oral drugs,...
The overall potential of siRNA-based therapeutics has attracted Chinese pharma companies to tap opportunities and bring promising innovative therapies across the globe. Against this backdrop,...
The COVID-19 pandemic has had a seismic impact in clinical trial investigations, halting studies in their tracks. Yet, while trial activity has since recovered to...
There are currently no Food and Drug Administration (FDA) approved treatments for eosinophilic esophagitis (EoE) in the US, says GlobalData. The leading data and analytics...
The neuromyelitis optica spectrum disorder (NMOSD) therapeutics market is highly genericized, with corticosteroids and immunosuppressants currently accounting for the highest portion of prescribed drugs in...
Pharmaceutical companies are focusing on novel promising treatment options such as gene therapy to fulfill unmet needs in several rare and complex diseases in recent...
Following today’s news (11 November) that the National Institute for Health and Care Excellence (NICE) has recommended Kyowa Kirin’s Poteligeo for the treatment of adult...
Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular (CV) disease or the need for dialysis or kidney transplantation. Currently, AstraZeneca’s sodium-glucose...
Following the news that Pfizer CEO Albert Bourla called people who spread misinformation on COVID-19 vaccines ‘criminals’, Emily Martyn, MPH, Healthcare Analyst at GlobalData, a leading...
At the end of September, results were presented at the European Academy of Dermatology and Venereology (EADV) Congress from a study exploring patterns in the rare skin disease hidradenitis suppurativa (HS). Currently, effective therapies for the disease...
Immune checkpoint inhibitors (ICIs) have transformed the treatment of many late-stage cancers. This success has caused pharma companies to invest heavily into investigating their use...
Gepants and monoclonal antibodies (mAbs) against calcitonin gene-relate peptide (CGRP) have transformed the treatment paradigm for migraine. Despite the availability of a plethora of drugs...
The diagnosed prevalent cases of hemophilia A and hemophilia B in China are expected to increase at an AGR of 2.51% between 2020 and 2030,...
Pfizer’s Cibinqo (abrocitinib) is likely to be approved by the EU for the treatment of ‘moderate to severe’ atopic dermatitis (AD) by this year-end ensuing...
The total prevalent cases of overactive bladder (OAB) in the eight major markets (*8MM) are projected to increase from 363.3 million cases in 2020 to...
Biogen’s tofersen has failed to achieve its primary endpoint in the Phase III VALOR study for amyotrophic lateral sclerosis (ALS). This setback is likely to...
India has the third largest pharma market in the world by volume, according to research by GlobalData, placing it behind giants such as the US...
At the 57th annual European Association for the Study of Diabetes (EASD) 2021 meeting, results were presented for a 3-year prospective study. The study results...
Following the news that Health Secretary, Sajid Javid, has confirmed that there are no plans to implement ‘Plan B’ rules - despite cases reaching above...
Data presented at the 14th AACR* Conference in early October revealing that black patients were significantly more likely to be excluded from pancreatic clinical trials...
The success of mRNA vaccines for COVID-19 has generated a lot of interest in companies globally. While a late entrant to the race, several South...
The sales forecast for Pfizer/BioNTech’s COVID-19 vaccine Comirnaty has been upwardly adjusted by GlobalData due to anticipated demand for booster shots. The leading data and...
The prevalence of major depressive disorder (MDD) symptoms are expected to increase due to COVID-19-related stress, as patients struggled with a loss of personal...
The percentage of the global population that are using insulin pumps for the treatment of type 1 diabetes (T1D) is expected to significantly increase from...
The lack of available treatments for axillary hyperhidrosis (AH), a disease characterized by increased sweat production in the armpits, offers an opportunity for pharmaceutical and...
Following the news that Valneva’s COVID-19 vaccine showed superior neutralizing antibody levels and an equal seroconversion rate and protection against SARS-CoV-2, compared to AstraZeneca’s Vaxzevria; Philipp...
The contract manufacturing industry for finished dose pharmaceuticals had the lowest growth rate in a decade in 2020, according to GlobalData estimates. The leading data...
Following the news that UK parliament will discuss a petition later today, backed by 101,910 signatures, calling for increased funding for research into endometriosis and...
Arcutis Biotherapeutics recently announced the submission of a New Drug Application (NDA) for its topical phosophodiesterase 4 (PDE4) inhibitor, roflumilast cream (ARQ-151), in the treatment...
Following the news that the Subject Expert Committee (SEC) provided a positive recommendation to the Drug Controller General of India (DCGI) for the use of...
The number of individuals with diagnosed plaque psoriasis in the seven major markets (7MM*) is projected to increase from around 15,720,000 in 2020 to over...
There has been a strong increase of vacancies in artificial intelligence (AI) related jobs in the pharmaceutical sector this year, despite the impact of COVID-19,...
Historically, anti-tumor necrosis factor (TNF) drugs were the key biologic therapies available in Japan for axial spondyloarthritis (axSpA) treatment. However, the overall competition with the...
Endometriosis has gained attention in the past several years with celebrities getting candid about their struggles. In September, comedian and actress Amy Schumer shared that...
AbbVie has recently announced that Qulipta (atogepant) has received FDA approval for the preventive treatment of episodic migraine in adults. Qulipta is the first and...
Digital therapeutics (DTx) uses digital technology to remotely prevent, treat, or manage a wide range of conditions through data-driven interventions. The digital therapeutics market for...
The pharmaceutical industry will need to outsource even more pharmaceutical manufacturing to keep up the pace with the expected developments of the COVID-19 vaccines and...
Diffuse intrinsic pontine glioma (DIPG) is an extremely rare pediatric brain tumor with a dismal prognosis. On average, less than 50% of patients are expected...
While GlobalData expects the approval of Opzelura (ruxolitinib) to be the first of many JAK inhibitors to enter the US market for the treatment of...
At this year’s European Society of Cardiology (ESC) Congress, positive results were presented from Bayer’s FIGARO-DKD Phase III trial of Kerendia (finerenone), providing insight into...
The recent ruling in favor of upholding Amgen’s patents for its phosphodiesterase inhibitor Otezla (apremilast) until its patent expiry in 2028 is an important safeguard...
The Delta variant continues to infect a substantial number of school-aged children as school begins throughout the US. This may exacerbate transmission to the general...
With Bristol Myers Squibb’s (BMS) Phase III CheckMate-498 and CheckMate-143 Opdivo (nivolumab) studies both failing to meet primary or secondary endpoints, the use of single-agent...
China’s National Medical Products Administration (NMPA) has approved its second chimeric antigen receptor T (CAR-T) cell immunotherapy product JW Therapeutics’ relmacabtagene autoleucel injection (relma-cel) shortly...
Following the recent shift in the FDA’s stance on Amylyx Pharmaceuticals’ AMX0035* new drug application (NDA), leading data and analytics company, GlobalData, expects that this...
The market for neuroendocrine tumors (NETs) – a rare type of tumor where cancerous growth can begin in any cell within the hormone or nervous...
Of the five late-stage pipeline products expected to be licensed in the 7MM* for cystic fibrosis (CF) between 2020 and 2030, four will be CF...
India currently has six approved COVID-19 vaccines. However, Zydus Cadila’s, Johnson & Johnson’s, and Moderna’s vaccines are not yet available in India. Considering the gigantic...
Returning to face-to-face GP appointments is drawing interest from all sectors, as it could be used as another indicator of routine life reverting to prepandemic...
Following the news that Pfizer/BioNTech will apply for authorization of their COVID-19 vaccine Comirnaty for children ages 5–11 after showing positive initial data from a...
In collaboration with the LaparoObeso center, the Indian state of Maharashtra has recently launched a digital campaign to raise awareness of diabetes and obesity. In...
India has a rapidly growing pharmaceutical market that, being the third largest pharmaceutical industry in the world by volume, holds a prominent place in global...
Servier and Neurochlore have recently announced that, following a lack of efficacy in two Phase III trials of bumetanide for autism spectrum disorder (ASD) in...
At the 2021 European Society of Cardiology (ESC) Congress, full results were presented for EMPEROR-Preserved, a Phase III trial investigating Eli Lilly and Boehringer Ingelheim’s...
The Respiratory Syncytial Virus (RSV) prophylactic population in the eight major markets (*8MM) is projected to increase from over 14.55 million cases in 2020 to...
Leading data and analytics company GlobalData has predicted that the arrival of biosimilar therapies in the EU will continue to fall in the coming years...
The burden of diagnosed HER2+/HR+ breast cancer is expected to increase at an annual growth rate (AGR) of 1.70% from around 100,000 cases in 2020...
Following the news that Health Secretary Sajid Javid has confirmed that plans for vaccine passports in England have been scrapped; Emily Martyn, MPH, Healthcare Analyst at...
The psoriasis (PsO) therapeutics market in Australia is dominated by biologics such as anti-TNF, anti-IL-17, anti-IL-23, and anti-IL-12/anti-IL-23 therapies. Among these, stiff competition exists among...
The burden of diagnosed neuroendocrine tumors (NETs) is expected to increase at an annual growth rate (AGR) of 2.37% from an estimated 108,000 cases in...
The lack of approved treatments for chronic hand eczema (CHE) demonstrates that there is a clear need for more targeted therapies. However, based on the...
Diagnosed prevalent cases of cystic fibrosis (CF) in the seven major markets (*7MM) are projected to increase from over 79,000 in 2020 to nearly 84,000...
Ono Pharmaceutical’s Braftovi (encorafenib) was recently approved in South Korea as a combination therapy with cetuximab to treat BRAF V600E mutant in previously treated metastatic...
Endometriosis is an indication that needs new therapy options. The variety of symptoms across cases, non-specificity of symptoms, and overlap of symptomology with other conditions...
Amneal Pharmaceuticals has recently announced that its pipeline product IPX-203 (carbidopa + levodopa, (CD/LD)) achieved key primary and secondary endpoints in the pivotal Phase III...
South Korea has recently decided to provide practical support to innovative pharmaceutical companies by revising the existing health insurance benefits system. The new system of...
The burden of diagnosed incident cases of severe sepsis is expected to increase at an annual growth rate (AGR) of 2%, from around 2.3 million...
An upcoming influx of new therapies into the Pompe disease (PD) pipeline in the next decade is expected by leading data and analytics company GlobalData...
The respiratory syncytial virus (RSV) prophylaxis market is expected to skyrocket from $454.8m in 2020 to $6.3bn by 2030 across the eight major markets (8MM*),...
The Food and Drug Administration (FDA) recently issued a Complete Response Letter (CRL) to Ardelyx concerning tenapanor’s New Drug Application (NDA) for chronic kidney disease...
The cystic fibrosis (CF) market is expected to grow from $8.2bn in 2020 to $12.7bn in 2030 in the seven major markets (7MM*) at a...
The diagnosed incident cases of head and neck cancers (HNCs) in urban China are expected to increase at an annual growth rate (AGR) of 4.07%...
The disease-modifying nature of cystic fibrosis transmembrane conductance regulator (CFTR) modulators has transformed the treatment paradigm for cystic fibrosis (CF) over the last decade, a...
The Food and Drug Administration (FDA) recently approved a new indication for Jazz Pharmaceuticals’ Xywav for the treatment of patients with idiopathic hypersomnia (IH), a...
The hematological cancer therapy market is diverse and highly genericized, with chemotherapies currently accounting for the highest number of marketed drugs. However, the availability of...
The increased use of virtual components such as eConsent, telemedicine, remote patient monitoring and wearables in clinical trials over the past decade has led to...
HIV drugs containing tenofovir alafenamide (TAF) are set to see sales over $15bn by 2029*, supported by the ingredient’s high tolerance in high-risk patients, according...
When it comes to insulin choice, price is currently the biggest barrier, as insulin brand preference is primarily determined not by a doctor, but through...
HIV drugs containing tenofovir alafenamide (TAF) are set to see sales over $15bn by 2029*, supported by the ingredient’s high tolerance in high-risk patients, according...
Gene therapies could revolutionize the management of chronic cardiovascular diseases (CVDs) such as heart failure, according to GlobalData. The leading data and analytics company notes...
Takeda Pharmaceutical’s TAK-994 has recently received breakthrough therapy designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness...
China’s overall focus within oncology research is increasing at a rapid pace. Moreover, the country recently approved its first chimeric antigen receptor (CAR)-T cell therapy....
Following today’s news (18 August) that diagnostic face masks developed by the Massachusetts Institute of Technology (MIT) and Harvard University are about to be commercialized: Sultan...
South Korea has recently unveiled a US$2bn plan to emerge as a global COVID-19 vaccine production hub and become one of the top five manufacturing...
Following the news that the US government is planning to recommend COVID-19 booster doses for all residents eight months after full vaccination; Philipp Rosenbaum, PhD, Senior...
Takeda is currently developing multiple microbiome-targeting agents through a number of collaborations with innovative small companies. Its latest partnership with Finch Therapeutics to advance FIN-524,...
UCB, a global biopharmaceutical company, has recently presented new interim data from BE BRIGHT, an open-label extension (OLE) trial of an interleukin (IL)-17A/F inhibitor ‘bimekizumab’...
While the suspension of patent extensions in Brazil could lead to lower drug prices and cheaper generic drugs, this move may deter large biopharma companies...
Seres Therapeutics’ announcement last month that it was discontinuing its ECO-RESET Phase IIb clinical trial (NCT03759041) investigating SER-287 in patients with mild-to-moderate ulcerative colitis (UC)...
Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a wide range of cancers. Analysis of NK cell therapies,...
Cancer remains the leading cause of death in Australia. Against this backdrop, the government is supporting the home-grown oncology research with committed funding. Moreover, the...
Novartis has recently announced that the Food and Drug Administration (FDA) has lifted a clinical hold on its spinal muscular atrophy (SMA) drug OAV-101, an...
Axsome Therapeutics recently announced that its pipeline product AXS-05 (bupropion + dextromethorphan) achieved primary and key secondary endpoints in the MERIT Phase II Trial for...
While the EMA’s recent recommended rejection of Kyowa Kirin’s Parkinson’s disease (PD) drug Nouryant (istradefylline) may have come as a surprise, key opinion leaders interviewed...
The Parkinson’s disease (PD) market is expected to almost triple in sales in the seven major markets (7MM*) by 2029, rising from $4bn in 2021...
Biogen recently announced that it has entered into a license and collaboration agreement with InnoCare Pharma for orelabrutinib, an oral small molecule Bruton’s tyrosine kinase...
China has seen a significant surge in biosimilar approvals over the last three years, with 13 new biosimilars approved during 2018–2021. Strong biosimilar pipeline and...
BioMarin’s Roctavian can significantly reduce the treatment burden on patients with severe hemophilia A Key opinion leaders believe that Roctavian’s benefit could decline over...
Since 2019, there has been an increase in the adoption of digital health technology in India, with collaborations between pharmaceutical companies, insurance companies, and digital...
People with diabetes that do not have access to an insulin pump – or simply do not wish to use one – now have greater...
The expiration of several biologic therapies for plaque psoriasis (PsO) this year gives these patients some hope for the arrival of more affordable treatment, according...
The prevention of thrombosis is one of many priorities in managing the COVID-19 patients, but there are several complex considerations, especially when examining anticoagulation strategies....
Astellas Pharma and Fibrogen announced on 25 June 2021 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
India’s public expenditure on healthcare has exposed weaknesses in its infrastructure, especially during the second wave of the COVID-19 pandemic. Against this backdrop, patients must...
Live biotherapeutic products (LBPs), which target microbial communities in the skin and gastrointestinal (GI) and respiratory tracts, are expected to offer hope to groups of...
Following a reported rise in RSV cases in the US, leading data and analytics company GlobalData notes that the country should test COVID-19-free patients that...
There are more than nine pharmaceutical companies developing therapeutics that can be used to treat non-proliferative diabetic retinopathy (NPDR) in the nine major markets (9MM*),...
Acquisitions of pharmaceutical contract manufacturing organizations (CMOs) are increasing, and the most common type of acquirer is private equity (PE) firms, which view the industry...
The atopic dermatitis (AD) space will completely transform over the next decade due to intense clinical activity, says GlobalData. The leading data and analytics company...
The 12-month total prevalent cases of migraine in the seven major markets (*7MM) are expected to increase from 72.7 million cases in 2020 to 73.7...
Hutchmed (China) Limited’s Orpathys (savolitinib) is now launched in China for patients with lung cancer and MET exon 14 skipping alterations that have progressed following...
As pharma companies continue to scale up digital transformation processes, a survey by GlobalData has highlighted that teaming up with experienced external vendors is driving innovative...
The approval of Roche / Chugai Pharmaceutical’s Evrysdi (risdiplam) as the first ever oral therapy in Japan for the treatment of spinal muscular atrophy (SMA)...
The type 2 diabetes (T2D) treatment landscape in Australia is mature with the availability of generics, insulin biosimilars and novel therapies. In this competitive market,...
Achieving glycemic control and managing hypoglycemia are two of the largest unmet needs in the treatment of Type 1 Diabetes (T1D), according to GlobalData. The...
Artificial intelligence (AI) and big data will play a major role in optimizing pharmaceutical drug discovery and development process, as indicated by 24% and...
Following the ADA update of the bacillus Calmette-Guerin (BCG) vaccine as a treatment for type 1 diabetes (T1D) earlier this month, leading data and analytics...
The size of the COVID-19 vaccine market across the seven major markets (7MM*) will increase from $13.6bn in 2021 to $19.5bn in 2026 at a...
New immunotherapy agents in the oncology pipeline aim to predict the most important tumor antigens and formulate a personalized vaccine against them. With multiple catalysts...
Seelos Therapeutics has recently announced that the first patient has been dosed in the second part of its registrational study of SLS-002 (intranasal racemic ketamine)...
Eli Lilly and Novo Nordisk will continue to compete over the glucagon-like peptide 1 receptor agonist (GLP-1RA) market, with the strong possibility that the two...
Microbiome is a space with high potential, a fact underlined by the complete absence of microbiome-targeting treatments on the market. This therapeutic area is set...
The adult epilepsy market is expected to grow from $5.82bn in 2020 to $8.35bn by 2030 across the seven major markets (7MM*) at a compound...
The Huntington’s disease (HD) market is projected to grow at a Compound Annual Growth Rate (CAGR) of 13.8%, reaching $917.7m by 2030 across the three...
The migraine treatment landscape in Japan is growing with the recent approval of calcitonin gene-related peptide (CGRP) inhibitors as preventative treatment. In this developing market,...
Corticosteroids are typically the first line of therapy for most patients with uveitis as these drugs are very effective and have anti-inflammatory effects. However, as...
The 2020 Olympic Games in Tokyo will take place from July 23 to August 8, 2021, with a one-year delay due to the COVID-19 pandemic;...
Over the past decade, disease-modifying cystic fibrosis transmembrane conductance regulator (CFTR) modulators have transformed the treatment paradigm for CF, according to GlobalData, greatly improving the...
Topical Janus kinase (JAK) inhibitors are becoming a major force in the atopic dermatitis (AD) space. An increasing number of JAK agents are filling the...
Following the news that Zydus Cadila has applied for emergency use authorization (EUA) to the Drug Controller General of India (DCGI) for its plasmid DNA...
Ardelyx presented interim data from its ongoing OPTIMIZE study at the European Renal Association. The primary endpoint of the Phase IV OPTIMIZE study is to...
The Olympic games are considered to be the world’s most prestigious sports competition, with more than 200 nations participating. However, this year’s Olympic games are...
Eisai and Biogen’s lecanemab (BAN2401) and Eli Lilly’s donanemab have recently received breakthrough therapy designation (BTD) by the US Food and Drug Administration (FDA) for...
UniQure recently announced the enrolment of the first two patients in the second cohort of a Phase I/II clinical trial of AMT-130, a micro ribonucleic...
Following today’s news (29 June) that Merck & Co’s Keytruda received EMA approval for patients with esophageal cancer (EC) or HER2-negative gastroesophageal junction (GEJ) adenocarcinoma...
Following the news that cases of COVID-19 due to the Delta variant in the UK have increased, despite record numbers of people being vaccinated; Emily Martyn,...
The Food and Drug Administration (FDA)’s Endocrinologic and Metabolic Drugs Advisory Committee voted in favor of Provention Bio’s teplizumab 10-7 to delay the onset of...
Untapped potential within the overactive bladder (OAB) market remains considerable due to under-diagnosis and under-treatment of this highly prevalent condition, according to GlobalData, a leading...
The diagnosed prevalent cases of uveitis in the nine major markets (*9MM) are projected to increase from 1.7 million cases in 2019 to 1.9 million...
Sage Therapeutics and Biogen have recently announced positive results from a pivotal Phase III trial for their novel, GABA A receptor allosteric modulator, antidepressant zuranolone....
The Tokyo Olympics will likely be an epicenter of transmission for COVID-19 and could increase variant of concern (VOC) spread, bringing new cases to Japan...
Gene therapies will provide a valid treatment option for patients that have developed resistance to chemotherapies across several cancer indications. With patient access set to...
The Fabry disease (FD) market in the US and Japan will see significant growth between 2020 and 2030, as total sales in these two major...
China’s Bio-Thera Solutions has recently initiated a Phase III trial of its proposed golimumab biosimilar BAT2506 in China and Eastern Europe. Against this backdrop, BAT2506...
Novavax has further demonstrated excellent results from its pivotal PREVENT-19 vaccine trial. Despite this positive data, it will likely see very little uptake in the...
Chinese biopharma companies are eyeing strategic collaborations with western counterparts to leverage their extensive networks and commercial capabilities to promote indigenously developed drugs in China,...
The systemic sclerosis (SSc) market is expected to grow from $498m in 2020 to $1.8bn in 2030 across the seven major markets (7MM*) at a...
CARsgen Therapeutics’ novel pipeline therapy for advanced hepatocellular carcinoma (HCC) stands out in the American Society of Clinical Oncology (ASCO) virtual annual meeting for being...
The non-small cell lung cancer (NSCLC) treatment landscape in Japan looks very mature with multiple drugs approved for targeted therapy, immunotherapy and chemotherapy. In this...
China has made its latest patent amendments effective from June 01, 2021, reforms which are likely to ensure protection against untimely and unfair generic competition....
Companies and organizations continue to report clinical trial disruptions across the globe due to the COVID-19 pandemic. These disruptions are being caused by a number...
26% of all cell and gene therapies in late-stage development in the US are being developed for oncology. The FDA has backed the use of CAR-T...
Since COVID-19 was officially declared a pandemic by the World Health Organization (WHO), the peak in total number of clinical trials for the virus was...
Preliminary safety results from the Oxford led Phase II Com-COV trial investigating immune responses in patients given heterologous prime-boost vaccine schedules indicate that mixing vaccines...
The COVID-19 pandemic saw certain markets such as anesthesia and respirator devices grow in 2020, while many others such as dental devices stagnated or saw...
The post-marketing data in the treatment refractory population of the COSMOS Phase IIIb study could allow J&J the opportunity to position interleukin (IL)-23 inhibitor Tremfya...
Following FDA’s approval of Aduhelm (aducanumab) for the treatment of Alzheimer’s Disease (AD), after no new drug for this indication has been approved in the...
Eli Lilly’s highly anticipated tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able...
The diagnosed prevalent cases of systemic sclerosis (SSc) in the seven major markets (*7MM) are projected to increase from 171,000 cases in 2020 to 187,000...
At the 70th annual American College of Cardiology (ACC) 2021 meeting, positive data from the EXPLORE-HCM trial was presented for Bristol-Myers Squibb’s mavacamten, a targeted...
Cadila Healthcare Ltd. is among the leading players in India which focuses on bringing in-house developed innovative therapies for patients. Cadila Healthcare has developed a...
Improved efficacy for HNSCC therapeutics able to demonstrate an overall survival benefit remains a key unmet need in the indication. The next decade may...
Following the news of Medtronic's latest financial report for Q3 FY2021 that medical device revenues have fully recovered through the anniversary of the COVID-19 pandemic,...
Rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) space in the three major markets (3MM): the...
Boehringer Ingelheim recently announced that its product, BI 425809, has received Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for Cognitive...
The UK regulatory review of Alexion Pharmaceuticals acquisition by AstraZeneca limits the ability of GlaxoSmithKline (GSK) to buy its way out of a proxy brawl...
Substance use rose by 13% in the US during 2020, which could result in an additional 252,000 cases in the number of Americans who abuse...
The neuropathic pain market is the most valuable segment within the pain indications and was valued at $10.8bn in 2020 globally. It is forecast to...
Annovis Bio recently announced positive results from a Phase IIa trial of its pipeline asset ANVS401 (posiphen) in patients with early Parkinson’s disease (PD). The...
NLS Pharmaceutics has recently announced new data confirming that its narcolepsy product, a controlled release (CR) formulation of mazindol, has agonist activity at orexin-2 receptors...
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain...
The multiple sclerosis (MS) therapeutics market is becoming increasingly crowded, but the overall fulfillment of unmet needs is medium. There are no curative therapies for...
Therapies targeting B-cell maturation antigen (BCMA) now account for approximately 10% of immuno-oncology drugs in Phase I-III development globally. With just two marketed agents available...
At the 70th annual American College of Cardiology (ACC) 2021 meeting, results were presented for the PARADISE-MI trial. The results demonstrate that for Novartis to...
Following Arcutis Biotherapeutics’ announcement of new data from its pivotal DERMIS-1 and DERMIS-2 studies of topical phosphodiesterase-4 (PDE4) inhibitor roflumilast for plaque psoriasis (PsO) at...
Prior to the COVID-19 pandemic, the diagnosed prevalence of type 1 diabetes (T1D) was predicted to grow annually by 0.93% in the US, and the...
Japanese pharmaceutical company Daiichi Sankyo received a major headway in the global oncology space with the launch of its first antibody drug conjugate (ADC) therapy...
While post-Brexit regulatory changes continue to cause significant uncertainty for the UK’s healthcare sector, the UK Government’s initiatives, such as the Medicines and Medical Devices...
The ankylosing spondylosis (AS) treatment landscape in India is moderately established with a few disease-modifying anti-rheumatic drugs (DMARDs) available from innovator companies along with biosimilars...
Vertex, the current owner of the entire cystic fibrosis transmembrane conductance regulator (CFTR) modulators’ market share, is expected to remain the market leader over the...
Diagnosed incident cases of endometrial cancer are expected to increase from 120,883 cases in 2020 to 133,690 in 2030 in the eight major markets (8MM*),...
India could reach approximately 1.4 million new daily COVID-19 cases by May 24, if current transmission risk is not reduced further, according to a two-week...
Over the past 20 years, the diabetes market has gone through significant maturation as a result of increased innovation and modernization of therapeutic treatments. The...
Following today’s news (18 May) that Bristol-Myers Squibb (BMS) has exclusively licensed Agenus’ bispecific anti-TIGIT antibody, AGEN1777, for up to $1.36bn; Sakis Paliouras, PhD, Senior Oncology...
While the UK-EU Trade and Cooperation Agreement (TCA) removed the prospect of a no-deal Brexit, it introduced a wide range of changes to the UK’s...
With pipeline approvals of varying mechanisms and an influx of newly diagnosed patients, the chronic kidney disease (CKD)-hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) market...
Following the news that cases of the Indian variant in the UK has tripled in one week during the same period lockdown rules are due...
GlobalData has partnered with BizInt Solutions for reporting drugs and clinical trials data from its Pharma Intelligence Center. BizInt Smart Charts software is used to...
Celiac disease (CD) represents an area of high unmet clinical need as there are no products that have been approved specifically for this indication. Historically,...
Following the news that the US Food and Drug Administration (FDA) has authorized Pfizer and BioNTech’s Comirnaty for adolescents 12 to 15 years of age,...
The Food and Drug Administration’s (FDA) accelerated approval program has recently come under fire due to high-profile withdrawals of immune checkpoint inhibitors (ICIs) from the...
The Food and Drug Administration (FDA) approved more biologic new molecular entities (NMEs) in 2020 than in any other year in the previous decade, while...
More than 50% of surveyed healthcare industry professionals from Europe believe that Brexit allowed the UK to accelerate its COVID-19 vaccines approval process 31% of...
In 2020, 92% of 5EU physicians stated that they used biosimilars in at least 25% of their RA patients, compared to 70% of physicians...
Diagnosed prevalent cases of chronic kidney disease (CKD) in the seven major markets (7MM*) combined is expected to increase from 8.57 million cases in 2020...
Merck & Co. and Bristol-Myers Squibb (BMS) have transformed the treatment paradigm in advanced and metastatic head and neck squamous cell carcinoma (HNSCC) settings by...
Following the news that Roche has received emergency use authorization (EUA) for a COVID-19 antibody cocktail casirivimab and imdevimab; Prashant Khadayate, Pharma Analyst at GlobalData, a...
The hepatocellular carcinoma (HCC) market is expected to grow from $1bn in 2019 to $5.3bn in 2029 in the eight major markets (8MM*) at a...
Thermo Fisher Scientific, a diversified life science company, has announced its intent to purchase PPD, a Clinical Research Organization (CRO), for $17B. PPD is a...
The surge in new variants for COVID-19 and an increase in subsequent cases is continuing to have an impact on clinical trials, while still allowing...
A post hoc analysis of the multicenter AMETHYST-DN study found that the use of Vifor Pharma’s Veltassa (patiromer) significantly reduced serum potassium in patients ages...
Freeline Therapeutics recently announced plans to progress dose escalation for its Phase I/II trial for FLT190, an adeno-associated variant (AAV) based gene therapy for Fabry...
China has reformed its regulatory system in recent years to include various fast-track programs similar to the US, EU, and Japan to incentivize the development...
Drugs being developed for COVID-19 were awarded the highest number of SBIR/STTR funding grants, at 187 grants. Most grants awarded to drugs that are currently...
The market landscape in the nine major markets (9MM*) for chronic hepatitis B (CHB) is expected to see significant change between 2019 and 2029. Projected...
It is expected that 15 therapeutics will launch in the Type 1 Diabetes (T1D) market in the eight major markets (8MM*) before 2030. They include...
COVID-19 infections continue to rise with several countries facing second-and third-wave infections with the newly evolved mutant strains, thereby increasing the demand for effective vaccines....
Although cell therapies such as CAR-T have been approved and used successfully to treat hematological cancers, there are currently no cell therapies approved for the...
As COVID-19 cases continue to soar in some countries, demand for Pfizer and Moderna’s vaccines is fast exceeding production capabilities, while restrictions placed on AstraZeneca...
The COVID-19 pandemic brought not just a more difficult business environment to operate in, but also opportunities for contract manufacturing organizations (CMOs), as even the...
The melanoma market has experienced moderate growth since 2016, and is expected to increase further, from $5.59bn in 2019 to $7.42bn in 2029 across the...
The Parkinson’s disease (PD) market is expected to see significant growth in the 7MM*, with the decade starting 2019 seeing an impressive 12.6% compound annual...
The burden of diagnosed small cell lung cancer (SCLC) is expected to increase at an annual growth rate (AGR) of 3.5% from around 180,000 cases...
In early April, AbbVie announced its submission to the US FDA for its selective interleukin (IL)-23 inhibitor, Skyrizi (risankizumab), for the indication of psoriatic arthritis...
Despite considerable improvements that blockchain could bring to the pharmaceutical sector, this technology-related revolution has not quite happened yet. While COVID-19 accelerated digital transformation in...
Australia has the highest age-standardized incidence rate for all cancers in the world and one of the countries with substantial cancer screening programs. Against this...
Following today’s news (26 April) that the Food and Drug Administration (FDA) has accepted Axsome Therapeutics’ new drug application (NDA) for its novel antidepressant therapy...
A novel ‘double mutant’ variant of SARS-CoV-2, along with other factors, has accelerated the COVID-19 pandemic in India, setting a global record of new daily...
The pancreatic cancer market has seen the launch of premium priced therapies in the last three to four years in late-stage pancreatic cancer patients, resulting...
Beijing-based pharmaceutical company Sinovac Biotech’s CoronaVac vaccine was recently found to be 49.6% effective in real-world data from Brazil. However, considering the global demand for...
In March 2021, SalioGen therapeutics raised $20m to support the preclinical validation of its non-viral gene therapy platform, exact DNA integration technology. The development of...
The emergence of new SARS-CoV-2 variants have been detected in over 40 countries and are disrupting drug development worldwide. The prevalence of these more transmissible...
The commercial launch of Urovant Sciences’ first product, Gemtesa (vibegron), a beta 3 adrenergic receptor agonist in the US, addresses overactive bladder (OAB) symptoms by...
Abbott’s rapid COVID-19 antigen self-test, the BinaxNOW, is now widely available across the US at CVS Pharmacy, Walgreens, and Walmart without a prescription; Dara Lo, Medical...
Diagnosed incident cases of melanoma in the eight major markets (8MM*) combined is expected to increase from 0.19 million cases in 2019 to 0.22 million...
With the Sputnik V vaccine’s recent approval, India now has three vaccines authorized for COVID-19 treatment. However, despite better efficacy over Serum Institute of India/...
Immuno-oncology (IO) agents will be the dominant class in the hepatocellular carcinoma (HCC) market by 2029 due to the launch of pipeline drugs targeting programmed...
Following today’s news (16 April) that Amgen has completed its planned acquisition of Five Prime Therapeutics for $1.9bn; Sakis Paliouras, PhD, Senior Oncology & Hematology Analyst...
Five delays in regulatory reviews for a single drug class in less than one month could serve as an early warning sign that the Food...
Pfizer/BioNTech’s Comirnaty (tozinameran) is forecast to have peak sales of $24.8bn by 2021, which is only its second year on the market. This is a...
Chinese domestic ICI brands poised for approvals across multiple oncology indications International brands seeking access in China should balance diminishing drug prices with the...
Following Roche’s announcement of new 2-year data from Part 2 of FIREFISH, a Phase II/III global study evaluating Evrysdi (risdiplam) in infants aged 1-7 months...
The University Technology Licensing Program (UTLP) was created to improve innovation in multiple sectors and facilitate more efficient licensing between commercial companies and the 15...
The approval of a Food and Drug Administration (FDA) emergency use authorization (EUA) for AstraZeneca’s COVID-19 vaccine AZD1222 will boost confidence and use of the...
The rheumatoid arthritis (RA) treatment landscape in Australia is well established with several novel disease-modifying anti-rheumatic drugs (DMARDs). However, stiff biosimilars competition is expected to...
The number of diagnosed prevalent cases of Parkinson’s disease is expected to rise in the seven major markets (7MM), which comprises the US, France, Germany,...
Following the news that the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) released a joint statement calling...
Primary research by data and analytics company GlobalData has revealed that 80% of asthma patients do not take their medication effectively. The reasons for this...
Given recent findings that nearly one-third of previously hospitalized COVID-19 patients in the UK are readmitted for further treatment within five months after infection, and...
The inherent heterogeneity of diseases such as cancer is driving the field of personalized (precision) therapies. Within personalized therapies, chimeric antigen receptor (CAR-T) therapies are...
Key opinion leaders (KOLs) in the US, 5EU* and China have confirmed that they are not satisfied with the current state of surveillance programs for...
There are diverse development strategies and trends in the Parkinson’s disease (PD) treatment at present, however only a few of them address the pressing need...
The burden of diagnosed chronic hepatitis B (CHB) is expected to increase at an annual growth rate (AGR) of 0.20% from an estimated 17.8 million...
Following the news that the European Medicines Agency (EMA) has confirmed a possible link between very rare cases of unusual blood clots after vaccination with...
Novavax’s investigational COVID-19 vaccine, NVX-CoV2373, is forecast to have $33.3bn total sales for 2021–2027 and to be the second-leading vaccine candidate by peak forecast sales...
Diagnosed prevalent cases of type 1 diabetes (T1D) in the eight major markets (8MM*) combined are expected to increase from 3.33 million cases in 2019...
The US is running the highest number of COVID-19 clinical trials in the world, according to the clinical trial database by data and analytics company...
Emergent BioSolutions has been one of the largest winners from the contract manufacturing of COVID-19 vaccines but, having ruined 15 million doses of J&Js COVID-19...
Immuno-oncology (IO) agents, particularly immune checkpoint inhibitors (ICIs) and CAR-T cell therapies, have extended the survival of patients in many cancer types and current investigational...
The major depressive disorder (MDD) market is expected to grow from $3.97bn in 2019 to $7.87bn by 2029 across the eight major markets (8MM*) at...
The coronavirus disease 2019 (COVID-19) is likely to have far-reaching consequences for the mental health of women with major depressive disorder (MDD), which is expected...
Newron Pharmaceuticals and Zambon’s planned pivotal trial to evaluate a label extension for Xadago (safinamide) in patients with Parkinson’s disease levodopa-induced dyskinesia (PD-LID) is a...
Following the news that the European Medicines Agency (EMA) has approved Novartis’ Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in...
Non-alcoholic fatty liver disease (NAFLD) is emerging as an important cause of a wide spectrum of liver diseases including non-alcoholic steatohepatitis (NASH) in India. A...
Following today’s news (30 March) that the FDA has accepted AbbVie’s new drug application for atogepant for the preventive treatment of migraine; Christie Wong, Pharma Analyst...
According to GlobalData’s clinical trial database, the landscape for endometriosis has greatly diversified in recent years. The number of companies initiating trials in the space...
Negative CAGRs of 0.61% and 3.89% is projected for the chemotherapy drug class in the US market for haematological and solid tumors, respectively. Sales...
Western China’s pharmaceutical production needs international and domestic investment, as there less number of facilities compared to other Chinese regions and few international pharma companies...
The latest wave of COVID-19 vaccines - those from AstraZeneca and Johnson & Johnson (J&J) - are recombinant vector vaccines, which are a different molecule...
Rising strategic partnerships between global pharmaceutical companies to develop therapies in the head and neck cancer space can serve as opportunities for increased scientific development...
Texas and several other states such as Mississippi, Louisiana, and Michigan rescinding previous executive orders that were intended to slow the spread of COVID-19 could...
The total chronic kidney disease (CKD) anemia drug market size for the 8MM* in 2019 was valued at $4.7bn, defined as sales of major branded...
Australia continues to focus on reducing healthcare expenditure and encouraging the use of biosimilars over their reference product. Cipla adopted deals route to capitalize on...
On March 7, 2021, the UK reported 5,265 daily confirmed cases, the lowest reported case count since the second-wave peak of over 68,000 cases on...
The field of immuno-oncology (IO) has been in need of novel biomarkers ever since 2011. The most promising or anticipated biomarker among high-prescribing physicians in...
Following the news that the European Medicines Agency (EMA) has approved Kixelle, Biocon/Mylan’s biosimilar of Novo Nordisk’s Novolog/NovoRapid (insulin aspart); Samisha Khangaonkar, Pharma Analyst at GlobalData,...
At the one-year anniversary of the World Health Organization’s official declaration of the COVID-19 pandemic, there has been record-breaking progress made towards developing a COVID-19...
Clustered regularly interspaced short palindromic repeat (CRISPR) therapies are one of the most potentially powerful and transformative technologies in human history, according to GlobalData, a...
The diagnosed prevalent cases of chronic kidney disease-anemia (CKD-anemia) in the eight major markets (*8MM) are projected to increase from four million cases in 2019 to...
Italy and France are witnessing another wave of COVID-19 infections probably caused by the spread of the UK B.1.1.7 variant and the only realistic solution...
High value deals have dominated the Asia-Pacific (APAC) pharmaceutical strategic partnership landscape in 2020. Within the region, China is well ahead of other countries, particularly...
The COVID-19 vaccination rate in the UK exceeds that of any other country in Europe and is on track to be the first country in...
Roche recently announced that its product, Evrysdi (risdiplam), which was approved by the US Food and Drug Administration (FDA) in August 2020, was recommended for...
The 12-month prevalent cases of major depressive disorder (MDD) is expected to increase from 53.37 million cases in 2019 to 55.36 million cases in 2029,...
Over a quarter of rare diseases trials were terminated between 2016 and 2020* due to low accrual rates, according to research by GlobalData, a leading...
If new SARS-CoV-2 variants continue to develop, they could affect not only the effectiveness of COVID-19 vaccines, but also the natural immunity that COVID-19 survivors...
The hepatitis C virus (HCV) therapeutics market in Japan is highly competitive with stiff competition between Gilead and AbbVie. However, AbbVie has taken an edge...
AstraZeneca/Medimmune Therapeutics’ Imfinzi (durvalumab), an immunotherapy targeting programmed death-ligand 1 (PD-L1), recently failed to demonstrate increased overall survival (OS) in patients with recurrent or metastatic...
Following Galapagos’ announcement of pooled interim results from its ongoing MANTA and MANTA-RAy safety studies for Jyseleca (filgotinib); Rose Joachim, Pharma Analyst at GlobalData, a leading...
During Colorectal Cancer Awareness month, it is important to highlight that precision medicine approaches are gaining traction in this indication. Positive results from any of...
The Trump administration’s decision to relax oversight of genetically modified (GM) animals for food prioritizes big businesses and the livestock industry, while overriding FDA scientists...
Following the news that Bharat Biotech’s COVID-19 vaccine Covaxin showed 81% interim efficacy; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers...
In February 2021, Novo Nordisk released impressive data from its Phase IIIa STEP1 trial for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in a bid...
With the COVID-19 pandemic recently passing one year in duration, clinical research continues to be significantly affected. Sponsors have had to modify trial designs to...
Following the news of President Biden’s announcement that the US will have enough COVID-19 vaccine supply for all US-Americans by the end of May; Philipp Rosenbaum,...
Even though the pharmaceutical sector used to display a more conservative stance toward the adoption of new technologies, the COVID-19 pandemic acted as a trigger...
The Central Drugs Standard Control Organization (CDSCO) has recently approved several generic versions of sunitinib to treat kidney cancer. Against this backdrop, the approval of...
The approval of Roche's Avastin (bevacizumab) plus Tecentriq (atezolizumab), in addition to the long list of pipeline products, opens up gaps in the treatment paradigm...
The number of clinical trials disrupted by the COVID-19 pandemic continues to increase into 2021, although the degree of disruption varies depending on the therapy area, says GlobalData, a leading data and analytics company. Scotty Chung-Siu, MPH, Senior Analyst at...
Innovative drug approvals increased in the US between 2019 and 2020. This increase happened despite the FDA’s stretched resources, as it had to reassign staff to cope with COVID-19-related activities. The agency approved 121 novel drugs in 2020, compared with 119 in in 2019, says GlobalData,...
While the US has excelled in vaccine development, its distribution and administration efforts did not go according to plan due to the dependence on states....
National Colorectal Cancer (CRC) Awareness Month is an opportunity to raise awareness about the disease and educate patients, especially about recurrence, one of the most...
The market performance of the top 20 Bio/Pharma companies is still being impacted by the COVID-19 pandemic, either positively for companies developing a vaccine for the disease or negatively for those working on a treatment, says GlobalData, a leading data and analytics company. Madeleine Roche, MSc, Analyst...
As pharmaceutical companies continue to grapple with issues ranging from lack of transparency on pricing, price gouging to questionable ethical practices and clinical data reporting processes, addressing environmental, social, and governance (ESG) issues will continue to be an...
The diagnosed prevalent cases of human immunodeficiency virus (HIV) in the seven major markets (7MM*) are projected to increase from 1.87 million in 2019 to...
Velphoro’s (sucroferric oxyhydroxide) recent VELREAL multicenter study showed a 20% decrease in serum phosphorus in addition to reduced parathyroid hormone level in chronic kidney disease...
The recent SARS-CoV-2 virus variant in South Africa (B.1.351) underscores a critical weakness in combatting the COVID-19 epidemic and may prolong it indefinitely, says GlobalData,...
The Parkinson’s disease (PD) pipeline has been hit significantly with a string of failures among its most anticipated mid-stage pipeline candidates. This news presents a...
The human immunodeficiency virus (HIV) therapeutics market was worth an estimated $22.9bn across the seven major markets (7MM*) in 2019. The market is expected to grow at a Compound...
Gilead and Galapagos recently announced the discontinuation of the ISABELA Phase III clinical trials investigating ziritaxestat, a once daily autotaxin inhibitor formerly known as GLPG-1690,...
China-based EOC Pharma has recently entered an in-licensing partnership with US-based biopharmaceutical company Aadi Bioscience for the development and commercialization of ABI-009 (Fyarro). This deal,...
Caladrius Biosciences’ initiation of the Phase IIb FREEDOM trial of its autologous CD34+ stem cell therapy, CLBS16, in coronary microvascular dysfunction (CMD), is an important development milestone. While concerns regarding the therapy’s scalability, potential cost and...
As of 2020, unmet needs in immuno-oncology (IO) revolve around three main pillars: Cost, efficacy and toxicity. While a multitude of pipeline agents are poised...
The need to develop novel innovative cancer drugs at affordable prices is forcing large pharmaceutical firms to collaborate with biotech companies and academic institutions. Japan-based...
Over 60% of diagnosed prevalent cases of lupus nephritis in the UK in are seen in class IV and V, says GlobalData, a leading data...
Through the Brexit deal struck between the UK and EU on 24 December 2021, the UK will be part of Horizon Europe, the EU’s next framework...
If Tidepool’s diabetes management app Tidepool Loop gains its 510(k) clearance from the Food and Drug Administration (FDA), it will have a significant impact on...
COVID-19 relief and vaccine roll-out should prioritize American Indians and Alaska Natives (AI/AN) populations, as they are a marginalized group in the US healthcare and...
Janssen Pharmaceuticals has recently partnered with Verana Health, which is specialized in data analytics in the field of ophthalmology and urology. The collaboration can help...
The FDA and EMA’s recent positive opinions on the expanded use of Merck & Co’s Keytruda (pembrolizumab) has the drug all set to catch up...
Many clinical trials were set to resume activity as the initial peak of the COVID-19 virus started declining. However, with the number of confirmed COVID-19...
The primary analysis of AstraZeneca/Oxford’s vaccine is likely to put pressure on other companies to demonstrate reductions in transmission as soon as possible, says GlobalData,...
Experts estimate that achieving herd immunity to COVID-19 will required upwards of 70–90% of the population to have immunity. While vaccine efficacy for Moderna’s mRNA-1273...
The recent deal between Coherus BioSciences and Shanghai Junshi Biosciences for Junshi’s PD-1 inhibitor named Tuoyi (toripalimab) is the fifth such deal between the US...
India has reported a gradual decline of the COVID-19 infections after reporting a high number of daily new cases in September and October 2020. The...
In its Union Budget 2021, India has more than doubled its spending on healthcare to boost the sector which has been strongly impacted by the...
Biogen recently announced Food and Drug Administration (FDA) approval of its new intramuscular (IM) injection route of administration for Plegridy (peginterferon beta-1a) for the treatment...
While governments are ramping up vaccination programs, continued research into the effectiveness of the vaccines is imperative to prevent a worsening of the impact of...
With the COVID-19 pandemic contributing to delays in clinical trial enrollment and routine cancer screening and treatment, many barriers have arisen preventing patients from seeking...
The implementation of new strategies will turn the hepatocellular carcinoma (HCC) market into a land of opportunity for manufacturers, leading to a wave of new...
Tonix Pharmaceuticals (Tonix) has recently announced a licensing deal with Katana Pharmaceuticals for its intranasal potentiated oxytocin with a view to expand its application into...
Brazil has been among the most heavily affected countries in Latin America during the COVID-19 pandemic, and it remains among the top three worst affected...
There has been a boom in bio/pharma special purpose acquisition companies (SPAC) deals in recent years. Last year seems to be no different as SPAC...
President Joe Biden brings a significant likelihood of federal marijuana reform, one of his key campaign promises. Amidst the ongoing opioid crisis, legalizing cannabis at...
The emergency use approval (EUA) of Covaxin in India will further strengthen its credibility and validate Bharat Biotech’s intent to make the indigenous vaccine popular...
Sonder’s European expansion plans have not been halted due to COVID-19 as the company is now exploring the Spanish market, with a keen eye on Madrid and Barcelona. Sonder is in a position to expand...
Since June 2020, the number of total disrupted trials has been falling slowly; however, this has leveled off in October 2020. Despite this, the number of clinical trials that have resumed continues to rise. The majority...
• COVID-19 will continue to impact all aspects of the pharma value chain in 2021 • Drug development activities, in particular clinical trials, will have the biggest impact on industry...
Following the news that Concert Pharmaceuticals is stopping development of its adjunctive treatment for schizophrenia, CTP-692 (D-serine), after it failed to meet its primary endpoint...
There has been a 639% increase in the number of COVID-19 clinical trials worldwide, from 549 COVID-19 clinical trials in early April 2020 to over...
Following the news that Novavax’s COVID-19 vaccine shows 89.3% while Johnson & Johnson’s (J&J) demonstrated 66% efficacy; Michael Breen, PhD, Director of Infectious Diseases and Ophthalmology...
Following Pfizer’s recent announcement of co-primary endpoint results from ORAL Surveillance (NCT02092467) in rheumatoid arthritis (RA) patients with cardiovascular (CV) risk factors; Rose Joachim, Pharma Analyst at GlobalData, a leading data and...
Despite seriously affecting the ability to carry out clinical research, COVID-19 is also proving to be a catalyst that may transform the drug development process, with technological innovations taking center stage in driving this...
The melanoma therapeutics market in Japan comprises of drugs approved for chemotherapy, immunotherapy, and targeted therapy. Among these, immunotherapy and targeted therapy are the leading...
One the most concerning secondary conditions of COVID-19 is myocarditis and research indicates that 60% of COVID-19 survivors, independent of the severity of the illness,...
The rapid advancement of mRNA vaccine development in recent months - in an attempt to halt the COVID-19 pandemic - is expected to continue to...
The COVID-19 pandemic has shown the many wide-ranging benefits of telemedicine. In a survey by GlobalData, pharmaceutical industry professionals noted that they expect telemedicine to...
This year is expected to provide significant insights into the future of cervical cancer treatment since out of the 107 ongoing clinical trials worldwide for cervical cancer, 30% are estimated to be completed by the end of the year, says GlobalData, a leading data and analytics company. Miguel Ferreira, MSc,...
The pharmaceutical industry will be shaped by several emerging trends in 2021. The industry will need to adapt quickly post-COVID-19 by overcoming the spread of...
Forxiga’s (dapagliflozin) latest priority review by the FDA for chronic kidney disease (CKD) further signifies the drug’s major advantages over existing treatments and will provide...
Artificial intelligence (AI) will transform the pharmaceutical industry in the coming years by delivering productivity improvements and efficiencies across the entire pharma value chain, says...
Following the news that AriBio announced the completion of a Phase II clinical trial of AR1001; Sarah Elsayed, MBA, Neurology Analyst at GlobalData, a leading data...
Myovant Sciences’ deal with Pfizer to co-develop and commercialize oral GnRH antagonist relugolix in oncology and women’s health in the US and Canada will substantially...
Aldeyra Therapeutics recently announced top-line results from the run-in cohort of the Phase III trial evaluating its product 0.25% reproxalap for patients with dry eye...
South Korea has become the third country in the Asia-Pacific region after Japan and Australia to approve the first ever triple combination therapy from Novartis...
China updated its National Reimbursement Drug List (NRDL) in December 2020 to include 119 new medicines, with an average price cut of 50.64% agreed by...
REMD Biotherapeutics recently announced the top-line results of its Phase II study of volagidemab, which aimed to determine whether volagidemab could decrease daily insulin requirements...
Israel is currently on track to be the first country in the world to inoculate its entire population. This could provide a gold standard for...
Ongoing COVID-19 lockdowns and requirements of social distancing have swiftly pushed healthcare provision and patient monitoring towards remote options. Even though remote patient monitoring (RPM) was already being used...
Governments need to place more focus on South Africa’s COVID-19 variant, 501.V2, as it is now considered more infectious than the UK variant based on...
The UK January lockdown measures should decrease the number of COVID-19 cases in the following weeks, with the possibility of falling as low as approximately...
The Food and Drug Administration (FDA) recently accepted Pfizer and OPKO Biologics Biologics License Application (BLA) for somatrogon for the treatment of pediatric growth hormone...
The rheumatoid arthritis (RA) market is expected to grow from $26.2bn in 2019 to $29.1bn in 2029 across the eight major markets (8MM*) at a compound annual growth...
The immuno-oncology (IO) therapeutic area is increasingly becoming recognized as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy and other targeted treatments due...
Biogen recently announced the first SMA (spinal muscular atrophy) patient treated in a study Phase IV RESPOND that will evaluate the efficacy and safety of...
On the heels of the highest single-day death total in the UK, the need for speed in the mass vaccination program against COVID-19 has become...
Following the news that the incoming Biden administration promises $20 billion for a national vaccination program, Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData,...
Japan is aggressively making efforts to vaccinate its population for COVID-19 with a strong focus on signing pre-orders. The country has signed multiple deals with...
Serum Institute of India’s (SII) Covishield and Bharat Biotech’s Covaxin have recently received emergency use authorization (EUA) in India. However, despite indigenous vaccine Covaxin’s approval,...
Technological advancements in oncology, such as the introduction of immuno-oncology therapies and targeted therapies, have improved quality of life (QoL) compared to conventional treatment options,...
Teva Pharmaceuticals and MedinCell are seeking to enter the long-acting injectable (LAI) schizophrenia market after their LAI mdc-IRM (risperidone ER) demonstrated a statistically significant increase...
The Japanese type 2 diabetes (T2D) therapeutics market is highly competitive with several generic, branded and biosimilar products available. Among the various types of therapies,...
Pfizer-BioNTech’s two-shot mRNA COVID-19 vaccine, BNT-162b2, is currently the leading prophylactic vaccine for COVID-19 based on forecast sales as it is expected to be the...
In 2021, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData,...
The diagnosed incident cases of hepatocellular carcinoma (HCC) in urban China are expected to increase by 44.41% over the next decade (2019-2029), according to GlobalData,...
Urban China is expected to have the highest number of diagnosed incident cases of non-small cell lung cancer (NSCLC) among the eight major markets 8MM*...
Up to December 1, 2020, mergers and acquisitions (M&A) deal value in the Bio/Pharma industry was down only 13% compared with last year, with a...
The World Health Organization (WHO) launched a global strategy on 17th November 2020 to eliminate cervical cancer. The move paves way for the prevention of...
As of November 30, 2020, the top reason for disrupted clinical trials is slow enrollment, which is causing delays in 49% of trials. The other...
The COVID-19 outbreak’s trajectory in Africa is expected to continue to increase for a prolonged period due to lower testing capacity and lack of vaccination...
A positive recommendation from an FDA Advisory Committee has set Novartis’ Entresto (sacubitril/valsartan) on track to become the first drug to be approved for the...
KBP Biosciences recently shared results for its BLOCK-CKD Phase IIb study and the positive trial results suggest KBP-5074 may become a viable competitor to the already established non-steroidal mineralocorticoid receptor antagonists (MRAs) for chronic kidney disease (CKD), according to GlobalData, a leading...
SoniVie and ReCor Medical both recently received US Food and Drug Administration (FDA) breakthrough device designation for their TIVUS and Paradise renal denervation systems. With...
NovoNordisk’s decision to investigate its recently launched Type 2 Diabetes (T2D) drug Rybelsus (semaglutide) in a pivotal Phase IIIa study of patients with early Alzheimer's disease may...
South Korea’s pharmaceutical sector is becoming increasingly innovative and attractive to foreign investment only 18 months into the government’s $1.7bn five-year biotech plan. The country’s...
The growing rate of new COVID-19 cases indicates the US is facing a major crisis of hospital shortages not yet seen in this pandemic, and...
The COVID-19 pandemic and the subsequent lockdown measures have led to the widespread adoption of telemedicine in India. Against this backdrop, the growing market can...
Novartis recently engaged in a flurry of collaborative agreements in the ophthalmology field and the scope of these collaborations will help the company to pull...
Juvenile Diabetes Research Foundation (JDRF) recently announced the launch of its ground-breaking screening initiative for type 1 diabetes (T1D), T1Detect, which aims to make early detection of T1D easier and more accessible to the broader population. This...
Following the news that the US Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for Roche’s Ocrevus (ocrelizumab) in patients with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS); Sarah...
The COVID-19 pandemic has pushed India to expedite focus on pharma research and development (R&D) to become more independent. The hope of getting indigenous COVID-19 vaccines...
The Japanese immunology market is highly competitive with many innovator products available for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), inflammatory bowel disease (IBD)...
The recently demonstrated superiority of AbbVie’s Rinvoq (upadacitinib) versus Regeneron and Sanofi’s Dupixent (dupilumab) across primary and all secondary endpoints in the Phase IIIb Heads Up study may well showcase its potential...
There are eight mRNA COVID-19 vaccine candidates currently in Phase II or Phase III clinical trials. These vaccines are faster to develop than traditional vaccine...
With a 2021 Food and Drug Administration (FDA) submission now on the cards, following impressive data from its pivotal trial HOPE-B, uniQure’s etranacogene dezaprvovec (EtranaDez)...
The overall level of unmet need in hepatocellular carcinoma (HCC) is high due to its severity and low survival. However, the needs will soon be...
Following the news that the US Food and Drug Administration (FDA) has recommended emergency approval for the Pfizer-BioNTech COVID-19 vaccine and that the US has...
Following Slovakia’s national testing program from 31 October – 1 November, where two-thirds of the population were tested and the number of new daily cases dropped substantially, Slovakia was applauded for its efforts and held...
With Pfizer/BioNTech’s COVID-19 vaccine becoming the first mRNA vaccine in the world to receive emergency use approval by the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA), the race is on for other bio/pharma companies with COVID-19 candidates to...
The lack of approved immune checkpoint inhibitors (ICI) in the gastric and gastroesophageal adenocarcinoma (G/GEJAC) market in the *5EU is expected to significantly enhance the...
Galapagos recently reported positive topline results from its Phase IIA PINTA clinical trial investigating the use of 100 mg GLPG1205 for the treatment of idiopathic pulmonary fibrosis (IPF). Although the trial had a promising...
Currently in the UK, there are over nine million lifetime diagnosed prevalent cases of asthma and approximately 13 million undiagnosed asthma patients, says GlobalData, a...
Lockdowns in the UK and some US states may be contributing to the slight slowing in the trajectory of ‘resumed’ trials, says GlobalData, a leading...
The diagnosed prevalent cases of rheumatoid arthritis (RA) in the eight major markets (*8MM) is expected to increase from 4.6 million cases in 2019 to...
Following the news that Janssen has submitted a Marketing Authorisation Extension to the European Medicines Agency (EMA) for its product paliperidone palmitate 6-Monthly (PP6M) for...
Two recent Phase III mRNA COVID-19 vaccine trials resulted in 95% efficacy and generally well-tolerated safety profiles for vaccines BNT162b2 and mRNA-1273, developed by Pfizer/BioNTech...
Following Prime Minister Justin Trudeau’s announcement of Canada’s vaccination schedules; James Spencer, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “With the...
Following recent news that the UK will become one of the first countries in the Western world to authorize a COVID-19 vaccine; Urte Jakimaviciute, Senior Director...
Following the news that Biogen have entered into a licensing agreement with Sage Therapeutics to jointly develop and commercialize zuranolone (SAGE-217) and SAGE-324; Philippa Salter, Neurology...
The field of regenerative medicine (RM) is rapidly expanding as there are currently 53 marketed RM products and 175 RM pipeline agents in development in...
Following the news that Pfizer/BioNTech’s COVID-19 vaccine BNT162b2 received emergency use approval from UK health authorities; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a...
The burden of diagnosed asthma is expected to increase at a compound annual growth rate (CAGR) of 0.31% from around 86.7 million cases in 2019...
The bladder cancer therapeutics market was valued at $670m in 2018 across the seven major markets (7MM*) and is expected to grow exponentially at a...
In the Northern Hemisphere, flu season is beginning in conjunction with the COVID-19 pandemic, however, influenza-like activity remains low in the US, with 40% fewer cases...
The number of diagnosed incident cases of acute lymphocytic leukemia (ALL) in the eight major markets (8MM*) is projected to increase from 23,729 in 2019...
Novartis recently registered a Phase III psoriatic arthritis (PsA) clinical trial of its IL-17 inhibitor Cosentyx (secukinumab) compared against Johnson & Johnson’s Stelara (ustekinumab). The...
The acute lymphocytic leukemia (ALL) market has enjoyed explosive growth since 2015 and is expected to increase further, albeit at a slower pace, from $1.46bn...
If the current trend in US COVID-19 cases continue, over 30% of the US population will have contracted the virus by July 2021, according...
China recorded the highest year-on-year increase in the number of clinical trials initiated investigating PD-1/PD-L1 targeted combination immuno-oncology therapies across the eight major markets (8MM*)...
A record number of late-breaking trials were submitted to the Annual Scientific Sessions of the American Heart Association (AHA) this year and unsurprisingly, a key...
The burden of diagnosed pancreatic ductal adenocarcinoma (PDAC) is expected to increase at an annual growth rate (AGR) of 2.60% from around 180,000 cases in...
Half of the companies in a ranking of top 20 global innovative pharmaceutical firms by data and analytics company GlobalData reported positive market capitalization (MCap)...
If Provention Bio’s rolling Biologic License Application (BLA) submission to the FDA for teplizumab is approved, teplizumab will be the first disease-modifying therapy for type...
Gmax Biopharm announced that the first patient has received its humanized monoclonal antibody drug, GMA301, as part of investigations around the drug’s efficacy for the...
The diagnosed prevalent cases of acromegaly in the seven major markets (7MM*) combined is projected to increase from 43,220 cases in 2019 to 47,340 in 2029,...
The idiopathic pulmonary fibrosis (IPF) market was valued at $2.5bn in 2019 across the seven major markets (7MM*), and is expected to grow to $3.6bn...
Following a controversial FDA Advisory Committee meeting for Biogen’s aducanumab for mild Alzheimer’s disease, where the panel members sharply recommended against approval, the therapy will...
Several pharmacological treatments for non-alcoholic steatohepatitis (NASH) are expected to be launched in the seven major markets (7MM*) over the next 10 years. It is...
Following the news that the Phase III study of the COVID-19 vaccine developed by Pfizer and BioNTech has been concluded and is showing 95% efficacy...
Akebia Therapeutics presented additional data from its Phase III PRO2TECT trial at the 2020 American Society of Nephrology Kidney Week conference, that evaluated the efficacy...
While Pfizer has witnessed a positive experience regarding the development of its Janus kinase (JAK) inhibitors, there is the distinct possibility that having so much...
Declining pharmaceutical research and development (R&D) efficiency has been an ongoing problem in pharmaceutical sector. With emerging technologies reshaping various business, pharma is looking to capitalize on...
Following Brainstorm Cell Therapeutics announcement of topline results for its anticipated amyotrophic lateral sclerosis (ALS) stem cell therapy NurOwn; Sarah Elsayed, Neurology Analyst at GlobalData, a...
Today (Wednesday 18 November) is World COPD Day 2020. Chronic obstructive pulmonary disease (COPD) is a group of respiratory diseases that hinder airflow cause breathing...
Marketed therapeutics for the treatment of acromegaly generated sales of at least $33m in Italy in 2019. The value of this market is expected to more than double, surpassing $75m in 2029, according to GlobalData, a leading data and analytics company. GlobalData’s recently published...
Vaccine developers are selecting contract manufacturing organizations (CMOs) close to home for their COVID-19 vaccine, as the US, UK and Germany are the most popular...
Several countries globally are now going through a second wave of COVID-19 infection. India is ranked second in terms of the confirmed COVID-19 cases globally....
Eli Lilly’s monoclonal antibody (mAb) bamlanivimab is unlikely to face payer pushback, despite its broad label, after recent FDA emergency use authorization (EUA) experts told...
COVID-19 is driving many small pharma companies that do not have the expertise or funds to run their own manufacturing facilities to outsource production. COVID-19...
The US Food and Drug Administration (FDA) recently announced the approval of Kala Pharmaceuticals’ Eysuvis, a topical steroid (0.25% loteprednol etabonate ophthalmic suspension), for short-term...
Following the news that Moderna has announced its COVID-19 vaccine, mRNA-1273, is 94.5% effective in first interim data readout; Michael Breen, PhD, Director of Infectious Diseases...
Type 2 diabetes (T2D) is a crowded and competitive landscape, with market growth primarily driven by an increasing diagnosed prevalent population across nine major markets...
Across the seven major markets* (7MM), the diagnosed prevalence of type 1 and 2 diabetes (T1D) was approximately 3.7 million and 49.7 million, respectively, in...
Following the publication of a review of Phase III clinical trials for drugs for schizophrenia by the FDA, which suggested improvements to clinical trial design; Philippa...
This year has been a record year for biotech initial public offerings (IPOs), with total deal value already up by 58% compared with all of...
Ardelyx and Kyowa’s tenapanor therapy for hyperphosphatemia (HP) in chronic kidney disease (CKD) patients who are on dialysis is likely to gain a front-line position...
Following the string of approvals this year for Roche's combination of Avastin (bevacizumab) and Tecentriq (atezolizumab), key opinion leaders interviewed by GlobalData from the five...
COVID-19 has been a wake-up call for pharma companies to rethink their operations and customer access. Embracing digital transformation will have an important role to...
With Pfizer and BioNTech announcing that a Phase III trial investigating the BNT162b2 vaccine to be 90% effective in preventing symptomatic COVID-19 in participants without...
In Japan, the breast cancer treatment landscape consists of various systemic therapies including chemotherapy, hormonal therapy, targeted therapy and immunotherapy. Key players in this space...
Ease of administration and dual protection of local and systemic immunity are promising drivers for intranasal vaccines’ adoption and compliance, particularly at a time when...
Following the news that Pfizer and BioNTech have announced their COVID-19 vaccine is more than 90% effective in first interim data readout; Philipp Rosenbaum, PhD, Senior...
Following the news that Pfizer and BioNTech have announced their COVID-19 vaccine is more than 90% effective in first interim data readout; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers...
A significant proportion of vaccine developers are smaller companies that lack the capacity and funds to manufacture their vaccines in-house. However, there is also simply not enough contract manufacturing capacity worldwide to cope with commercial COVID-19 vaccine demand,...
In response to the COVID-19 pandemic, Horizon 2020 (H2020), the EU’s biggest research and innovation program, invested almost €6M ($7.1M) for COVID-19 related research and drug development in...
COVID-19 is set to be a major catalyst for the pharmaceutical industry. The rush to adapt to new social distancing and lockdown norms has led...
One of the surprising notes around the interim results of the Phase II/III SOLIDARITY trial for COVID-19 is that remdesivir showed little to no effect....
The US currently makes up 38.4% of the global medical device market, according to leading data and analytivs company GlobalData - signifying that adopting Medicare...
Contract development and manufacturing organizations (CDMOs) are busier than ever, and their work will increase as the pandemic prompts pharma companies to increase redundancy in...
Following the release of FDA documents today noting support for the safety and efficacy of Biogen’s treatment for Alzheimer’s Disease (AD), aducanumab, it is looking...
The gastric and gastroesophageal adenocarcinoma (G/GEJAC) market is expected to grow from $1.6bn in 2019 to $3.9bn in 2029 across the eight major markets (8MM*)...
Fujifilm Diosynth Biotechnologies USA Inc., a contract development and manufacturing organization (CDMO), has shown a 200% increase in all deal volume for infectious disease drugs...
Trump and Biden have sharply contrasting policies on female patient accessibility to reproductive healthcare. Trump has repeatedly expressed his mandate to overturn the Affordable Care...
The number of diagnosed prevalent cases of Sjögren’s Syndrome (SS) in the seven major markets (7MM*) is projected to increase from 1.63 million in 2019 to...
Despite the high unmet needs within hepatocellular carcinoma (HCC), the market was stagnant from 2007 until 2018, when the FDA approved Eisai’s Lenvima (lenvatinib) in...
COVID-19 death rates in Poland have increased at an alarming pace since early April, from 4.7 deaths per million population to over 100, as of October 20....
A total 65% of industry experts are of the opinion that Joe Biden and the Democratic Party have the better approach for handling healthcare issues...
Hyperimmune intravenous immunoglobulin (hIVIG), derived from plasma, could improve on efficacy of the Food and Drug Administration’s (FDA) authorized COVID-19 convalescent plasma treatment, but whether...
Following new data from Imperial College London (ICL) suggesting that antibody levels against SARS-CoV-2 wane over time; Michael Breen, PhD, Director of Infectious Diseases and Ophthalmology...
Telemedicine use in the US increased from the low ten thousands to around 1.3 million patients in 2020, representing more than 100-fold increase, according to...
The use of Emergency Use Authorizations (EUA) has been deeply polarizing in the US. With only days left until the presidential election, a growing number...
The current COVID-19 pandemic has caused the granting agency Innovate UK to prioritize innovative COVID-19 projects. Infectious disease has become the priority in terms of...
The contrast between US President Donald Trump and the Democrat nominee Joe Biden’s stances on healthcare are quite stark. While it is not immediately clear...
Dose contract manufacturing organizations (CMO) contract revenue in 2019 only grew 3.1% compared to 2018 revenue, which is one of the lowest rates since 2012,...
With the US’ Food and Drug Administration’s staging an all-day virtual meeting yesterday (22 October) regarding its planned standards for authorizing a COVID-19 vaccine; Reynald Castañeda,...
With over three-quarters* of US and European healthcare professionals saying they will continue using telemedicine after the COVID-19 crisis ends, governments are under pressure to...
Bristol-Myers Squibb’s (BMS) blockbuster combination of Opdivo and Yervoy is facing increasing scrutiny in various oncology indications as to whether the financial burden and clinical toxicity added by Yervoy is worth it. According to leading data and analytics company GlobalData, clinical trials with Opdivo monotherapy outnumber...
Following Amylyx’s announcement that AMX0035, its amyotrophic lateral sclerosis (ALS) pipeline drug, showed potential to prolong patient survival in addition to slowing rapid disease progression in the open label extension of Phase II/III clinical trial...
Following the news that the US and EU have blocked India's fight for intellectual property rights (IPR) waiver for COVID-19 drugs; Prashant Khadayate, Pharma Analyst at...
Reproductive health topics are perhaps some of the most divisive in US politics, with President Donald Trump, and his Democratic opponent, former Vice President Joe Biden, taking vastly different positions on several key issues in...
The launch of pentavalent vaccines from GlaxoSmithKline and Pfizer that protect against the meningococcal serogroups A, B, C, W, and Y (MenABCWY) in the nine...
The diagnosed prevalent cases of ulcerative colitis (UC) in the eight major markets (*8MM) are projected to increase from 1.7 million cases in 2019 to...
With recent pipeline approvals of varying mechanisms and an influx of newly diagnosed patients, the pulmonary arterial hypertension (PAH) market is expected to grow at...
Senior management of biopharma companies were more optimistic about the COVID-19 pandemic’s effect on imports/exports in Q3 compared to Q1, according to respondents who completed...
Following the news that the Indian state of Maharashtra has fixed the price of remdesivir; Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics...
Pharma companies across the globe are working to develop a vaccine against COVID-19, which has already infected more than 38 million globally. Against this backdrop,...
Diagnosed prevalent cases of diabetic retinopathy in the nine major markets (9MM*) are expected to increase from 14.3 million in 2019 to 17.8 million in 2029, at...
The Crohn’s disease (CD) market is expected to grow from $7.4bn in 2019 to $12.6bn by 2029 across the eight major markets (8MM*) at a...
New data unveiled at the United European Gastroenterology Week (UEGW) virtual conference showed that Eli Lilly’s Crohn’s disease (CD) hopeful, mirikizumab, can deliver durable endoscopic and symptomatic efficacy...
Second waves of COVID-19 worldwide will coincide with the start of the winter months in the northern hemisphere and with the flu season, making the...
Following reports that COVID-19 may cause lingering heart damage; Vinie Varkey, M.Sc, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers her view:...
Following the announcement of positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory...
October is Breast Cancer Awareness Month, a worldwide annual campaign that highlights the importance of breast cancer awareness, education and research. One of the consequences of...
The total number of trials disrupted by COVID-19 since June has been falling slowly, while trials impacted by slow enrollment continue to increase. For trials...
The daily confirmed cases of COVID-19 in France is increasing, which could indicate that the country is experiencing a second wave of COVID-19. The spike...
Czechia is experiencing a spike in daily confirmed cases of COVID-19, indicating the onset of a second wave. However, despite the increase in new cases,...
The COVID-19 pandemic created an unprecedented demand for digital solutions for the delivery of safe and effective mental health treatment such as telemedicine. Even now,...
As US President Donald J. Trump puts his weight behind Eli Lilly and Regeneron Pharmaceuticals’ bid for an FDA Emergency Use Authorization (EUA) for their...
Pfizer’s recent investment of $200m in China’s CStone Pharmaceuticals for the development of a second-generation immuno-oncology agent is the latest partnership between US and Chinese...
Should the latest guidelines proposal by the US Preventive Services Task Force (USPSTF) for the screening of lung cancer take effect, GlobalData epidemiologists predict that...
Following the news that Axovant announced positive six-month follow-up data from its Phase II trial of AXO-Lenti-PD for the treatment of Parkinson’s Disease (PD); Philippa Salter,...
There is an M&A opportunity for large contract manufacturing organizations (CMOs) in North America and Europe to acquire facilities able to produce medicines with lower...
Clinical trials disrupted by COVID-19 are expected to resume at a much slower rate than originally anticipated, as more nations are re-enforcing lockdown due to...
With the European Medicines Agency (EMA) announcing today that it will also initiate a rolling review of the COVID-19 vaccine developed by Pfizer and BioNTech...
Acceleron Pharma’s sotatercept, was granted priority designation by the European Medicines Agency for pulmonary arterial hypertension (PAH) in May 2020. This further signifies the drug’s...
The FDA has removed a boxed warning concerning the risk of leg and foot amputations for Janssen’s sodium glucose co-transporter (SGLT) inhibitor, Invokana (canagliflozin) -...
Senior management of biopharma companies across North America, Europe and the Asia Pacific (APAC) region were more optimistic about the COVID-19 pandemic’s impact on annual...
Many surgical procedures have been postponed during 2020 due to COVID-19. This will lead to over 11% loss of revenue from urinary tract stents in...
Gaining approval by the EC and Japanese Ministry of Health, Labour and Welfare (MHLW) on the same day for adults with moderate-to-severe active rheumatoid arthritis...
Bausch Health recently announced that it had entered into an agreement with Allegro to acquire an option to purchase all of the latter’s ophthalmology assets....
Oral GnRH antagonists have off-label potential in the female infertility space, beyond the indications of endometriosis-associated pain and uterine fibroids, which constitute the main development...
Three-fourths of dose manufacturing facilities acquired by dedicated CMOs in 2019 were located in Europe, according to an analysis of sites supplying the US, Canada,...
The pharma manufacturing in the three Southern Indian states of Karnataka, Tamil Nadu and Kerala, and Goa (Western India) has a high merger and acquisition...
Pharma companies around the world are exploring innovative approaches to develop therapeutics and vaccines against COVID-19. One of these innovations is using a nasal spray...
Following President Trump’s announced executive order directing the Department of Health and Human Services (HHS) to issue rules ensuring that specific regulatory changes to telemedicine...
Following the news that Roche has announced new positive two-year data for Evrysdi (risdiplam) in infants with spinal muscular atrophy (SMA); Philippa Salter, Neurology Analyst at...
Following the news that Roche has announced new positive two-year data for Evrysdi (risdiplam) in infants with spinal muscular atrophy (SMA); Philippa Salter, Neurology Analyst at...
The late-stage ALS pipeline has several promising therapies that look to address some of the unmet needs in the market. Pipeline strategies have focused on...
The clinical success of Amgen’s Blincyto has amplified the intensive pace of development for bispecific antibodies in oncology. According to GlobalData’s drugs database, there are...
In light of another setback in the Alzheimer’s disease (AD) drug development field, with the failure of Roche and AC Immune’s antitau antibody, all eyes...
The diagnosed prevalent cases of Crohn’s disease (CD) in the eight major markets (*8MM) are projected to increase from 1,339,543 cases in 2019 to 1,629,940 cases...
Following a review of data from the Phase I STRONG study of the intrathecal (IT) formulation of Novartis’ one-off gene therapy Zolgensma (onasemnogene abeparvovec) in...
The diagnosed prevalent cases of pulmonary arterial hypertension (PAH) in the seven major markets (*7MM) is expected to increase from 67,400 cases in 2019 to...
The diagnosed prevalent cases of amyotrophic lateral sclerosis (ALS) in the eight major markets (*8MM) is expected to increase from 57,800 cases in 2019 to...
The opioid use disorder (OUD) market is expected to grow from $1.6bn in 2018 to $3.7bn by 2028 across the eight major markets (8MM*) at...
Eli Lilly’s baricitinib, marketed as Olumiant in rheumatoid arthritis, has received a recommendation of approval from the European Medicines Agency’s (EMA) Committee for Medicinal Products...
Several COVID-19 outbreaks across the US since mid-June have been traced back to bars and nightclubs as the source of contagion. This coincides with a...
One of the most worrying issues in regard to US healthcare is that the cost of treatment and therapeutics is unreasonably high - often to...
World Alzheimer’s Day 2020 (21 September) serves as a timely reminder that drug development in this space is slow, as the Alzheimer’s disease (AD) drug...
A second spike of cases was seen in the UK at the start of August, and while the new daily cases are currently increasing at...
Following the news that India-based Dr. Reddy’s Laboratories (Dr Reddy’s) has partnered with the Russian Direct Investment Fund (RDIF) to distribute the COVID-19 vaccine Sputnik...
Eli Lilly and Boehringer Ingelheim’s (BI’s) Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) are expected to drive heart failure (HF) market growth and achieve high uptake...
Alkermes’ schizophrenia/bipolar disorder candidate ALKS-3831 weight gain data will be at the forefront of a 9 October FDA Advisory Committee (AdCom) meeting, but how the panel members will evaluate it is up for debate, as reported...
At least 99 publicly owned pharma companies and contract manufacturing organizations (CMOs) – many with substantial market value and access to capital markets – were approved to receive PPP loans that were intended to help small businesses in...
Following the publication of new positive data from the Phase IIIb CASTING trial of Roche’s Ocrevus (ocrelizumab) in patients with relapsing-remitting multiple sclerosis (RRMS); Alessio Brunello,...
Phase IIb results were published in July for Shield Therapeutics’ oral iron-based phosphate binder PT20 for the treatment of hyperphosphatemia (HPT) in dialysis-dependent chronic kidney...
Amarin Corporation recently presented final results from the EVAPORATE trial in which Vascepa (icosapent ethyl) reduced patients’ coronary plaque by 17% compared to placebo following...
Many pharmaceutical companies have performed well, despite the impact of COVID-19, as all of the top 20 global innovative bio/pharma companies, ranked by market capitalization...
The US biosimilar drugs market has failed to deliver on the promise of making biologics more affordable and widespread. The education of all sectors of...
In Japan, the treatment landscape for inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is mature and encompassing many conventional therapies...
Inovio was one of the first of the over 200 companies to enter the pre-clinical development of a prophylactic COVID-19 vaccine (INO-4800), but the progress...
A total 73% of cardiology, gastroenterology, pulmonology, and respiratory specialists in the US, Europe, the UK and Japan indicated that their use of telemedicine has...
The diabetic retinopathy (DR) market has been dominated by neovascularization inhibitors, and this group of therapies is expected to generate more than $6.8bn in sales...
As more than 7,000 cell and gene therapies progress through the development pipeline and only 152 CMOs have the capabilities to manufacture them, production bottlenecks...
The COVID-19 induced lockdown resulted in an unprecedented rise in e-commerce transactions across India. In line with this, e-pharma sector also witnessed growth despite regulatory...
While the COVID-19 pandemic continues to cause high numbers of confirmed new cases in Brazil, the patient population available for the increasing number of COVID-19...
Sanofi’s progress in research and development (R&D) has been adversely impacted by the COVID-19 pandemic. As of late August, six of Sanofi’s clinical trials, which...
A total of 198 small- and mid-cap Bio/Pharma companies are currently involved in vaccine or therapeutic development for COVID-19, with a total of 244 unique...
Gene therapies dominate the pipeline landscape for retinitis pigmentosa (RP) with the gene coding for retinitis pigmentosa GTPase regulator (RPGR) the most common target among these...
Following the news that Type 2 diabetes sufferers in the UK were put on a soup and shake diet by the NHS; Akash Patel, Cardiovascular &...
If AbbVie is successful with its FDA application submission for JAK inhibitor Rinvoq in adult patients with ankylosing spondylitis (AS), the drug is expected to...
Healthcare experts have noted that their number one primary concern amid the COVID-19 pandemic was the delay to initiation or inability to conduct clinical trials,...
Reimbursement for dialysis patients on AstraZeneca’s/FibroGen’s roxadustat needs to be untangled such that it can be billed separately and be accompanied by hikes in eventual...
More than 1,200 therapeutics and vaccines have entered the research and development (R&D) pipeline since January 2020, according to GlobalData, a leading data and analytics...
Following the news that the FDA granted an EUA for convalescent plasma as a treatment option for COVID-19; Angad Lotay MPharm, Infectious Diseases Analyst at GlobalData,...
India is overhauling its pharma regulatory norms to expedite approval process and promote innovation. Given that the country is now focused more than ever on...
Following the news that Takeda and Ovid’s epilepsy drug soticlestat achieved positive Phase II trial results in children with hard-to-treat epilepsy syndromes; Philippa Salter, Neurology Analyst...
In a recent GlobalData poll* 38% felt that mRNA COVID-19 vaccines are the most promising of the vaccine technologies, noticeably beating DNA vaccines, which only...
The digital hospital-to-pharmacy referral scheme is taking time to materialize despite the significant benefits it would provide to the UK. With adverse drug events being...
The market for graft versus host disease (GvHD) prophylaxis and treatment in the five growth markets (5GM*) in the Asia-Pacific (APAC) region will undergo steady...
Use of telemedicine by US physicians has increased significantly as a result of the COVID-19 outbreak. In a survey conducted by data and analytics company...
Japan is now experiencing a second wave that is much larger than the first after having COVID-19 under control for over a month. The country...
Trilaciclib’s new drug application (NDA) acceptance signals a significant moment for cancer patients that need support with chemotherapy-induced toxicities - further highlighted by the fact...
Hepatocellular carcinoma (HCC) treatment has been deferred due to overburdened healthcare systems as a result of the COVID-19 pandemic. Leading data and analytics company GlobalData...
In a global prescription drug market worth over $600bn, oncology has become the dominant area, claiming a market share of 23.4% as of 2019, followed...
At present, more than 200 prophylactic vaccines are in development for COVID-19. While promising candidates should be selected for diversity, the novel nature of SARS-CoV-2...
Biotech company initial public offering (IPO) valuations have shown resilience during the COVID-19 pandemic, compared to other industries. This is largely due to the unique...
Global pharmaceutical industry job postings see recovery in Q3 thus far, following a decline in Q2 2020 Takeda’s workforce size of 49,578 as of...
In a recent GlobalData poll*, healthcare experts estimated that it would take some time for the clinical trials that were disrupted due to COVID-19 to...
In light of AstraZeneca’s denial that is it speaking to the FDA to push an emergency use authorisation for its COVID-19 vaccine, AZD1222; Reynald Castañeda, Pharma...
Telemedicine looks to be here to stay as leading companies in this space have reported dramatic increases in demand for their services in the US...
Following the recent news that BioMarin received a Complete Response Letter (CRL) from the Food and Drug Administration (FDA) indicating that its gene therapy for severe hemophilia A, ValRox (valoctocogene roxaparvovec), was not yet ready for approval; Tajekesa Chapman, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers...
COVID-19 cases began increasing in Spain from July, which, while could be partially down to an increase in COVID-19 testing, does coincide with the holiday...
Aimmune’s Palforzia (peanut allergy powder) has seen a slower uptake due to a knock-on effect of the COVID-19 pandemic. Uptake of new drugs such as...
Gilead received a big shock following the FDA’s complete response letter (CRL) for filgotinib. While there has always been concerns surrounding the Janus kinase (JAK)...
The use of stem cells to “re-awaken” the ovaries in women with premature ovarian failure (POF) pave the way for novel treatments for this cause of infertility, says GlobalData, a leading data and analytics company. Despite their young age, POF patients face...
Following the news that UK Health Secretary Matt Hancock has announced National Institution for Health Protection; Michael Breen, Director of Infectious Diseases at GlobalData, offers his...
Adcetris is the market-leading drug in the world’s 7MM* (US, 5EU and Japan) and the main contributor to the market growth in Hodgkin’s lymphoma (HL)...
India’s contract manufacturing organization (CMO) and pharma market has strongly attracted investment from global private equity firms in recent times, driven by favorable government policies...
At present, 37.8% of oncology trials that were disrupted by COVID-19 have resumed, according to GlobalData, a leading data and analytics company. This marks the...
The UK has one of the highest flu vaccination rates in the world. However, the COVID-19 pandemic is increasing appointment times due to extra precautions...
The number of total disrupted clinical trials has begun to fall since June, however, only trials that suspended enrollment have been on a downward trajectory,...
Opdivo is set to become the market leader in gastric in gastro-oesophageal cancer following the latest data from two label expansion trials, which were noted...
India is making rapid progress in the development of indigenous COVID-19 vaccines. With increase in the number of COVID-19 positive cases, their success will make...
Following the news that Russia has approved the first COVID-19 vaccine; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company,...
Following the news of Eli Lilly and Company initiating a Phase III trial for their monoclonal antibody, LY-CoV555, for the prevention of COVID-19 in nursing...
Recent study findings from the US Centers for Disease Control and Prevention (CDC) suggest there may be a difference in disease severity when comparing pregnant...
AstraZeneca’s Farxiga (dapagliflozin) is expected to significantly strengthen its presence in the the sodium-glucose co-transporter-2 inhibitor (SGLT-2I) class of the cardiovascular and metabolic arena after...
Following the FDA’s recently granted accelerated approval for Morphosys and Incyte’s CD19 targeting antibody Monjuvi (tafasitamab), Morphosys and Incyte partnership now pushes forward to compete...
Licensing agreements are decreasing in the rare disease space in favor of more complex collaborations and partnerships. Indeed, of the strategic alliances formed by the...
With the rapid proliferation of clinical trials addressing COVID-19, the US National Institutes of Health (NIH) launched the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)...
As another great year for the innovation bio/pharma industry, 2019 saw 17 of the top 20 mega cap players reporting YoY revenue growth, according to...
Following the news that the first subcutaneous (SC) formulation of Celltrion’s Remsima (infliximab-dyyb/CT-P13) was granted marketing authorization by the European Commission (EC) for all indications...
Since early May, there has been a second surge of the COVID-19 pandemic in Iran. In comparison to other countries, the number of daily deaths...
Following the publication of positive top-line data from the Phase II EMPhASIS trial of IMU-838 (vidofludimus calcium) in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) by...
Following the news that there is evidence that COVID-19 infection in pregnant women can exhibit signs that mimic a severe form of preeclampsia such as...
Regulatory bodies such as the National Pharmaceutical Pricing Authority (NPPA) and the Drug Controller General of India (DCGI) are keeping a close eye on remdesivir...
The US is seeing a steep rise in the number of new cases each day. The failure of the country to adopt a widespread use...
Novaliq recently announced its agreement with the US Food and Drug Administration (FDA) regarding the second registrational trial ESSENCE-2 for its late-stage therapy, CyclASol, for...
Biocon Sdn. Bhd., Malaysia, a subsidiary of Biocon Biologics, and digital therapeutics company Voluntis have recently announced a global collaboration agreement to develop and distribute...
Following the news that the Food and Drug Administration granted AstraZeneca’s Breztri approval in the US for chronic obstructive pulmonary disease (COPD); Angad Lotay, MPharm, Pharma...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from oncology influencers increased significantly, with content peaking in...
Nearly half of all 12-month total prevalent cases of opioid use disorder (OUD) occur in the population ages 18–39 years, followed by the age group...
The costs of treatment and the impact that the COVID-19 pandemic is having on the healthcare system remains a concern, says GlobalData, a leading data...
Although AstraZeneca, Johnson & Johnson/AbbVie and BeiGene all have oncology therapies, known as BTK inhibitors, repurposed for COVID-19 treatment, there are still important nuanced differences,...
Nearly half of global respondents to a poll by GlobalData believe that those in high-risk groups such as the elderly and patients with co-morbidities, should...
Liquidia Technologies’ planned acquisition of RareGen in Q4 will be a significant opportunity for Liquidia to expand its rare diseases pipeline, bolster its pulmonary arterial...
There are more than 1,039 COVID-19 potential drugs and 2,737 clinical trials for COVID-19 globally, with more than 430 of these being run in the...
Findings from Phase II trials of Clinigen’s Proleukin (aldesleukin) have suggested an overall shift toward immunosuppression in amyotrophic lateral sclerosis (ALS) patients who were given...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from infectious diseases influencers increased significantly, with content peaking...
Infectious disease drugs have overtaken oncology as the year’s top therapy area for contract service agreements (CSAs) as companies are shifting their current focus to...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from metabolic disorders influencers increased significantly, with content peaking...
Following today’s news (Thursday 23 July) that Incyte’s Jakafi (ruxolitinib) met its primary endpoint in its Phase III REACH-3 chronic graft-versus-host-disease (GvHD) study; James Mather, MChem,...
Based on the current trajectory of COVID-19 daily confirmed cases, South Africa is among the most heavily affected countries in the world, with a forecast of...
The transthyretin amyloidosis (ATTR) market is expected to grow from $585m in 2019 to $14.1bn in 2029 across the seven major markets (7MM*) at an...
Following Synairgen’s positive interim results from its inhaled interferon beta therapy, SNG001; Johanna Swanson, Product Manager at GlobalData, a leading data and analytics company, offers her...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to COVID-19 from cardiovascular influencers increased significantly, with content peaking in April,...
Following the news that Biogen is planning a Phase IV trial to test Spinraza (nusinersen) in patients with spinal muscular atrophy (SMA) who have already...
Australia’s initial response to the novel coronavirus was among the most successful worldwide. However, a recent increase in daily confirmed cases since the start of...
Following the news that interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune...
Following the news that AstraZeneca and Oxford University published Phase I/II results of their COVID-19 vaccine candidate ChAdOx1/AZD1222; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst and...
Following the news that Chinese biotech CanSino published Phase II results of its COVID-19 vaccine candidate Ad5-nCoV; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData,...
Following the news that UK biotech Synairgen announced reductions in COVID-19 disease progression and increased rates of recovery relative to placebo; Michael Breen, PhD, Director of...
Following the recent launch of Covifor (remdesivir) by Hetero in India, remdesivir has emerged as the most sought-after drug for the treatment of moderate to...
As countries begin to reopen from COVID-19, one of the currently important issues to examine is that of school re-openings. As infected children generally have...
The COVID-19 pandemic has caused some disruptions in Contract Manufacturing Service Agreements (CSAs), says GlobalData, a leading data and analytics company. Johanna Swanson, Product Manager at...
China is among the leading countries that are aggressively involved in developing vaccines for COVID-19, with one vaccine each from Sinopharm Group and Sinovac Biotech...
Janssen, a subsidiary of Johnson and Johnson (J&J), recently announced that Tremfya (guselkumab) received Food and Drug Administration (FDA) approval for patients with active psoriatic...
As the COVID-19 pandemic continues to disrupt companies, some have come out as winners or losers. Developers with COVID-19 therapies and vaccines will benefit in...
Following the recent news that the US Department of Health and Human Services (HHS) will be receiving data on COVID-19 hospitalizations from hospitals directly, bypassing...
Following the results of a Phase IIb/III trial that showed GSK’s investigational HIV prevention drug cabotegravir had superior efficacy over Gilead’s Truvada; Arafa Salam, PhD, Infectious...
Following the promising results from Moderna’s mRNA vaccine Phase I trial; Johanna Swanson, Product Manager at GlobalData, a leading data and analytics company, offers her view: “The...
As a vaccine product passes through clinical development, manufacturers will have to ensure that they are taking the required steps to ramp up production, as...
There are indications that some companies may be expediting the approval of COVID-19 vaccines, sometimes with subpar effectiveness, in response to pressure from governmental organizations....
The northern Chinese province of Hebei offers great potential for pharmaceutical investment as it has been one of the leading regions for pharmaceutical production. Though...
COVID-19 research and development (R&D) has started to see the first set of novel drug candidates enter clinical trials by way of monoclonal antibodies (mAbs)....
Strict lockdown measures in Peru have done little to curb the spread of COVID-19. GlobalData’s forecast for Peru indicates that the country may have reached...
Following the news that India-based biopharma company Biocon’s plaque psoriasis drug itolizumab (ALZUMAb) has secured approval from the Drugs Controller General of India (DCGI) for...
Following the FDA’s approval of Hulio (adalimumab-fkjp), a biosimilar of AbbVie’s Humira that was the highest grossing drug for eight years running with $19.2bn in...
Despite recent advances in idiopathic pulmonary fibrosis (IPF), significant unmet needs remain including increased earlier diagnosis, improved drug safety and efficacy, improvement in patient quality...
COVID-19 has had a catalytic effect on emerging technologies and has pushed several technologies into the forefront of methods to manage the pandemic. This is likely to be a watershed event and...
Pharma manufacturing is exempted from the lockdown measures in India; however, the movement of materials appears still to be limited, the workforce to carry out...
After three months of increasing trial disruptions, the number of disrupted trials began to fall between June and July. Most disruption was caused by the...
The US Federal Government’s Biomedical Advanced Research and Development Authority (BARDA) award of $354m to Phlow Corporation for the manufacture of COVID-19 medicines and other...
South Korea-based bio/pharma company Celltrion has recently agreed to acquire a portfolio of 18 prescription pharmaceutical products and over-the-counter medicines across the Asia-Pacific (APAC) region...
India-based Cipla has recently entered into a partnership with Boehringer Ingelheim (BI) India Pvt. Ltd. to co-market three new oral anti-diabetics drugs in India, mainly...
The Hodgkin’s lymphoma (HL) market is expected to grow from $1.2bn in 2019 to $2.1bn in 2029 across the eight major markets (8MM*) at a...
Following Biogen’s submission of a Biologics License Application (BLA) to the FDA of aducanumab; Alessio Brunello, Managing Pharma Analyst at GlobalData, a leading data and analytics...
Following the news that US biotech Novavax announced it will receive $1.6bn funding for the development of its COVID-19 vaccine candidate NVX-CoV2373; Philipp Rosenbaum, PhD, Senior...
The number of diagnosed prevalent cases of AL amyloidosis is expected to increase from 75,033 in 2019 to 89,637 in 2029 at an annual growth...
The burden of diagnosed Hodgkin lymphoma (HL) is expected to increase at an annual growth rate (AGR) of 0.90% from around 25,000 cases in 2019...
Following the news that Indian pharmaceutical giant Dr. Reddy’s Laboratories (Dr Reddy’s) has signed tripartite agreement with Tokyo-based FUJIFILM Toyama Chemical and Dubai-based Global Response...
Long-term complications arising in COVID-19 patients after recovering from the initial illness are expected to increase healthcare costs in the long-term. Complications such as stroke,...
In the seven major pharmaceutical markets (7MM*), less than half of non-alcoholic steatohepatitis (NASH) cases were diagnosed in 2019, says GlobalData, a leading data and...
Following Bristol Myers Squibb’s positive topline results from its pivotal Phase III TRUE NORTH trial, it is possible that oral sphingosine1‐phosphate (S1P) Zeposia could have...
As the world continues to brace for a COVID-19 triggered economic downturn and with the Brexit transition period extension deadline ending on 30 June; Urte Jakimaviciute,...
Following the news that the US secured virtually all available short-term stock of remdesivir; Brian Hicks, Medical Devices Analyst at GlobalData, a leading data and analytics...
Following the US FDA’s issuance of its guidance document; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his view: “The US Food and...
The COVID-19 pandemic has led to temporarily increased drug sales for biggest bio/pharma companies in the first quarter (Q1) of 2020. This increase over sales...
COVID-19 could be causing patients with Hodgkin lymphoma and other cancers to delay seeking care, which in turn could delay those patients from receiving a...
Since early March, over a hundred companies have publicly announced disruptions to planned and ongoing clinical trials in their press releases, SEC filings, as well...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from neurology influencers increased significantly, with content peaking in...
Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from immunology influencers increased significantly, with content peaking in...
The number of social media posts made by digital pharma influencers related to COVID-19 has increased significantly since it was declared a pandemic in March,...
In the UK and US, there is a pattern of minority ethnic groups having a higher risk of death due to COVID-19 compared with their...
The usefulness of adenovirus-vectored vaccines for COVID-19 is currently questionable as these should only be administered two times over the lifetime of an individual and...
The short duration of the COVID-19 antibodies throws into doubt the concept of immunity passports for this illness, as those who caught the disease could potentially catch it again. This is...
A total *76% of people, as surveyed by GlobalData, expect telemedicine to be used widely once the pandemic had abated. Kathryn Whitney, MSc, Director of Thematic...
At the beginning of June, more than 70% of trials were being run by non-industry sponsors, and the majority of clinical trial sponsors were based...
There are concerns over the pricing of remdesivir and how to make it available in low-income and lower-middle income countries, says GlobalData, a leading data...
The myelodysplastic syndromes (MDS) market is expected to grow from $1.6bn in 2018 to $2.4bn in 2028 across the seven major markets (7MM*) at a...
Following the FDA approval of Ferring Pharmaceuticals’ once-weekly progesterone vaginal ring for luteal phase support in women undergoing assisted reproductive technology (ART) treatment cycles, the...
The health and fitness wearables that monitor physiological parameters such as heart rate, body temperature, sleeping patterns, blood pressure and oxygen saturation levels may become...
Tonix Pharmaceuticals and Southern Research have partnered to create a COVID-19 vaccine based on Tonix’s proprietary horsepox vaccine platform. The use of the horsepox vector...
While researchers investigate recovered patient antibody treatments for COVID-19, intravenous immunoglobulin (IVIg) is a similar type of treatment that is already available and could be...
After receiving a world-first approval by the UK Government, following groundbreaking data showing it can reduce COVID-19 deaths among hospitalized patients, the inexpensive and widely...
Following Gilead’s announcement that it will begin Phase I clinical trials for inhaled remdesivir in healthy volunteers, data and analytics company GlobalData anticipates that a...
Acute myeloid leukemia (AML), a serious haematological cancer, remains a disease often defined by poor prognosis. However, less than 30% of diagnosed incident cases of...
Despite the COVID-19 challenges, most of the big bio/pharma companies had reported temporary increase in drug sales in Q1 2020, mainly due to the stockpiling...
Drug sales for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) collectively reached $2.2bn in 2018 across the eight major markets (8MM*). By the end...
Following the news that Indian drug firms cheer dexamethasone’s efficacy in severe COVID-19 patients;Nag Madhavi, Pharma Analyst at GlobalData, a leading data and analytics company,...
Following the news that domestic pharma giants Cipla and Hetero have received the Drugs Controller General of India’s (DGCI) approval to launch generic versions of...
The launch of new therapies between 2018 and 2028, including new classes of drugs with novel mechanisms of action (MOAs), and an anticipated increase in...
The phase distribution of clinical trials in Europe suggests that sponsors are focusing primarily on repurposing available therapies to treat COVID-19 and that the level...
Following the news that Glenmark Pharmaceuticals has become the first company in India to receive regulatory approval for oral antiviral favipiravir for the treatment of...
The effects of the COVID-19 pandemic on the market capitalization (market cap) of companies are mitigated by having a COVID-19 drug in their pipeline, with...
As the COVID-19 pandemic continues to sweep across the US, around 12% of intensive care hospitalized COVID-19 patients need to be placed on a ventilator. Not...
BeiGene has recently received approval for its second-generation Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) from the China National Medical Products Administration (NMPA). The China-based...
COVID-19 deaths are most likely being underreported in the US, according to GlobalData, a leading data and analytics company. Excess deaths measure the difference between observed...
The burden of diagnosed myelodysplastic syndrome (MDS) is expected to increase at an annual growth rate (AGR) of 2.40% from around 90,000 cases in 2018...
Comorbidity is a major concern in people with angina pectoris as, in 2019, there were nearly 20 million diagnosed prevalent cases of angina pectoris in...
Countries are beginning to reopen due to economic and social pressures, while keeping an eye on the threat of resurgences. Based on trends observed in...
In order to achieve ‘herd immunity’ to COVID-19, there are estimates that anywhere from 50–90% of the population will need to achieve immunity. This will...
The adoption of telemedicine has been accelerated significantly in the wake of COVID-19 outbreak. However, despite the increasing usage of the telehealth solutions, this innovation...
The COVID-19 pandemic presents significant growth opportunities for mental health and wellbeing technologies, however, telemedicine cannot replace in-person visits and these innovations will not resolve...
Clinical trial results for Gilead Science’s remdesivir have shown modest improvement in the recovery of moderately ill COVID-19 patients and remdesivir’s success in humans could...
The acute myeloid leukemia (AML) market is expected to grow from $1.4bn in 2019 to $5.1bn in 2029 across the eight major markets (8MM*) at...
Having a COVID-19 drug in a bio/pharma company’s pipeline resulted in a smaller decrease in market capitalization (market cap) during the first quarter (Q1) of...
The International Alliance of Amyotrophic Lateral Sclerosis (ALS)/ Motor Neuron Disease (MND) Associations, recognizes June 21 as the ALS Global Day. The goal of this...
Some children have developed a severe inflammatory response due to COVID-19 infection that appears similar to Kawasaki disease. Doctors are referring to this response as...
Despite receiving Food and Drug Administration (FDA) approval for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) before Novartis’s Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) will...
Serum Institute of India (SII) is the world’s largest vaccine producer in terms of volume. SII is currently working on three candidates for COVID-19, including...
The pharma sector saw promising year-on-year (YoY) growth in 2019, compared to the previous year, with 16 of the top 20 companies by market capitalization...
Oral selexipag could improve treatment for the pediatric population based on its convenient administration, better safety and better tolerability profile compared to currently available options...
Hydroxychloroquine may have resulted in a large amount of wasted effort towards finding a treatment for COVID-19 as another hydroxychloroquine study has shown no benefits...
The clean energy sector had been one of the biggest and fastest-growing sectors in the US since 2015, having employed over 3 million people. However,...
As the COVID-19 pandemic continues to evolve across the globe, a large amount of data on its epidemiology has been generated. Finding relationships and predictive...
Latin American countries are showing dangerous trends of increasing COVID-19 cases. Brazil, Peru, Chile, and Mexico are now ranked second, tenth, thirteenth, and fourteenth, respectively,...
More than 200 trials that were previously disrupted from the COVID-19 pandemic by delayed initiation and slow or suspended enrollment are now ongoing or completed....
The global COVID-19 pandemic has become a catalyst for the pharma industry and the US Food and Drug Administration (FDA) to implement long-awaited innovations. The...
Following the publication of a new study of the long-term effectiveness of midomafetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD);Philippa Salter, Neurology Analyst...
Following today’s news (Monday 15 June) that the FDA has pulled emergency use authorization of hydroxychloroquine for COVID-19;Johanna Swanson, Product Manager at GlobalData, a leading...
Gilead is likely preparing for remdesivir’s approval and launch, based on an analysis of GlobalData’s Job Analytics database. As an operational reaction to the COVID-19...
Moderna’s mRNA-1273 vaccine for COVID-19 is currently in Phase I development and is targeted for an aggressive commercial launch in 2021. The vaccine candidate’s peak...
The COVID-19 pandemic has exposed weaknesses around the US healthcare system and resulted in a large amount of uncertainty around the healthcare and health insurance...
Following the news that the Indian state of Maharashtra is planning to procure Gilead Sciences' antiviral drug remdesivir from Bangladesh-based pharmaceutical giant Eskayef Pharmaceuticals; Anupama...
Moderna Therapeutics recently received Fast-Track designation from the FDA for its COVID-19 candidate vaccine, mRNA-1273 together with the green light to initiate a Phase II clinical...
After a little over 100 days since the first confirmed case of COVID-19 reported on 28 February 2020, New Zealand has lifted almost all restrictions...
COVID-19 presents a challenge to physicians managing patients with multiple sclerosis (MS), due to concerns about using immunotherapies to treat this neurological condition, in the...
A recent research study showed that for 16 COVID19 positive women there were evidences that their placentas had blood clots and indications of abnormal blood...
Bayer donated millions of tablets of chloroquine to national health authorities around the world in anticipation of its possible usage as a treatment for COVID-19....
While Gilead Sciences’ remdesivir has been declared the new standard of care for COVID-19 despite some mixed trial results, it will continue to face challenges...
Recently, Brazil has steadily climbed the chart of the top 10 countries with the highest total of COVID19 cases, now ranking number two just behind...
If the development of Liquidia Technologies’ LIQ-861 dry powder inhaled formulation of treprostinil, indicated for the treatment of pulmonary arterial hypertension (PAH) is successful, the...
There is no clinical evidence that hydroxychloroquine is effective against COVID19. Some studies using hydroxychloroquine have shown no benefits or even an increase in risk...
As of mid-May, there were 131 contract manufacturing organizations (CMOs) in Spain with 161 Spanish sites, according to the GlobalData’s Contract Service Provider database, which...
A large number of COVID-19 treatment options (620 novel and repurposed drugs as of mid-May) have joined the drug development pipeline, with over 72% of...
The news that at least five publicly traded contract manufacturing organizations (CMOs) took out Paycheck Protection Program (PPP) loans from the US Government’s $659bn loan...
Oyster Point announced that top-line results from its Phase III Onset-2 trial evaluating OC-01 for dry eye disease (DES) in early May. The results demonstrated...
COVID-19–accelerated adoption of emerging technologies will revolutionize the frontline staff education and training process and become a new normal once the COVID-19 crisis ends, says...
GlobalData anticipates that Gilead’s remdesivir will target a select severity group of COVID-19 patients, and it remains questionable as to how treatment with the drug...
When clinical trials that were delayed since the beginning of the COVID-19 pandemic resume, it is highly probable that potential trial subjects will have a...
Based on the current trajectory of COVID19 daily confirmed cases, India will be the fourth most heavily affected country in the world behind the US,...
The COVID-19 pandemic has been disrupting clinical trials globally, but as countries reopen, these trials are now resuming. As of 28th May, over 130 COVID-19 disrupted...
The spread of the COVID-19 can be slowed by the use of interferon-lambda, which has the ability to inhibit replication of COVID-19 in the lungs...
A recent Phase I clinical trial performed at the University Medical Center Hamburg-Eppendorf for a Middle East respiratory syndrome (MERS) vaccine has produced positive results...
Following the news that the US Government’s ‘Operation Warp Speed’ picked AstraZeneca, Johnson & Johnson, Merck, Moderna, and Pfizer as finalists for COVID-19 vaccine funding; Philipp...
Nearly 60% of all diagnosed prevalent cases of dry eye syndrome (DES) occur in women. Women who are pregnant, on certain types of birth control,...
Remicade (infliximab) and Humira (adalimumab) are the established anti-tumor necrosis factor (TNF) therapies that have been shown to decrease inflammation in diseases such as rheumatoid arthritis (RA) and...
Even though blockchain stands out as a potential solution to improve pharmaceutical supply chains, COVID-19 may become a hindrance rather than a trigger in the...
The ongoing COVID-19 pandemic has increased the demand for drugs used to sedate the mechanically ventilated COVID-19 patients and has resulted in shortages for some of these...
Following the review extension from the Food and Drug Administration (FDA) of anti-CD20 monoclonal antibody drugs for multiple sclerosis (MS) to September 2020, which will...
The local production of the active pharmaceutical ingredients (API) for some of the key COVID-19 repurposed drugs including remdesivir, favipiravir and hydroxychloroquine (HCQ) is likely to offer a...
Paycheck Protection Program (PPP) loans from the US Government were taken out by at least 49 publicly traded bio/pharmaceutical companies from the $659bn loan program,...
Ferring Pharmaceuticals recently gained FDA approval for Milprosa, a once-weekly progesterone vaginal ring for the luteal phase support in women undergoing Assisted Reproductive Technology (ART)...
The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) declined by 10.1% during the week ended May 31, 2020...
The launch of the generic versions of dasatinib, following the expiration of Indian patent in April 2020 will increase the accessibility for treatment of chronic...
Following the news that India-based Sun Pharmaceutical Industries Ltd (Sun Pharma) has received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesylate in COVID-19 patients; Prashant...
At least 49 publicly traded bio/pharmaceutical companies took Paycheck Protection Program (PPP) loans from the US Government’s $659bn program despite official guidance that the money...
With a total of nearly 200,000 confirmed cases and over 5,500 deaths reported due to COVID-19 in the past three months, India stands in tenth position in...
As the global COVID-19 crisis continues, countries are taking stock of the current epidemiology information on the disease and attempting to evaluate if it is...
As of May 2020, six clinical trials for investigational medical marijuana products have been suspended as a result of COVID-19. Four of these trials had...
The Drug Controller General of India (DCGI) has recently given approval to Indian pharma companies Glenmark and Strides Pharma Science to initiate clinical trials of...
The US remains the most heavily affected country by the COVID-19 pandemic, with more than 1.7 million total confirmed cases. In comparison, South Korea is now thought...
In Japan, the plaque psoriasis (PsO) treatment landscape is highly competitive with the availability of conventional topical therapies, as well as biologics including anti-TNF, anti-IL-17, anti-IL-23 inhibitors, and...
As novel immuno-oncology (IO) drugs become established in the market, a new trend of combinatorial treatments is arising. The race to develop combinatorial drugs is...
As many COVID-19 patients may experience long-term complications from the illness such as intensive care unit (ICU) delirium, post-traumatic stress disorder (PTSD), lung damage, heart...
The concept of an immunity passport is under scrutiny and it is crucial that the underlying scientific, ethical, legal and practical issues must be addressed...
The elderly and those with pre-existing conditions have now been drafted onto the front lines in order to restart economies as we face a balancing...
Novo Nordisk’s recent announcement of positive topline data from its Phase IIIa study STEP 4, investigating the use of semaglutide to treat obesity, will enable...
The clinical trial landscape has had multiple disruptions due to the COVID-19 pandemic, including the cardiovascular and metabolic disorder (CVMD) space. Despite a few trials...
As Gilead Sciences’ remdesivir continues to steal the COVID-19 spotlight, the antiviral is likely to be considered for inclusion in the top-secret US Strategic National...
Following the news that India-based BDR Pharmaceuticals has sought the Drug Controller General of India (DCGI)'s approval to manufacture and sell the generic version of...
The number of deals announced in the global healthcare sector grew by 0.6% during the week ended May 24, 2020 compared to the previous week,...
Although the number of clinical trials that have suspended enrolment due to COVID-19 is leveling off, the overall disruption of trials continues to expand, says...
Following the announcement that Novavax has agreed a $167m deal to acquire Praha Vaccines to aid its manufacturing capabilities for its Phase I COVID-19 vaccine...
Messenger RNA (mRNA) based vaccine technology is emerging as one of the frontrunners among the technologies being evaluated to develop a vaccine for COVID-19, with...
CytoDyn’s Leronlimab is a promising candidate for the treatment of COVID-19 and is currently forecast by GlobalData to have global peak sales of $747m in 2026...
Pharmaceutical software development has been less impacted by the COVID-19 crisis as it facilitates remote working and already had group collaboration tools and software processes...
A new report, published in Nature Reviews Drug Discovery, reveals that the cellular immunotherapy landscape continues to expand, with 472 more cellular therapies in development now...
Roche recently announced the Food and Drug Administration (FDA) approval of Tecentriq (atezolizumab) as a first-line monotherapy for the treatment of metastatic non-small cell lung...
As a result of the COVID-19 pandemic, the treatment access for opioid use disorder (OUD) may increase; Philippa Salter, Neurology Analyst at GlobalData, a leading data...
Following the recent news that Sunovion Pharmaceuticals has received Food and Drug Administration (FDA) approval for Kynmobi (apomorphine), a novel sublingual film for the acute...
Following the FDA’s safety review on sodium glucose-transporter-2 (SGLT-2) inhibitors, a label update was issued stating that patients undergoing any scheduled surgery should discontinue treatment...
The COVID-19 pandemic caused a decrease in childhood vaccinations as preventative care was disrupted by the pandemic. The lack of vaccination could lead to another...
Alexion is investigating monoclonal antibody treatments Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) as potential therapeutics for COVID-19. While these drugs have established safety data, they both...
Yale University launched a clinical trial of ibudilast (MN-166) to assess it as a treatment for COVID-19 patients with acute respiratory distress syndrome (ARDS), a...
An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments...
The University of Oxford has reported positive findings from preclinical animal studies of its potential COVID-19 vaccine ChAdOx1, which involved nine rhesus macaques. The vaccine...
The diagnosed prevalent cases of angina pectoris is expected to increase from 19.58 million cases in 2018 to 22.79 million cases in 2028, at an...
Italy is a major active pharmaceutical ingredient (API) supplier to the global market, and its stringent lockdown measures has caused disruption of the supply chains that relied...
Following the announcement of Moderna’s interim data for its Phase I COVID-19 vaccine trial; Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, offers his...
Researchers from Washington University School of Medicine are now conducting a clinical trial of antidepressant drug fluvoxamine, as a potential treatment for the ‘cytokine storm’...
COVID-19 pandemic and opioid use disorder (OUD) are intersecting and worsening each other, demanding a rapid response to correct the underlying factors, says GlobalData, a...
In response to the global pandemic, biopharma companies have put a renewed emphasis on finding treatments for infectious diseases, including COVID-19 and other infectious diseases...
Clinical trials across the globe continue to be disrupted due to COVID-19. According to GlobalData, a leading data and analytics company, among global clinical trials that have been...
In the nine major pharmaceutical markets (9MM*), less than half of age-related macular degeneration (AMD) cases were diagnosed in 2019 in adults aged 50 years...
With the number of COVID-19 cases and deaths increasing with each passing day, the need for a therapeutic or a vaccine for the pandemic intensifies. Currently, 21...
As China opens up for businesses, the country is witnessing a new surge of travel-related COVID-19 cases in Jilin province in Northern China. The country had successfully...
With the scale and complexity of cybercrime increasing, and the fact that hospitals are moving toward digitalization and remote patient care, the number of cyberattacks...
A study by Sama et al. published in the European Heart Journal found that the ACE2 concentrations in heart failure patients are not affected by...
The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) grew by 4.4% during the week ended May 10, 2020...
Targeted therapies have delivered on their promise to make oncology more personalized. However, the addition of immunotherapy agents without first testing for patients who are...
Following the news that Indian Council of Medical Research (ICMR) and India-based Bharat Biotech have partnered to develop an indigenous COVID-19 vaccine; Anupama, Pharma Analyst at GlobalData, a...
In 2019 the US Food and Drug Administration (FDA) accepted 119 New Drug Approvals (NDAs) and Biologics License Applications (BLAs) including New Molecular Entities (NMEs)...
With Fujifilm Toyama Chemical’s Avigan (favipiravir) already approved in Japan for influenza, that country had announced plans to stockpile two million courses of the oral drug for...
Cerus Endovascular’s secured CE approval for coil-assisted flow diverter Neqstent was a great win for the company, but the path ahead may be slow-going. GlobalData,...
Following the news that Moderna’s mRNA COVID-19 vaccine candidate received FDA approval to start Phase II clinical studies; Philipp Rosenbaum, PhD, Infectious Diseases Analyst at GlobalData,...
A significant increase in the total prevalence of PTSD is expected globally amid the COVID-19 pandemic - with the risk for women being twice as...
As the COVID-19 pandemic continues to spread, researchers are examining reasons why various countries were impacted differently. It has been suggested that the severity of...
In April, Eli Lilly joined the fight in treating COVID-19 with an announcement that it had agreed to study Olumiant (baricitinib) as an arm in...
More than half of the top 20 global innovative pharma companies by market cap (Mcap) value saw a decrease in their MCap in the first...
Japan has already witnessed a significant downturn in the number of new daily COVID-19 cases since the national emergency was declared. However, the country is likely to see...
Despite the COVID-19 outbreak, China managed to launch its national blockchain-based service network (BSN) in April 2020, as scheduled earlier, in an attempt to promote the mass...
The unprecedented events of the past few months have upended societies and healthcare systems alike. With the increased need for medical innovation and research to...
The Department of Science and Technology - Science and Engineering Board (DST-SERB) has recently initiated several special research projects. These efforts could help contain community spread of the...
Recent results have shown that high-dose chloroquine has potential safety concerns resulting in QTc prolongation, a heart rhythm disorder that serves as a surrogate indicator...
The COVID-19 pandemic is set to impact the pharmaceutical industry in a profound way, according to GlobalData, a leading data and analytics company. From postponed...
Following the news that India has approved nearly US$2bn* towards ‘India COVID-19 Emergency Response and Health System Preparedness Package’; Sasmitha Sahu, Pharma Analyst at GlobalData, a leading data...
A survey conducted by GlobalData between 6 April and 20 April about the use of telemedicine during the COVID-19 crisis saw an overwhelming majority of...
Cereno Scientific’s preclinical candidate CS-1 (valproic acid) was recently granted Orphan Drug Designation (ODD) by the Food and Drug Administration (FDA) for the US market for pulmonary arterial hypertension (PAH)...
Regeneron and Sanofi recently announced the preliminary results from the Phase II portion of an ongoing Phase II/III trial evaluating Kevzara (sarilumab), an antibody targeting...
With an unexpected spike in COVID-19 cases, India has extended the countrywide lockdown till 17 May 2020. The move reflects India’s dependency on lockdown to contain the pandemic...
Organizations are relying on real-world evidence (RWE) to help tcontain the spread of COVID-19. Real-world data can provide valuable insights to help organizations better understand,...
Start-up companies in the UK are turning to artificial intelligence (AI) for analysis of existing drugs and new molecules. The use of AI in this...
The fast-paced adoption of digital technologies is emerging as a key element of remodeling healthcare delivery and scaling up systems. While the risk-averse culture, legacy...
As COVID-19 spreads through the global population, the rate of hospital admissions increases daily and threatens to overwhelm health systems. Certain patient populations have been...
With the EMA announcing today that it will start a rolling review of Gilead Sciences’ remdesivir for COVID-19 and wide expectations that US Emergency Use Authorization (EUA)...
The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) grew by 12.3% during the week ended April 26, 2020...
Pharmaceutical industry professionals around the world believe that employee safety and supply chain disruption are their businesses’ number one concerns from COVID-19, the latest survey...
The COVID-19 pandemic that has swept the globe has led to a massive search for a drug with which to combat this deadly virus. Yet,...
People with severe obesity, defined as having a body mass index (BMI) of 40 or higher, are now considered to be at risk for developing...
Concerns have arisen that treatments for cancer patients could be affected by shortages in cancer drug supply and distribution as valuable medical resources are being...
As the COVID-19 global pandemic grows with the UK, active inflammatory bowel disease (IBD) patients could be at a higher risk, as patients using prominent therapies...
Following the news that India-based Strides Pharma has developed and commenced the export of generic favipiravir antiviral tablets to potentially treat COVID-19 infection; Sasmitha Sahu, Pharma Analyst at GlobalData, a...
Following the announcement that SeaStar Medical will initiate a pilot study of aselective cytopheretic device (SCD) in COVID-19 patients; Azadeh Laffafian, Medical Device Analyst at GlobalData,...
Interest in a class of drugs called JAK inhibitors to manage COVID-19 is building, and with three such therapies already approved for other diseases, the...
As the COVID-19 pandemic continues, pharmaceutical companies are working on finding treatments to lessen the symptoms of the disease. Several drugs are being investigated for...
India-based Wockhardt Ltd has recently received US FDA qualified infectious disease product (QIDP) status for WCK 677 (currently filed Investigational New Drug Application/Clinical Trial Application (IND/CTA)) to...
The rheumatoid arthritis (RA) treatment landscape in Japan is highly competitive with many novel disease-modifying anti-rheumatic drugs (DMARDs). To stay ahead of the competition, the branded support offered...
Following the news that Gilead’s antiviral remdesivir has met its primary endpoint in a clinical trial run by the National Institute of Allergy and Infectious...
Propeller Health, a respiratory digital health company, released data last week showing that asthma and COPD patients have become more adherent to their medication since...
Free goods movement restrictions, imposed by the majority of EU countries at their borders to control the spread COVID-19, are disrupting supply chains, including crucial...
Roche’s Actemra (tocilizumab) generated $687m in the first quarter of 2020, a 30% increase compared to the same period in 2019, due to evidence of...
Following the news that the launch of Neurocrine Biosciences’ Ongentys (opicapone) has been delayed due to the disruption caused by COVID-19, after receiving Food and...
As the COVID-19 pandemic continues, developing a vaccine for the disease becomes a pressing manner, but a reasonable time frame for accomplishing a working vaccine...
India-based Natco Pharma has recently launched a generic version of AstraZeneca’s patented anti-diabetes drug Forxiga (dapagliflozin). Natco’s sodium glucose co-transporter-2 (SGLT2) inhibitor, Dapnat, is indicated for the treatment...
As the COVID-19 pandemic continues to spread, understanding how the differences in each countries response to the situation affected the outcome of the spread of...
Clinical trials evaluating pain and mental health conditions are the neurology indications most affected by the ongoing COVID-19 pandemic, says GlobalData, a leading data and...
Up to 80% of COVID-19 cases are mild or asymptomatic and therefore unlikely to be diagnosed. Determining what percentage of the population is asymptomatic will...
The National Health Service’s (NHS) data platform will help the country implement a co-ordinated and effective response to the rapidly evolving COVID-19 crisis in the...
Following the news that President Trump discussed in a press conference how UV rays and certain disinfectants may kill the coronavirus,Johanna Swanson, Product Manager at...
The European Union needs more solidarity and coordinated actions to effectively respond to the COVID-19 outbreak, says GlobalData, a leading data and analytics company. Urte Jakimaviciute,...
Following the news that China trials of Gilead Sciences Inc’s antiviral drug remdesivir in patients with mild symptoms of coronavirus (Covid-19) have been suspended due...
Following the Food and Drug Administration’s (FDA) authorization of the first COVID-19 diagnostic test with a home-collection option; Aliyah Farouk, Medical Device Analyst at GlobalData, a...
The majority of the top 20 global innovative pharma companies, identified by GlobalData, declined in market cap (MCap) in Q1 2020 (quarter ended 31 March...
Austerity measures, dissatisfaction with politics, lack of transparency in the EU’s decisions and uncontrolled immigration may have been the major factors influencing the Brexit vote....
A total of 892 deals were announced globally during the week ended 19 April, 2020, which is a decrease of 0.8% over 899 deals announced...
Preliminary results for the Phase II study for high dose chloroquine disphosphate (CQ) for COVID-19 patients showed hazardous side effects of a QTc prolongation, resulting...
The UK National Health Service (NHS) has been forced to rapidly adapt its digital stance in the fight against the COVID-19. These digital shifts are...
Following the announcement that Renalytix AI’s KidneyIntelX™ platform will be used to assess the risk of kidney injury in COVID-19 patients;Azadeh Laffafian, Medical Device Analyst at...
As the COVID-19 pandemic spreads rapidly throughout the world, the urgency of finding a treatment has magnified. The Coronavirus Treatment Acceleration Program (CTAP), a special...
Emerging three-drug combinations are poised to redefine the immuno-oncology treatment paradigm in advanced malignancies with high unmet need, according to GlobalData, a leading data and...
Regulatory bodies worldwide are taking action to combat COVID-19. In Europe, the European Medicines Agency (EMA) has established the COVID-19 EMA pandemic Task Force (COVID-ETF), which...
With the continuation of the COVID-19 pandemic and possible vaccines approximately one year away from launch, the race to find a treatment for the disease...
As the COVID-19 pandemic continues to spread, collaborations between companies with differing areas of expertise could accelerate the availability of a treatment for the disease....
In response to the COVID-19 pandemic, a large-scale randomized clinical trial is to initiate in the UK to assess some of the potential treatments for...
Several companies developing mesenchymal stromal cells (MSCs) for COVID-19 saw significant stock movement after announcing their plans, and early data is indeed encouraging for further...
The Biomedical Advanced Research and Development Authority (BARDA) has agreed to provide up to $483m to assist Moderna in developing its COVID-19 vaccine candidate, but reporting...
The American Society of Reproductive Medicine (ASRM) issued guidance on fertility treatments during COVID-19 and called for suspension of most new treatment cycles such as...
Novartis’ Isturisa (osilodrostat) leads recent innovation in Cushing’s disease (CD) with its latest Food and Drug Administration (FDA) approval, says GlobalData, a leading data and...
With the accelerating global burden from the COVID-19 pandemic, researchers are rapidly searching for a viable vaccine or therapeutic to combat the global public health...
A number of pharmaceutical companies have RNA-based therapeutics and vaccines in development for COVID-19. However, there are a number of safety concerns around the use of viral vectors with...
India-based Curadev’s licensing agreement with Bayer in March 2020 for the discovery and development of novel stimulator of interferon genes (STING) antagonists across indications with high unmet...
AbbVie was one of the first companies to donate its combination of HIV protease inhibitors Aluvia (lopinavir/ritonavir), also known as Kaletra, to help China treat patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)....
The number of deals announced in the global healthcare sector (including pharmaceuticals and medical equipment) declined by 28% during the week ended April 12, 2020 compared to the previous week, according to GlobalData’s deals database. Aurojyoti Bose, Analyst at GlobalData, comments: “The decline was subsequent to two...
The pharmaceutical market for age-related macular degeneration (AMD) was worth an estimated $8.6bn across the nine major markets (9MM*) in 2018. This is expected to grow to $18.7bn in 2028 at a modest compound annual growth rate...
India's coronavirus (Covid-19) lockdown has impacted the manufacturing and supply chain operations of pharmaceuticals despite pharmaceutical manufacturing being considered an essential service and excluded from the lockdown. However,...
Following the news that AstraZeneca’s Koselugo (selumetinib) has been approved by the US Food and Drug Administration (FDA) for the treatment of a rare neurological...
A comparison analysis of COVID-19 deaths from seven major markets (7MM*) shows disproportionate rates among older age groups says GlobalData, a leading data and analytics...
With the global COVID-19 pandemic, many patient groups are at an increased risk of infection and this extends to rheumatology patients prescribed immunosuppressant medication. The...
There has been an overall increase in clinical trials that have pushed back their estimated start dates since the beginning of January 2020, largely due...
With many countries putting clinical trials studies on hold, pharmaceutical companies are shifting their overall priorities away from some current indications toward COVID-19. This could...
Novartis has taken a lead in actively promoting heart failure awareness across India through unbranded digital initiatives that can successfully deliver message to a large population at risk,...
Biomarkers are a beneficial tool in the search for a COVID-19 vaccine and will help speed up clinical trials, reduce costs of development, guide subject...
Novo Nordisk will continue to dominate a large share of the glucagon-like peptide-1 receptor agonist (GLP-1RA) market with the arrival of Rybelsus and Ozempic’s strong global sales of $1.65bn in 2019. This will enable the company to maintain its well-established position in the wider diabetes market, according to GlobalData, a leading data and analytics company. Akash Patel...
Use of virtual mental health tools is expected to rise significantly over the coming months as self-quarantine and social distancing measures show no signs of being lifted, says GlobalData, a leading data and analytics company. Kathryn Whitney, MSc,...
As the number of confirmed COVID-19 cases reaches nearly 1.5 million worldwide, with almost 430,000 in the US alone, the urgency of finding a treatment mounts. One of...
As the COVID-19 pandemic grows across the world, companies are beginning to accelerate their clinical trials for therapeutics and the number of trials has been...
There has been an increase in clinical trial delays due to concerns for patient and investigator safety, travel restrictions, subject quarantine, clinical site closures and...
The COVID-19 pandemic has disrupted nearly every part of supply chains within the healthcare industry, once again exposing the vulnerabilities of many organizations, especially those...
Gilead Sciences’ remdesivir is more likely to work in mild-to-moderate COVID-19 patients rather than severe cases, according to reporting from Reynald Castañeda, Pharma Writer for the Investigative...
Following the news that the continual disruption caused by COVID-19 is starting to have an impact on the drug development programme timings of leading pharma...
Given the speed and rapidity of spread of the COVID-19 epidemic, identifying already available compounds to use on patients has the promise of being able...
With the advent of COVID-19 reaching over one million cases worldwide, a concerted effort will be needed to approach this growing problem. Drug development partnerships...
As COVID-19 spreads, the search for a treatment is ramping up. The antimalarial and immunosuppressant hydroxychloroquine has received some attention, including that of President Trump. There are currently around 60 planned...
In this unprecedented time of uncertainty, key markets have lost 20–70% of their value year-to-date due to COVID-19, according to GlobalData’s COVID-19 Executive Briefing. Sharon Cartic,...
Coronavirus (COVID-19) has now spread across 184 countries with approximately 1.5 million total confirmed cases worldwide as of 09.04.2020;Katie Wrenn, Associate Epidemiologists at GlobalData, a leading data...
As the COVID-19 situation grows, intensive care units (ICUs) in hospitals have to handle more patients with severe cases of the virus. COVID-19 can be...
It is likely that Italy has reached a peak in COVID-19 transmissions as the country has seen a continued decrease in new laboratory-confirmed cases for...
According to new guidelines published by the US Preventive Services Task Force (USPSTF), hepatitis C virus (HCV) screening will now expand to include all adults ages 18 to 79...
Following the introduction of social distancing measures, brought in to reduce the spread of COVID-19 across the globe;Emily Carter-Richardson, Pharma Analyst at GlobalData, a leading...
From Francis Collins’ tweet on the NIH clinical trial of an investigational vaccine for COVID-19 to the flu and coronavirus striking at the same time, leading data...
In the race to find treatments for COVID-19, repurposing therapies already approved for other indications to fight the SARS-CoV-2 virus is one key strategy. Approved...
The market for graft versus host disease (GvHD) prophylaxis and treatment in the seven major markets (7MM*) will undergo rapid growth, at a compound annual growth rate...
Alexion Pharmaceuticals is revving up to enter the COVID-19 drug development race with Soliris (eculizumab), a drug that is already approved for other indications, a source...
An estimated 1.5 billion people around the world have been asked to practice social distancing amid the outbreak of coronavirus (COVID-19) that has caused the...
While checkpoint inhibitors as monotherapies have fulfilled expectations in some indications, novel combinations are on the horizon in a broader range of cancers says GlobalData,...
In the key markets most heavily affected by the coronavirus (COVID-19), case trends are expected to follow a low-risk forecast, with the exception of the...
COVID-19 has a significant impact on patients with pre-existing conditions, many of which fall under the cardiovascular (CV) and metabolic disorder (CVMD) category. The current...
India’s agility so far in handling the coronavirus (Covid-19) situation is an exemplar, given its large population and the public healthcare challenges. As the country gears up...
Thepneumococcal vaccines market is expected to grow from $5.11bnin 2018 to $6.24bnin 2028across the nine major markets (9MM*) at a compound annual growth rate (CAGR)...
Thus far, the novel coronavirus (COVID-19) pandemic has surpassed 860,000 confirmed cases globally and while the economic impact is weighing heavily across sectors, organizations are exploring creative ways of how to combat the outbreak. The responses are not only fighting COVID-19, supporting the general public and propping up the healthcare system,...
Of the more than 230 nanopharmaceuticals in clinical development, 75% are for oncology indications, including many hard-to-treat cancers with few treatment options, according to GlobalData, a leading data and analytics company. Nanopharmaceuticals have many physical and biological advantages...
Following the news that Intarcia has received a second rejection from the Food and Drug Administration (FDA) regarding its subcutaneous osmotic pump implant, ITCA 650, for type 2 diabetes (T2D) patients; Akash Patel MSc, Pharma Analyst...
Following a number of recent global news stories about viral load and its impact on Coronavirus (COVID -19) patients; Michael Breen, Director of Infectious Diseases at GlobalData,...
As the novel coronavirus (COVID-19) pandemic continues to spread globally, virtual platforms will experience an extra boost after already having a transformational impact on the...
Despite the plethora of drugs currently available for patients with psoriatic arthritis (PsA), several key unmet needs remain, according to GlobalData, a leading data and analytics company.The company’s report: ‘Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028’ reveals...
The FDA recently lifted an import ban it had imposed in 2015 on India’s Ipca Laboratories due to quality issues and non-adherence to good manufacturing...
India has recently sought feedback from the top pharmaceutical companies to make regulatory changes that offer specific tax benefits for specialized research. With the government’s inclination towards promoting...
The value of the US transcatheter mitral valve repair (TMVR) device market was just over $250m in 2019 and is set to be worth $1.4bn by 2028...
Novartis recently announced new anticipated long-term positive data for its one-time infusion gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), which is set to help the drug generate global...
Following the recent news that the coronavirus (COVID-19) has now spread across 176 countries with approximately 530,000 total confirmed cases worldwide as of 27.03.20; Katie Wrenn, Associate...
Invasive pneumococcal disease (IPD) presents a significant public health concern globally. India leads the way with the highest number of diagnosed incident cases of IPD, says GlobalData, a...
As the number of global coronavirus (COVID-19) cases continues to rise, governments around the world are taking unprecedented measures, to contain the spread and support their economies...
With several mega cap biopharma companies having their vital manufacturing steps in Chinese facilities, the novel coronavirus (Covid-19) outbreak is putting the complicated global biopharma industry's supply chain...
Following the news that India has approved US$1.3bn* (INR10Kbn) healthcare package to boost the domestic manufacturing of active pharmaceutical ingredients (API); Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and...
Last week, the GlobalData epidemiology team conducted a three-scenario forecast model of the coronavirus (COVID-19) transmission in the US, with the moderate estimate projecting more...
The current multiple sclerosis (MS) pipeline is strong and diverse with a total of 49 products in all stages and phases of clinical development. However,...
The Asia-Pacific (APAC) has emerged as the most prominent region for conducting clinical trials, accounting for over 40% of the annual share of globally conducted clinical trials in...
Synairgen has received approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 (inhaled...
Use of telemedicine in the US has been low to date. However, it is expected that demand for these services will increase dramatically over the...
The axial spondyloarthritis (axSpA) market across the five growth markets (5GM*) in the Asia-Pacific (APAC) region will experience moderate growth over the next 10 years,...
There has been an exponential increase of coronavirus (COVID-19) cases in the US since the beginning of March, from less than 70 to more...
Tessa Therapeutics’ TT11 has become the first CAR-T therapy to receive the Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation and is set to become...
Microvascular angina (MVA) is being increasingly recognized in clinical practice, says GlobalData, a leading data and analytics company. According to key opinion leaders (KOLs) interviewed by...
The impact of the coronavirus (Covid-19) outbreak on industries ranging from technology to automotive has been the subject of intense analysis in the recent months. This has...
Diagnosed incident cases of renal cell carcinoma (RCC) in the eight major markets (*8MM) are projected to increase from 0.20 million cases in 2018 to...
Following the news that MedDay Pharmaceutical’s MD1003 for the treatment of non-active progressive forms of multiple sclerosis (MS) failed in a Phase III clinical trial; Philippa...
Covid-19 transmission in China is reportedly winding down as reported new cases are decreasing, but the virus is just starting to make the rounds in...
Following the recent news that The Drug Controller General of India (DCGI) has approved Zydus Cadila’s new drug application (NDA) for Lipaglyn (saroglitazar) for treatment...
The numbers of breast cancer cases in men are growing steadily in the US. Epidemiologists at leading data and analytics company GlobalData forecast an increase...
Out of all the drugs that are currently in the pre-registration phase and are expected to launch in 2020, ten have the potential to reach...
The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market is expected to grow from $935.9M in 2018 to $1.6bn by 2028 across the seven...
vTv Therapeutics recently announced positive Phase 2 results for its oral antidiabetic drug, TTP-399, when used as an adjunct therapy to insulin in type 1...
The statement from the World Health Organization (WHO) that we are in “uncharted territory” on the coronaries outbreak comes as no surprise as Covid-19 infections...
The bladder cancer market is expected to significantly grow from $733m in 2018 to $4.0bn by 2028 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 18.5%, according to GlobalData, a leading data and...
Gut bacteria research is seeing a resurgence in drug development, including beyond gastrointestinal disorders, with pharmaceutical companies diving into microbiome-focused cancer therapeutic candidates. Experts, however,...
Digital marketing in pharma is gaining increasing importance in recent times and Indian multinational pharmaceutical company Cipla Limited can be termed as a pioneer in this space from...
The financial burden of diagnosed bladder cancer is expected to grow between 2018 and 2028 in the seven major markets (7MM)* due to an increase...
There are currently 445 chimeric antigen receptor (CAR-T cell) therapies under development by companies headquartered across the Asia-Pacific (APAC) region. With research in progress and increased understanding of...
As patients, clinicians and researchers prepare for Rare Disease Day on February 29 2020, GlobalData’s analysis shows the number of drugs awarded orphan drug designations...
Agile Therapeutics’ Twirla (ethinyl estradiol + levonorgestrel) could have an edge over competitors based on milder side-effects and a potentially safer profile, says GlobalData, a leading data and analytics company. As the largest contraceptives market,...
Following today’s news that Clover and GSK have announced a research collaboration to evaluate a coronavirus (COVID-19) vaccine, and also that the US government wants...
Following the news that the Food and Drug Administration (FDA) has approved Vyepti for the prevention of migraines in adults, Philippa Salter, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, offers her view: “Vyepti becomes the latest FDA approved drug for prevention of migraines in adults, following the approval of Amgen’s Aimovig, Eli Lilly’s Emgality and...
Current treatment options for dry eye syndrome (DES) are limited to artificial tears, mostly on its own for milder forms of DES and in combination with anti-inflammatory and corticosteroid therapies for more severe forms of DES. However, this treatment paradigm is expected to see...
The dermatophytic onychomycosis market is expected to grow from $208.8m in 2018 to $676.4m in 2028 within the US, at a compound annual growth rate...
Following the recent news that Dr Reddy's Laboratories (DRL) has agreed to acquire Wockhardt Ltd’s select divisions of branded generics business in India, Nepal, Sri...
Following the recent news that new data from the Centers for Disease Control and Prevention (CDC) has revealed that life expectancy is once again on...
Following the recent news that The Food and Drug Administration (FDA) has suspended investigators from China in light of the increasing number of coronavirus cases; Angad...
A new case definition for COVID-19 in China has resulted in a spike in the number of reported cases of the disease, says GlobalData, a...
Following the recent official gazette notification from the Ministry of Health & Family Welfare (MOHFW) of India that from March 2021 onwards Indian pharmaceutical companies that market drugs...
Following today’s news that Pfizer’s rare disease oral drug Vyndaqel (tafamidis) has gained a new European Medicines Agency (EMA) approval for treating adults with wild-type or...
India-based Zydus Cadila’s licensing agreement with China Medical System (CMS) Holdings Limited in January 2020 for the development and commercialization of desidustat will provide a momentous boost...
Oncology is set to dominate the clinical trials activity in 2020 based on an early preview of trials that are expected to start and be...
The recently published final roadmap for Stem Cell Therapies Mission (SCTM), grant opportunities and stem cell research regulations will further streamline an already agile stem cell research...
Following the failure of a trial for two monoclonal antibody drugs for Alzheimer’s disease (AD), Eli Lilly’s solanezumab and Roche’s gantenerumab, in patients that have...
Novartis has recently sold its anti-diabetic drug vildagliptin (branded as Zomelis, Vysov and Vysov M) to Ahmedabad-based Eris Lifesciences and Mumbai-based pharmaceutical major Cipla Ltd, in India. The...
Expectations for biosimilars are high in 2020, and the drug class will finally begin to make its mark in the US, says GlobalData, a leading...
In 2020, big data and artificial intelligence (AI) will continue to trend as integral parts of the future of pharmaceutical research and healthcare service delivery,...
Malaysia’s aspiration to push HealthTech to the forefront will provide myriad opportunities to innovative domestic and foreign companies, according to GlobalData, a leading data and analytics company. Through supportive...
The end of January 2020 marked the start of the Brexit transition period as, after more than three years of anticipation, the UK separated from...
China-based Qilu Pharmaceutical received approval in December 2019 for QL-1101 under the trade name Ankada, a biosimilar to Avastin (bevacizumab), to treat advanced, metastatic or recurrent non-small-cell...
Following Incyte’s announcement about positive topline Phase III results for topical Jakafi (ruxolitinib) in the treatment of mild-to-moderate atopic dermatitis (AD); Reynald Castaneda, Pharma Writer for...
Looking to the horizon for 2020, Michael Breen, Associate Director of Infectious Diseases, and Philipp Rosenbaum, Infectious Diseases Analyst, at leading data and analytics company...
In recent years, an increasing number of partnerships have been forged between large technology companies, start-ups developing healthcare-specific applications, hospitals, and research centers in the...
Lack of progressive and proactive e-pharmacy regulatory framework is impacting the overall growth potential and future investments in the Indian e-pharmacy sector, says GlobalData, a leading data and...
Following the news that the spread of the Wuhan coronavirus developed into a dangerous epidemiology outbreak with potential impact worldwide; Kasey Fu, Director of Epidemiology at GlobalData, a...
In the search for non-opioid options to treat pain, Mesoblast has turned to a stem cell approach, which is currently in late-stage development for chronic...
As 2020 commences for the pharmaceutical industry, Fern Barkalow, PhD, Senior Director of Oncology and Hematology, as well as members of her analyst team at...
Following the news that Roche reported positive results from Part 2 of the pivotal FIREFISH trial for spinal muscular atrophy (SMA) patients; Vinie Varkey, Senior Analyst...
The human immunodeficiency virus (HIV) pipeline is robust, with 450 products in active development that display a high degree of novelty and diversity. Promisingly, there are 87 first-in-class products that act on a range of 50 molecular targets, which can broadly be...
In November 2019, China updated its National Reimbursement Drug List (NRDL) to include 70 new medicines, with an average price cut of 61% agreed by...
News earlier this week highlighted that new data have emerged suggesting that sepsis is a bigger killer than cancer. Sepsis has proven to be deadly, but...
From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry. Patrick Aiyes,...
Following the news that cases of people infected with the Wuhan coronavirus rose to more than 270 laboratory-confirmed cases and the virus may spread from...
Nearly three quarters of global industry stakeholders identified immuno-oncology (I-O) or personalized medicine as the most impactful trends that will shape the pharmaceutical sector in...
Following the news that sepsis has been found to be a bigger killer than cancer worldwide in a study by Rudd et al; Kasey Fu, Director...
The heart failure (HF) market is expected to grow from $3.7bn in 2018 to $22.1bn in 2028 across the eight major markets (8MM*) at an...
The pharmaceutical industry is mixed on the factors that will have the greatest positive impact on the industry in 2020, with patent expiry of biologics and vertical integration highlighted as some of the key...
In 2020, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData,...
The size of the seasonal influenza vaccine market across the three major Asia-Pacific (APAC) growth markets (3GM*) will grow at a modest compound annual growth...
As 2019 draws to a close, Valentina Gburcik, PhD, Senior Director of Cardiovascular and Metabolic Disorders, as well as Gender Health and Digital Teams at...
The multiple sclerosis (MS) therapeutics market has entered an exciting phase, with an upsurge of available treatment options and several promising late-stage pipeline products offering...
Nearly 40% of all diagnosed prevalent cases of Chronic Heart Failure (CHF) in the eight major markets (8MM*) occur in the elderly population, and this...
The global pharmaceutical industry spends a significant amount of revenue on research and development (R&D) activities that are failing to deliver projected returns. A recent...
The spinal muscular atrophy (SMA) market across the five growth markets ((5GM) Australia, China, India, Japan and South Korea) in the Asia-Pacific (APAC) region is...
The introduction of the Universal Health Care (UHC) Act coupled with business and corporate tax regulatory reforms in the Philippines is likely to open up...
The diagnosed prevalent cases of axial spondyloarthritis (AxSpA) are expected to increase from 6.1 million cases in 2018 to 8.0 million cases in 2028, at...
Respiratory syncytial virus (RSV), a common respiratory infection in children, has increasingly been identified as a leading cause of respiratory disease in the elderly. Continuing...
The respiratory syncytial virus (RSV) market is expected to grow at a compound annual growth rate (CAGR) of 44.7% from US$36.88m in 2018 to US$1.48bn...
Sun Pharmaceutical Industries Ltd (Sun Pharma) has recently entered into a licensing agreement with AstraZeneca UK to launch novel ready-to-use oncology drugs in China. The...
Following the news that European Medicines Agency (EMA) granted accelerated assessment of OTL-200; Vinie Varkey, Senior Analyst of Neurology and Ophthalmology at GlobalData, a leading data...
‘Personalized medicine’ and ‘precision medicine’ are both defined as using a patient’s genomic and phenotypic data to find targeted therapies. These therapies use a proactive...
Following the news that the US Food and Drug Administration (FDA) has halted a trial of Novartis’s gene therapy Zolgensma due to safety concerns; Fiona Chisholm,...
This year’s CPhI Worldwide pharma event in Frankfurt, Germany, will take place from 5-7 November 2019. It will feature presentations by Bonnie (Bornadata) Bain, Global Head and Executive...
The number of immuno-oncology (IO) therapies in clinical development and volume of clinical investigations testing these therapies for the treatment of cancer patients continue to grow, and will...
Following the news that Biogen’s aducanumab seems to reduce disease progression in Alzheimer’s disease (AD) after new data was published from the Phase III trial...
Ongoing collaborations between different industry players and a buildup of real-world evidence establishing safety and efficacy are expected to drive the growth of gene therapies...
Following the news that Novartis’ Sandoz is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics (DTx) back to Pear...
Following the news that ICER has published its latest draft of the evidence report, ‘Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value’; Rose Joachim, Pharmaceutical...
China is currently the second largest pharmaceutical market in the world. Big data and artificial intelligence (AI) will have significant technological impact across all the...
The luminal unfolding microneedle injector (LUMI) capsule in development at MIT in collaboration with scientists from Novo Nordisk, aims to orally deliver drugs that would...
From 2014 to the first half (H1) of 2019, there were more than 1,300 separate strategic partnerships and 1,000 licensing agreements made in the global...
From 2014 to the first half (H1) of 2019, the pharmaceutical and healthcare industry recorded 2,882 deals that fell within the gene therapy, immuno-oncology, microbiome...
From 2014 to the first half (H1) of 2019, the global pharmaceutical industry saw more than 400 mergers and acquisitions (M&A) in the gene therapy,...
The Indian Pharmaceutical Alliance (IPA) has recently urged the government to set up a fund to boost technological innovation in the bio/pharma space. This push...
Following the recent news that China has revised its drug laws to remove drugs that are legal in foreign countries but not approved in China...
The hidradenitis suppurativa (HS) market is expected to grow from $898m in 2018 to $1.81bn in 2028 across the seven major markets (7MM*) at a...
Recently, a first-in-human, Phase I clinical trial was successfully completed for a novel chlamydia vaccine. The trial results hold great promise for the development of...
Following the news that US-based start-up Harmony Biosciences’ Wakix (pitolisant), a first-in-class drug for the treatment of excessive daytime sleepiness (EDS) in adult patients suffering...
The young adult population (ages 20–39 years) contributed the highest number of new cases for alopecia areata (AA) out of all the age groups across...
Healthcare industry professionals around the world believe that Brexit will not happen on the current withdrawal agreement on 31 October, but there will also be...
Zolgensma’s recent challenge of finding favor with the majority of the insurance companies in the US may just be about to get tougher with the...
Japan has recently become the first country to approve Roche/Chugai’s personalized medicine Rozlytrek (entrectinib) for adult and pediatric patients with neurotrophic tyrosine receptor kinase (NTRK)...
Following the news that DBV Technologies has submitted a biologics license application (BLA) to the US FDA for Viaskin Peanut, an epicutaneous immunotherapy for the...
Approximately 69% of contract manufacturing organization (CMO) high-containment facilities in Europe can be found in the five major European markets (5EU*) and Switzerland, according to...
The diagnosed incident cases of ovarian cancer in the seven major markets (7MM*) will increase at an annual growth rate (AGR) of 0.42% from over...
The systemic lupus erythematosus (SLE) pipeline is characterized by a high level of first-in-class innovation when compared to other therapy areas and the industry as...
South Korea’s plans to invest more than US$1.7bn in its biotechnology and biopharmaceutical sectors over the next five years will attract foreign investment as pharmaceutical...
Following the news that Bayer and Orion’s Nubeqa (darolutamide) has gained US Food and Drug Administration (FDA) approval for the treatment of non-metastatic, castration-resistant prostate...
Indian pharmaceutical companies are finding lucrative opportunities for growth in the Chinese pharma market, which is set to rise from nearly US$132bn in 2018 to...
The diagnosed prevalent cases of hemophilia in the US are likely to exceed that of China over the next decade, with 18,723 cases in the...
The number of 12-month total prevalent cases of post-traumatic stress disorder (PTSD) was higher in women than in men in the seven major markets (7MM*),...
The diagnosed prevalent cases of type II spinal muscular atrophy (SMA) made up the highest proportion with 10,574 cases, nearly one half of all diagnosed...
The B-cell non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7bn in 2017 to $9.2bn by 2027 across the seven major markets (7MM*) at...
The burden of diagnosed B-cell non-Hodgkin’s lymphoma (NHL) is expected to increase at an annual growth rate (AGR) of 1.87% from around 154,000 cases in...
The total post-traumatic stress disorder market was estimated to be worth US$211.4m across the seven major markets (7MM*) in 2018. This is expected to grow...
Following Novartis’ acquisition of Takeda’s dry eye drug Xiidra, Alessio Brunello, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view...
The total spinal muscular atrophy (SMA) market was estimated to be worth US$1.5bn across the seven major markets (7MM*) in 2018. This is expected to...
Following the news that the FDA has approved Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis, Philippa Salter, Pharma Analyst at GlobalData, a leading...
Following the latest research published in The Lancet highlighting the potential impact HPV vaccinations could have on cervical cancer rates, James Mather, Senior Pharma Analyst...
A major barrier to the widespread use of digital therapeutics (DTx) is the limitation or lack of reimbursement by public and private health insurance providers,...
Following the news that Sanofi has withdrawn from a gene therapy deal with Voyageur Therapeutics, Vinie Varkey, Pharma Analyst at GlobalData, a leading data and...
Following the news that a number of people have low confidence in vaccination, James Mather, Senior Pharma Analyst at GlobalData, a leading data and analytics...
The global robotic surgery market is expected to grow at a compound annual growth rate (CAGR) of 7.7% to reach US$7.4bn by 2028, according to...
Following the news that OxyContin manufacturer Purdue Pharma are being sued by three more US states for exploitation of the opioid crisis, Magdalene Crabbe, Pharma Analyst...
Following the recent news that the FDA has recommended an additional Phase III trial for Novavax’s vaccine to prevent medically significant RSV disease in infants, Paul...
Following the recent news that Roche’s Phase III influenza drug Xofluza met its primary endpoint for influenza prevention, Philipp Rosenbaum, Pharma Analyst at GlobalData, a leading...
Following the recent news that NICE has recommended Merck’s Prevymis for preventing cytomegalovirus (CMV) reactivation in recipients of hematopoietic stem cell transplantation (HSCT), Paul Jeng, Senior...
Within the next ten years, up to six new drugs are projected to be approved for the treatment of chronic hepatitis B virus (HBV) infections...
Following the recent news that Congolese Health Minister Oly Ilunga Kalenga is pushing for licensure and exclusive use of Merck’s Ebola vaccine in the current...
Following the news that microbiome therapeutics developer Vedanta has completed an extended $45.5m series C round, Paul Jeng, Senior Pharma Analyst at GlobalData, a leading...
Following news that the FDA has finalized its guidance on interchangeable biosimilars; Rose Joachim, PhD Senior Immunology Pharma Analyst at GlobalData, a leading data and analytics...
The news that pharmaceutical companies will be required to include drug prices on TV adverts comes as part of President Trump’s commitment to promote lower...
Following the news that Takeda has agreed to sell dry eye drug Xiidra to Novartis for $3.4bn, Maura Musciacco, Senior Director of Neurology & Ophthalmology...
The global surgical adhesion barriers market is expected to grow at a compound annual growth rate (CAGR) of 3% to reach $1.4bn by 2028, according...
Following the news that the US, UK and France top UNICEF’s report of children unvaccinated against measles between 2010 and 2017, James Mather, Senior Pharma...
Following the release of additional Phase III clinical trial (Prepare) data of Novavax’s ResVax, presented at the World Vaccine Congress in Washington, D.C., Paul Jeng, Senior...
Following the publication, at the International Liver Congress (ILC) 2019, of top-line data from a proof-of-concept study into Gilead’s combination therapy for NASH; James Mather, MChem,...
Following the news that Novo Nordisk and Gilead Sciences have partnered on a clinical trial combining drugs to treat the progressive fatty liver disease NASH,...
The FDA recently rejected a marketing application for Zogenix’s Fintepla, an anti-epileptic drug candidate for Dravet syndrome. Magdalene Crabbe, Neurology and Ophthalmology Analyst at GlobalData,...
In light of World Parkinson’s Day (11 April 2019), there have been a number of successes over the past half century in the treatment of...
Following the news on April 8, 2019 that Alnylam and Regeneron have entered into an $800m pact to develop RNA interference (RNAi) therapies for eye...
Louisiana’s Department of Health recently announced that Gilead’s subsidiary Asegua Therapeutics has been selected as the pharmaceutical company for hepatitis C procurement model. Arafa Salam, PhD,...
The approval of UCB’s Cimzia marks the first anti-tumor necrosis factor biologic therapy for non-radiographic axial spondyloarthritis (nr-axSpA) patients in the US, having been already...
Following the PM’s third consecutive defeat on the original set date of Brexit, companies within the UK healthcare sector are in angst as the future...
On 20 March 2019, the European Medicines Agency (EMA) announced that it has put Pfizer’s blockbuster JAK inhibitor drug, Xeljanz (tofacitinib), under review following signs...
A recent study conducted at Bar-Ilan University in Israel found that DNA repair in damaged neurons is most efficient during sleep, and treating sleep disorders...
Results posted from the MOMENTUM-3 clinical trial at the 68th American College of Cardiology Scientific Session on 17 March 2019, revealed that the HeartMate 3...
Estimated to be approximately 15% of the embolization devices market, the flow diversion stent market is growing at a Compound Annual Growth Rate (CAGR) of...
Following the news of a UK patient (The London Patient) who has been in remission with undetectable levels of HIV viral load for 18 months,...
On March 8, the FDA granted the accelerated approval of Roche’s programmed cell death protein 1 (PD-1) inhibitor Tecentriq in combination with Abraxane (protein-bound paclitaxel)...
Following the news that a UK patient has shown undetectable levels of HIV virus 18 months after after receiving transplanted stem cells from an HIV-resistant...
Following the news on 28 February 2019 that Novavax’s respiratory syncytial virus (RSV) disease vaccine for infants – ResVax – did not meet its primary...
Following the news (25 February 2019) that the FDA has granted a Fast Track designation to Themis Bioscience’s lead Phase II experimental vaccine (MV-CHIK) for...
Following the news (25 February 2019) that Roche has entered into a definitive merger agreement to fully acquire Spark Therapeutics for $4.3bn, Tajekesa Chapman, Pharma...
Following the news (20th February 2019) that, according to a study published in the journal Neurology, blood neurofilament light chain can be a biomarker of...
Merck & Co Inc’s abstract presentation regarding KEYNOTE-426 trial at ASCO GU 2019 (16 February 2019) has confirmed that Keytruda, an anti-PD-1 therapy, in combination...
PCSK9 inhibitors have struggled to gain momentum since their US launch in 2015. As a result, PCSK9 inhibitor developers slashed prices in 2018 in order...
A study funded by the Medical Research Council, British Heart Foundation and the National Institutes of Health has revealed that an ultrasound scan of blood...
Immuno-Oncology (IO) development is booming across the 8MM*, with IO agents being investigated in most cancer types, in combination or alone, representing a huge commercial...
As the GDP per capita increases, India’s affluent market will drive demand for best-in line drug delivery devices and reward innovations in the years to...
Asia Pacific (APAC) region contributed 21% of global revenue in 2016 and the region is expected to witness higher growth compared to other regions. The company’s...
